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ABSTRACT 
 
 
          Lanthipeptides are natural products that belong to the family of ribosomally synthesized 
and posttranslationally modified peptides (RiPPs). They contain the characteristic lanthionine 
(Lan) or methyllanthionine (MeLan) structures that contribute to their diverse biological 
activities. ProcM is a promiscuous bifunctional synthetase that catalyzes both dehydration and 
cyclization of the lanthipeptides. Its 30 substrate peptides (ProcAs) have a high level of 
conservation in the N-terminal leader region and hypervariability in the C-terminal core region. 
A chimeric peptide with a ProcA leader peptide and LctA (the precursor peptide for lacticin 481) 
core peptide was constructed and co-expressed with ProcM in Escherichia coli. ProcM 
dehydrated this chimeric peptide up to 5-fold (WT lacticin 481 is dehydrated 4-fold), and also 
catalyzed the formation of 2~3 rings (WT lacticin 481 has 3 rings). The modified peptide was 
digested with protease to remove the leader peptide, and the resulting product was demonstrated 
to have antimicrobial activity against Lactococcus lactis HP. These results showed the 
promiscuity of ProcM and suggest it may be used to generate cyclic peptide libraries from 
substrates with a ProcA leader peptide.  
            The product specificity and the regulation of product formation of ProcM were also 
studied.  Despite its structurally very diverse substrate set, high selectivity of product formation 
from each substrate was observed. The effects of mutation of the conserved residues in the active 
site, including three zinc ligands (Cys924, Cys970, and Cys971), the proposed active site 
acid/base His859, and Asp804 that is hydrogen-bonded to His859 were investigated. Mutation of 
the zinc ligands to alanines or the unique zinc ligand Cys971 to histidine resulted in a decrease of 
the cyclization rate, especially for the second cyclization of ProcA1.1, ProcA2.8 and ProcA3.3. 
In the case of ProcA3.3, these mutations also altered the regioselectivity of ProcM and generated 
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a new major product. The H859A mutation completely deactivated the cyclization activity of the 
enzyme, while the D804N mutation also decreased the cyclization rate but maintained the initial 
regioselectivity for ProcA3.3. ProcM was not able to correct the ring topology of incorrectly 
cyclized intermediates and products, suggesting that thermodynamic control is not operational. 
Instead, the high regioselectivity of product formation appears to be governed by the selectivity 
of the initially formed ring. 
           By studying truncated enzymes of ProcM, LctM, and CylM, I showed that the N-terminus 
of these LanMs catalyzed the dehydration and the C-terminal domain catalyzed the cyclization. 
These two domains were active on their own, indicating that they are relatively independent. The 
N-terminus of LctM completely dehydrated its substrate LctA with efficiency similar to WT 
LctM. The N-terminus of CylM also dehydrated CylLs completely. The N-terminus of ProcM 
catalyzed one dehydration efficiently in ProcAs, but in the presence of the C-terminus, the 
dehydration reactions were complete. These results may suggest a different mode of catalysis for 
these LanMs. 
          The precursor peptides of lanthipeptides are ribosomally translated and are composed of an 
N-terminal leader peptide and a C-terminal core peptide. Sequence alignments of class II 
lanthipeptide leader peptides showed that they are typically rich in aspartates and glutamates. 
The leader peptide is believed to be recognized by the biosynthetic enzymes and guide the 
process of the post-translational modifications. Moreover, it is proposed that the binding of 
leader peptides to the enzymes shifts the equilibrium of the inactive and active enzymes to the 
latter form. Efforts were made to obtain an LctA leader peptide with better binding affinity to 
LctM for the following reasons: 1. Increased binding affinity of LctA to LctM might result in 
improved catalytic efficiency, and 2. Increased binding affinity might facilitate finally obtaining 
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a crystal structure of a LanM with the substrate bound to it. Yeast surface display was selected to 
engineer the LctA leader for better binding affinity to the LctM enzyme. Two rounds of sorting 
resulted in several mutations in the leader region, including three consistent aspartate mutations. 
Using fluorescence polarization assay, it was confirmed that the binding affinity of the mutant 
leader peptide was about 5-fold stronger than the WT leader peptide. Furthermore, LctA 
containing the engineered leader peptide was shown to be a more efficient substrate for LctM.  
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CHAPTER I: INTRODUCTION-THE BIOSYNTHETIC PATHWAY AND 
MODE OF ACTION OF LANTHIPEPTIDES* 
 
1.1 OVERVIEW 
Natural products have been a proven source for drug and drug leads discovery, especially 
in the area of antimicrobial and anticancer drugs. In the 20th century, many classes of natural 
products have been identified including four particularly prevalent groups: terpenoids, 
alkaloids, polyketides, and non-ribosomal peptides.1 The genome sequencing efforts of the past 
decade have illustrated that ribosomally synthesized and posttranslationally modified peptides 
(RiPPs) are much more prevalent than previously anticipated.1 RiPPs are encoded in the 
genomes of organisms in all domains of life, their structural diversity is vast, and their 
biological activities are equally diverse. Most RiPPs are biosynthesized from a larger precursor 
peptide that consists of a core peptide that is converted to the final product and an N- or C-
terminal extension called the leader or follower peptide, respectively. These extensions guide 
many, but not always all, of the posttranslational modifications that take place in the core 
peptide.2  
 
 
________________________ 
*Reproduced in part with permission from Yu, Y., Zhang, Q., and van der Donk, W. A. 
(2013) Insights into the evolution of lanthipeptide biosynthesis, Protein Sci. 22, 1478-1489.
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    RiPPs are typically macrocyclic, similar to the high incidence of cyclization in non-
ribosomal peptides. Cyclization can offer several advantages such as increased metabolic 
stability, improved cellular uptake, and preorganization to recognize cellular targets. 
Lanthionine-containing peptides, or lanthipeptides, are the largest group of RiPPs based on the 
frequency of their biosynthetic gene clusters in the currently available genomes. Over 90 
members of the lanthipeptide family have been identified to date, most with distinct ring 
topologies.3 This thesis describes studies designed to gain insight into the lanthipeptide 
biosynthesis process and lanthipeptide engineering. 
 
1.2 THE STRUCTURES OF LANTHIPEPTIDES 
As mentioned above, lanthipeptides are named after the characteristic lanthionine 
structures. The lanthionine structure, abbreviated as Lan, consists of two alanine residues that 
are linked through a thioether that connects their b-carbons (Figure 1.1). Many lanthipeptides 
also contain methyllanthionines, abbreviated as MeLan, which carry an additional methyl 
group on one of the -carbons (Figure 1.1). Biosynthetically, lanthionines and 
methyllanthionines originate from Ser and Thr residues that are first dehydrated to generate 
dehydroalanine (Dha) and dehydrobutyrine (Dhb) residues, respectively (Figure 1.1).3 
Subsequently, the thiol of a Cys is added across the carbon–carbon double bond of these 
dehydroamino acids in a Michael-type addition to produce the Lan and MeLan structures, 
respectively (Figure 1.1). Since typical lanthipeptide substrate peptides have multiple Ser, Thr, 
and Cys residues, the final products are polycyclic and display remarkable diversity in structure 
as illustrated by a select set of lanthipeptides depicted in Figure 1.2.  
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Figure 1.1. A. The dehydration step in lanthionine formation involves activation of the side 
chain hydroxyl group of Ser and Thr to generate dehydroamino acids (blue). For the class I 
enzyme NisB involved in nisin biosynthesis, activation involves glutamylation (magenta). The 
ester bond is likey made with the  carboxylate of glutamate. For class II-IV lantibiotics, 
activation of the hydroxyl group involves phosphorylation (orange) and elimination. B. The 
cyclization step in lanthipeptide biosynthesis also comes in different flavors. For class I, II, and 
IV lanthipeptides it is believed that cyclization involves activation of the Cys nucleophile (red) 
by an active site Zn2+. For class III lanthipeptides, the Zn2+ is not present in the cyclase and 
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thiol activation is achieved by an alternative, currently unknown mechanism. Class III 
cyclization is also unusual in that it results either in the formation of (methyl)lanthionines or 
the formation of labionins, which contain a carbon-carbon crosslink formed from one Cys (red) 
and two dehydroalanines (blue and green).4 An example is labyrinthopeptin shown in Figure 
1.2.2. Abu, 2-aminobutyric acid; Lab, labionin. 
 
Currently known lanthipeptides have a range of different activities including antimicrobial 
(called lantibiotics),5 morphogenetic,6 antiviral,7 and antiallodynic.4 The longest known family 
member, nisin (Figure 1.2), has been used for more than 50 years as a food preservative to 
combat food-borne pathogens.8 In addition, several other lanthipeptides are currently under 
development for various therapeutic applications including a semisynthetic analog of 
actagardine,9 the chlorinated lantibiotic microbisporicin,10, 11 duramycin,12 and 
labyrinthopeptin A2 (Figure 1.2).4 
   Diverse posttranslational modifications besides Lan/MeLan are also present in 
lanthipeptide family (Figure 1.2), including -hydroxylated aspartate and lysinoalanine (in 
cinnamycin), aminovinylcysteine (in mersacidin and others), D-alanine (in lacticin 3147 and 
lactocin S), and several α-ketoamide and α-hydroxyamide N-terminal caps (in Pep5, lactocin 
S, and others). Many of these modifications are considered to improve peptide stability through 
protection from proteolysis. In the case of cinnamycin, the -hydroxylated-Asp15 residue is 
believed to contribute to the interaction with the glycerophosphoethanolamine head group of 
its target phosphatidylethanoamine (PE), which is a component of the bacterial membrane.13 
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Figure 1.2. Structures of a representative set of lanthipeptides, demonstrating the vast diversity 
of ring topologies. The same short hand notation is used that is shown in Figure 1.1. (Me)Lan 
segments derived from Cys are shown in red and originating from Ser/Thr are shown in blue. 
Additional posttranslational modifications are shown in orange. Dehydroamino acids are 
shown in green. 
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1.3 BIOSYNTHESIS OF LANTHIPEPTIDES 
The lanthipeptide precursor peptides (generically termed LanAs) contain an N-terminal 
leader region in addition to a C-terminal core peptide that is processed to the mature compound. 
The general route for Lan/MeLan synthesis involves the dehydration of select serine and 
threonine residues to dehydroalanine (Dha) and dehydrobutyrine (Dhb) residues, respectively, 
followed by intramolecular conjugate additions of cysteines to the dehydro amino acids, 
resulting in extensively cross-linked polycyclic structures. After complete modification of the 
precursor peptide, the N-terminal leader sequence is removed by a protease to release the 
mature peptide (Figure 1.3).  
 
 
Figure 1.3. Overview of class II lanthipeptide biosynthesis. The canonical post-translational 
modifications are shown.  
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Although all lanthipeptides are made by dehydration of Ser and Thr residues followed by 
the addition of Cys residues to the resulting dehydroamino acids, the catalytic machinery that 
carries out these reactions is remarkably diverse. At present, four different enzymatic processes 
to lanthionines have been identified, some of which are evolutionarily related (Figure 1.4)3. 
Class I lanthipeptides are synthesized by two separate enzymes. The dehydration reactions are 
catalyzed by a dehydratase LanB, and the cyclization reactions are catalyzed by a cyclase LanC. 
For class II lanthipeptides, both the dehydration and cyclization reactions are carried out by a 
bifunctional enzyme LanM, which contains an N-terminal dehydratase domain that has no 
homology with LanB and a C-terminal LanC-like cyclase domain. Chapter II and III describe 
studies designed to understand one particular class II synthetase called ProcM, and chapter IV 
describe studies on the individual domains of several class II synthetases. The synthetases for 
class III lanthipeptides (LanKC) are trifunctional enzymes with an N-terminal lyase domain, a 
central kinase domain and a C-terminal putative cyclase, which does not contain the conserved 
zinc ligand residues. The synthetases for class IV lanthipeptides (LanL) share a similar scaffold 
with LanKC, except that the C-terminal cyclase domain is homologous to LanC. 
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Figure 1.4. Schematic representation of the four different classes of lanthionine synthetases. 
Class I systems consist of dedicated dehydratases (generically called LanB) and cyclases 
(generically called LanC). Class II enzymes are bifunctional, containing an N-terminal 
dehydratase domain and a C-terminal cyclase domain that has homology with the LanC 
proteins including the Zn-ligands (purple lines). Class III and IV enzymes contain a central 
kinase domain and an N-terminal lyase domain. The C-termini of these synthetases differ, with 
class III enzymes containing a cyclization domain that has homology with LanC proteins but 
that lacks the Zn-ligands, whereas class IV enzymes have the canonical LanC-like cyclization 
domain. 
 
1.3.1 Class I lanthipeptide biosynthesis 
 For nisin and other class I lanthipeptides, the dehydration reaction is carried out by LanB 
dehydratases and the cyclization by LanC cyclases. The LanB enzymes are large, about 120 
kDa, and do not have homology with any other characterized proteins in the databases. NisB, 
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the LanB dehydratase involved in nisin biosynthesis, requires glutamyl-tRNAGlu to carry out 
the dehydration of eight Ser/Thr residues in the precursor peptide.14, 15 In this process, the 
hydroxyl groups of Ser and Thr are first converted to glutamyl esters, which are then eliminated 
to form the carbon–carbon double bonds (Figure 1.1). The transient glutamylation constitutes 
a novel posttranslational modification of a peptide or protein; the only other known examples 
of glutamylation of Thr occur not on a peptide or protein substrate but rather on the enzymes 
glutaminase-asparaginase and -glutamyltranspeptidase as a catalytic acyl enzyme 
intermediate during the hydrolysis of glutamine and glutathione, respectively.16, 17  
The addition of the thiol of Cys to Dha and Dhb catalyzed by NisC, the cyclase involved 
in nisin biosynthesis, is believed to involve an active site Zn2+ ion that was identified by both 
spectroscopic and crystallographic studies.18, 19 Analogous to other enzymes that activate thiol 
nucleophiles such as farnesyl transferase,20 the Zn2+ ion is believed to activate the Cys thiols 
in the substrate peptide. Not only is the mechanism of catalysis similar, NisC also has structural 
homology with farnesyl transferase, sharing the same ,-barrel toroidal fold, with a Zn2+ at 
the top of the barrel.19 Interestingly, whereas LanB enzymes have no sequence homologs other 
than other putative dehydratases, LanC-like (LanCL) proteins of unknown function are also 
found in a wide variety of higher organisms including plants,21 insects, and mammals.22, 23 
 
1.3.2 Class II lanthipeptide biosynthesis 
The class II enzymes, generically called LanM, first phosphorylate Ser/Thr residues in the 
substrate peptides, followed by elimination of the phosphate to generate the dehydroamino 
acids (Figure 1.1).24 This net dehydration activity is located in the N-terminal domain of LanM 
proteins, which are about 110–120 kDa in size. Like the LanB proteins, the dehydratase 
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domains of LanM proteins have no clear sequence homologs in the protein databases other than 
other class II lanthionine synthetases, but the C-terminal cyclase domains of LanM proteins 
have clear sequence homology with the class I LanC cyclase enzymes, including the conserved 
Zn2+ ligands (Figure 1.4). Chapter III describes studies focused on the cyclization process of 
the class II synthetase ProcM. 
 
1.3.3 Class III and class IV lanthipeptide biosynthesis 
Class III and IV lanthionine synthetases, generically called LanKC and LanL, respectively, 
display an interesting domain architecture. These enzymes contain a central domain with clear 
sequence homology with Ser/Thr protein kinases (Figure 1.4).25 Indeed both classes of 
enzymes have been shown to phosphorylate the Ser and Thr residues in the substrate peptide 
that are destined to be dehydrated,26, 27 similarly to the catalytic strategy employed by the class 
II LanM enzymes. However, the elimination of the phosphate group to form the alkenes 
appears to have evolved differently because class III and IV enzymes contain a 
phosphothreonine (pThr) lyase domain at their N-termini that is not found in LanM enzymes,26, 
28 at least not at the sequence level; the possibility of structural homology cannot be ruled out 
in the absence of crystal structures. Phosphothreonine lyases are employed as effector proteins 
in various pathogens like Shigella to attenuate part of the immune response of the host by 
eliminating a phosphate group from a phosphorylated Thr residue in MAP kinases.29 Whereas 
the N-terminal lyase and central kinase domains are very similar in class III and class IV 
enzymes, the C-termini of these enzymes differ. Class IV proteins again have a canonical LanC 
cyclase domain including the conserved Zn2+ ligands,26 but class III enzymes contain a C-
terminal domain with sequence homology to LanC but lacking the Zn2+ ligands.30 Indeed, 
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analysis of one class III enzyme, AciKC, showed that the C-terminal domain is essential for 
cyclization and that the enzyme did not contain Zn nor any other metals. The cyclization 
domains of class III and IV enzymes also differ in the reactions they catalyze. Whereas the 
only class IV enzyme that has been analyzed thus far generates (methyl)-lanthionines,26 the 
class III enzymes form either (methyl)lanthionines25, 31 or labionins.4, 30 The latter structures 
are believed to be formed by initial attack of a Cys residue onto a dehydroamino acid, resulting 
in an enolate. Instead of protonation of the enolate, which would give a (Me)Lan structure, it 
presumably attacks another dehydroamino acid, resulting in a carbocyclic structure (Figure 
1.1).22 
 
1.4 THE EVOLUTION OF LANTHIPEPTIDE SYNTHETASES  
The high frequency of their occurrence in genomes as well as the emergence of four 
different routes to lanthipeptides likely reflects the ease by which complex polycyclic 
compounds can be generated by two relatively easy chemical reactions, water elimination from 
Ser/Thr and Michael type addition of Cys to dehydroamino acids. Enzymes involved in 
secondary metabolism often have descended from proteins involved in primary metabolism.32 
The current knowledge of the mechanisms and structures of lanthipeptide synthetases, and their 
sequence homology with known proteins, suggests that the modern lanthipeptide synthetases 
may have evolved from stand-alone posttranslational modification proteins. 
For class III and IV this is most obvious, as fusion of protein kinase and pThr lyase 
domains created a dehydratase. Whereas most protein kinases and pThr lyases have evolved to 
be highly specific with respect to their substrates, the respective domains of class III and IV 
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lanthipeptide synthetases appear to have maintained the low substrate specificity of primitive 
progenitors, but they have become dependent on the leader peptides for activation. For class II 
LanM enzymes, it remains to be established whether phosphorylation and elimination occur in 
the same or different active sites. The origin of the class I LanB dehydratases is less clear. 
Presumably, their ancestor was involved in utilization of glutamyl-tRNAGlu, but for what 
purpose is currently not clear.  
It is interesting that whereas the dehydration enzymes apparently have independently 
evolved at least three times, the cyclization domains all have clear sequence homology. The 
closer relation of the four cyclization domains/enzymes is somewhat surprising since Michael-
type addition of Cys residues to dehydroamino acids is a relatively facile process that even 
takes place readily in the absence of any enzyme.33-37 Hence, a priori one might have expected 
greater divergence in the enzymes that catalyze the cyclization reaction. For the Zn-dependent 
enzymes, presumably their ancestor had a different activity involving a Zn2+ and they were 
recruited because they accelerated the Michael addition process and/or they fortuitously 
favored the formation of products with a ring topology that provided an evolutionary beneficial 
activity. Interestingly, the phylogenetic analysis shows that the eukaryotic LanCL proteins are 
closer related to the cyclization domain of class II LanM proteins than the standalone LanC 
enzymes (Figure 1.5). 
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Figure 1.5. A. Cytoscape diagram showing the various cyclase-containing enzymes. In green 
are the class I LanC clade, in red the class II LanM clade, in magenta the class III LanKC 
enzymes, in blue the class IV LanL proteins, and in yellow and turquoise, the mammalian 
LanCL1 and LanCL2 proteins, respectively. B. Bayesian MCMC phylogeny of the class I, II, 
and IV cyclization enzymes as well as the LanCL proteins found in Eukarya. The ProcM-like 
enzymes are found in a separate subclade in the LanM clade.38 Color scheme is the same as in 
panel A. Figure generated by Dr. Qi Zhang. 
 
1.5 LANTHIPEPTIDE PRECURSOR PEPTIDES AND THEIR POSSIBLE 
EVOLUTIONARY HISTORY 
The most challenging task for the lanthipeptide biosynthetic enzymes is control over the 
ring topology of their products. As can be seen from the structures of a small subset of currently 
known lanthipeptides in Figure 1.2, each cyclase enzyme generates a series of rings that all 
have different sequences and sizes. To provide an idea of this challenge, for nisin the 
dehydrated substrate peptide contains five Cys and eight dehydroamino acids (Figure 1.6). 
Thus, the number of isomers differing in ring topology that can be generated by a cyclization 
process lacking any selectivity would be 6720.39 When also considering all of the possible 
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stereoisomers that can be formed, this number would be at least 8.6 × 105. However, NisC 
generates a single product out of all these potential structures. How the cyclization enzymes 
achieve these feats, which would be very challenging for a chemist, is still an open question, 
but some insights have recently started to emerge. One possibility is that the fully dehydrated 
intermediate drawn in Figure 1.6 actually is never formed. For instance, it is possible that the 
dehydratase and cyclase may be alternating in modifying the substrate peptide such that 
cyclization commences well before all dehydrations have taken place.40-42 This scenario would 
decrease the number of electrophiles that each Cys has to distinguish. Indeed, directionality 
has been observed for several lanthipeptide synthetases.30, 40, 41, 43 
 
Figure 1.6. Biosynthesis of nisin A.  
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1.6 THE ROLE OF LANTHIPEPTIDE LEADER PEPTIDES 
For almost all RiPPs, the precursor peptides contain an N-terminal leader peptide in 
addition to the C-terminal core peptide that is processed to the mature compound. There are 
several proposed roles for the leader peptides including guiding the biosynthesis process and 
providing self-immunity of the producing strain. The role most commonly proposed for the 
leader peptides is that of a secretion signal. However, the leader peptides of most RiPPs have 
no homology with the peptides of the typical secretory (Sec) pathways in archaea, the twin-
arginine translocation pathways that are used in bacteria, and protein translocation pathways in 
plants.2 Another frequently postulated role for the leader peptide is that of a recognition motif 
for the post-translational modification (PTM) enzymes in the biosynthesis pathways. From a 
natural product engineering perspective, this function is of great interest as it may allow 
generation of analogs of RiPPs simply by attaching core peptide variants or even very different 
peptides to the leader peptides. A related proposed function for the leader peptide is that of a 
cis-acting chaperone to actively assist the PTM process. Other possible functions for the leader 
peptides include providing assistance in the proper folding of the precursor peptide, stabilizing 
the precursor against degradation, and keeping the peptide inactive during biosynthesis inside 
the host cell. Support for almost all of these roles has been reported, but the function of the 
leader peptide differs for different classes of RiPPs and sometimes even within a certain natural 
product group.  
For class I lanthipeptides, the leader peptides are typically 25 amino acids in length and 
are rich in aspartate residues.2 NMR studies on the fully modified nisin with the leader peptide 
attached showed no interactions between the leader peptide and the nisin molecule in aqueous 
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solution and in micelles.44 Moreover, none of the investigated lanthipeptide leader peptide 
showed any secondary structures in aqueous solution, although they displayed -helical 
conformation in trifluoroethanol,45 and computational analysis based on the amino acid 
sequence predicted helical structures. Together, these observations argue against the hypothesis 
that the leader peptides act as cis-acting chaperone for folding. Leader peptides attached to the 
modified core peptides reduce or abolish the antimicrobial activities, suggesting a role of leader 
peptides in self-immunity of the producing strain. Moreover, the leader peptide of nisin was 
fused to nonlanthipeptide cargo peptides and was successfully processed by the ATP-binding 
cassette (ABC) transporter NisT,46 the dehydratase NisB,47, 48, and the cyclase NisC.19 
Crystallographic studies showed that NisC is made up of an -barrel that contains the active 
site and a separate domain proposed to contain the leader peptide binding site. More directly, 
a co-crystal structure of NisB and NisA provided the first structural insights into the leader 
peptide binding of lanthipeptide synthetases.15 
For class II lanthipeptides, the leader peptides are also typically rich in negatively charged 
aspartate and glutamate residues and usually end in a double glycine (Gly-Gly or Gly-
Ala/Ser/Thr) motif, which is the protease cleavage site.2 Like class I lanthipeptides, the leader 
peptides of class II lanthipeptides also participate in the self-immunity of the host cell by 
keeping the modified compound inactive inside the cell. Interestingly, in vitro studies on 
lacticin 481 have shown that the leader peptide is important for efficient dehydration and 
cyclization catalyzed by LctM, but is not essential.49 Moreover, an LctM enzyme with the LctA 
leader peptide attached through a flexible linker was able to modify linear LctA core peptide 
without leader sequence.50 These observations indicate that the binding of the leader peptide to 
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the enzyme might shift the equilibrium of inactive and active enzyme towards the latter form. 
However, for class II lanthipeptides synthetases, no crystal structures and co-crystal structures 
with the substrate bound have been reported so far. Further structural and mechanistic 
investigation of the functions of lanthipeptide leader peptides will provide deeper 
understanding of the biosynthesis of the lanthipeptides and may improve the opportunities to 
engineer lanthipeptides to tune their activities for specific purposes. Chapter V provides one 
potential strategy, the use of yeast surface display to select for tighter binding leader peptides. 
 
1.7 POTENTIAL APPLICATIONS OF LANTHIPEPTIDE 
BIOENGINEERING 
The increasing appearance of drug resistance of antibiotics makes the discovery of new 
antibiotics an urgent topic.51 As mentioned above, the lantibiotic nisin has been widely used as 
a food preservative for half a century without causing significant drug resistance. Lantibiotics 
have been thought not to be prone to development of resistance because many of them target 
the pyrophosphate group of lipid II, which is not easy to be mutated and some of the lantibiotics 
have a dual mode of action to reduce the chance of generating resistance in host cell.52 Thus, 
the lanthipeptides are great candidates for alternative drugs. Despite the promising 
antimicrobial activities displayed by many lanthipeptides, there are several factors preventing 
their wide therapeutic applications, including potency, stability, and solubility. In the past 
decades, an increased understanding of their biosynthesis pathway has facilitated the 
engineering efforts of lanthipeptides both in vitro and in vivo.3 Besides the widely reported 
antimicrobial activities of lanthipeptides, the extensively cross linked structures makes them 
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one of the structurally most complex group in the RiPP family. The cyclic peptides are of great 
therapeutic interest due to their enhance stability and constrained structures. There are 
increasing studies on engineering cyclic peptide libraries to reach specific goals, including 
obtaining de novo activities.53, 54 Lanthipeptides are potential candidates for the creation of 
cyclic peptide libraries for selection of improved properties as antibiotics as well as new 
activities such as disrupting protein-protein interactions of pharmaceutical interests.  
The early manipulations of lanthipeptides were achieved using the producing strain or 
closely related heterologous hosts. In 2008, a complementation approach was reported 
combining random and site-saturation mutagenesis of nisA generated nisin mutants with a 
variable hinge region between the C and D rings, and several of these mutants demonstrated 
improved activities against pathogenic strains that were tested.55 In 2011, our lab reported the 
production of diverse lanthipeptides including prochlorosins, haloduracin and nisin in 
Escherichia coli (E. coli), which greatly reduced the time and cost required for the production 
of lanthipeptides, significantly increased the yield, simplified the purification process, as well 
as allowed the incorporation of noncanonical amino acids.56 However, there are no reports of 
the engineering of lanthipeptides for de novo functions, and the lanthipeptides family remains 
an under-explored resource for cyclic molecules of therapeutic interests. 
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CHAPTER II: CHIMERIC PEPTIDES WITH PROCA LEADER 
PEPTIDE* 
 
2.1  INTRODUCTION 
Prochlorosins were discovered in 2010 from the planktonic marine cyanobacterium 
Prochlorococcus MIT9313 in a genome-mining effort to search for novel lanthipeptides in the 
unexplored genomes.1 Remarkably, the genome of Prochlorococcus MIT9313 contains only 
one lanM gene encoding ProcM but 30 lanA genes encoding precursor peptides.1, 2 The ProcA 
peptides have a high level of conservation in the N-terminal leader region and hypervariability 
in the C-terminal core region (Figure 2.1). The activity of ProcM has been confirmed for all 18 
precursor peptides investigated thus far.1-3 Giving the high degree of sequence conservation in 
the leader peptides, it is very likely that all 30 ProcAs are substrates of ProcM. In contrast, 
most LanM enzymes that have been investigated have only a single substrate.4 The molecular 
details that allow this high substrate tolerance are largely unknown.  
 
 
________________________ 
Reproduced in part with permission from Yu, Y., Zhang, Q., and van der Donk, W. A. 
(2013) Insights into the evolution of lanthipeptide biosynthesis, Protein Sci. 22, 1478-1489, 
Zhang, Q., Yu, Y., Velásquez, J. E., and van der Donk, W. A. (2012) Evolution of lanthipeptide 
synthetases, Proc. Natl. Acad. Sci. U. S. A. 109, 18361-18366, and Yu, Y., Mukherjee, S., and 
van der Donk, W. A. (2015) Product Formation by the Promiscuous Lanthipeptide Synthetase 
ProcM is under Kinetic Control, 137, 5140-5148. 
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Figure 2.1. Sequence alignment of 30 ProcAs. The strictly conserved regions in the leader 
peptide are labeled in blue and other partially conserved regions in the leader peptide are 
labeled in green. Cysteines residues in the core peptide are labeled in red, serines and threonines 
are labeled in purple.  
 
Discovery of this extraordinarily catalytic promiscuity of ProcM brought up the prospect 
of producing a variety of lanthipeptides utilizing the unique synthetase ProcM. Previous 
attempts in our lab to utilize the promiscuous catalytic activity of ProcM included constructing 
a fusion protein of ProcM with the ProcA leader peptide attached to it. This fusion protein was 
envisioned to catalyze the dehydration and cyclization of diverse peptides containing Ser, Thr, 
and Cys residues. This hypothesis was based on a previous study in our lab carried out by Dr. 
Oman, in which LctM fused with the LctA leader peptide catalyzed the modification of the 
LctA core peptide without its leader peptide attached to it.5 But the fusion enzyme of ProcM 
did not exhibit similar activity. Thus, in this study, another approach was used, which involves 
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constructing chimeric peptides with a ProcA leader peptide attached to the target lanthipeptide 
core peptide. 
 
In this chapter, efforts were made to use ProcM to synthesize nisin, a class I lanthipeptide 
of great commercial value,7 epilancin 15X,8 an effective antimicrobial peptide which also 
belongs to class I lanthipeptides, and lacticin 481,9 a class II lanthipeptide originated from 
Lactococcus lactis. Nisin was the first member of the lanthipeptides to be characterized.10 It is 
a highly effective antimicrobial peptide with a MIC value in the nanomolar range against a 
broad range of gram-positive bacteria. It has been widely used as a food preservative for half a 
century, but has not been reported to cause significant resistance in bacteria. The biosynthesis 
of nisin involves the dehydration of Ser/Thr residues catalyzed by the dehydratase NisB and 
formation of five thioether rings by the cyclase NisC (Figure 1.6 and Figure 2.2). Commercially, 
it is obtained by fermentation using its original producing strain L. lactis.11 Epilancin 15X is a 
recently discovered lanthipeptide, which has impressive antibacterial activity against 
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci 
(VRE).8 Besides the three thioether rings, it contains an unusual N-terminal (R)-2-
hydroxypropionyl group (Lactate, Lac) (Figure 2.2). The Lac group potentially contributes to 
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the bioactivity of the lanthipeptide, but epilancin 15X without the N-terminal modification is 
also active against L. lactis HP.8, 12, 13 Lacticin 481 (Figure 2.2) is a class II lanthipeptide 
produced by several strains of L. lactis, which has been suggested to display antimicrobial 
activities against gram-positive bacteria through the interaction with the membrane component 
lipid II.14 
 
 
Figure 2.2. Structures of epilancin 15X, nisin and lacticin 481. Lan/MeLan segments derived 
from Cys are shown in red and originating from Ser/Thr are shown in blue. Additional 
posttranslational modifications are shown in orange. Dehydroamino acids are shown in green. 
 
There have been extensive studies of utilizing the substrate-tolerance of lanthionine 
synthetases to produce lanthipeptide analogs or generate thioether crosslinks in 
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nonlanthipeptide targets.15-18 Site-directed mutants of various lanthipeptide precursor peptides 
are recognized and successfully processed by the biosynthetic machinery in in vitro enzymatic 
assays as well as in vivo experiments with homologous and heterologous hosts, resulting in 
lanthipeptide variants.15, 19-22 Two most extensive examples for the in vivo studies are complete 
alanine scanning of both peptides of the two-component lanthipeptide lacticin 314723 and the 
investigation of all possible single amino acid mutations for mersacidin.24 Several of these in 
vivo studies have resulted in compounds with improved properties.25, 26 In vitro studies have 
also demonstrated that core peptides containing nonproteinogenic amino acids can be modified 
to lantibiotic analogs with improved antimicrobial activities.27 ProcM is the lanthionine 
synthetase identified thus far with the most diverse native substrate set. In this study, attempts 
were made to utilize ProcM for the production of both class I and class II lanthipeptides and 
expanding the possibility of a simplified route for lanthipeptide engineering. 
 
2.2  RESULTS 
2.2.1 The chimeric peptide strategy to utilize ProcM to synthesize other lanthipeptides 
The leader peptides of the 30 ProcA precursor peptides are highly conserved, but the core 
peptides are hypervariable in terms of peptide length, amino acid composition, and positions 
of ring forming residues (Figure 2.1). Thus, it is reasonable to propose that the leader peptide 
is the crucial element for substrate-enzyme recognition while the core peptide is most likely to 
have little or no effect on the substrate-enzyme binding process. Chimeric peptides composed 
of one ProcA leader peptide (ProcA3.2 leader was used in this study) and the core peptide of 
the target lanthipeptides (NisA, ElxA and LctA core peptides were used in this study) were 
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constructed. It was envisioned that ProcM would likely accept these chimeric peptides as 
substrates and install thioether crosslinks in the core region. Engineering a hinge region 
incorporating recognition sites for endoproteases would enable the removal of the leader 
peptide after these modifications. If the native ring topologies of the target lanthipeptides are 
maintained by ProcM, bioactive products are proposed to be generated using this highly 
simplified and efficient method (Figure 2.3).  
The construction of pET15b-ProcALea_NisAStr, pET15b-ProcALea_ElxAStr and 
pET15b-ProcALea_LctAStr was done by overlapping PCR (section 2.4.2). The procM gene 
was cloned into the MCS1 of pRSF-Duet1 vector to increase the yield of ProcM using 
procedures described in section 2.4.3. The peptide and protein overexpression and purification 
processes are described in section 2.4.5 and 2.4.6. In vitro enzymatic assays and digestion of 
the chimeric peptides were carried out as described in section 2.4.7. Samples were desalted 
using Zip-Tip, and analyzed by Matrix-Assisted Laser Desorption Ionization-Time-of-Flight 
(MALDI-TOF) mass spectrometry (MS). The cyclization of the peptides was evaluated using 
an iodoacetamide (IAA) assay described in section 2.4.8. 
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Figure 2.3. The chimeric peptide strategy utilizing ProcM to generate Lan/MeLan containing 
peptides. 
 
2.2.2 Chimeric peptide with ProcA leader peptide and NisA core peptide 
Incubation of the chimeric peptide composed of the ProcA3.2 leader peptide and NisA 
core peptide (ProcALea-NisAStr) with ProcM under the conditions listed in section 2.4.7 
resulted in up to five-fold dehydration. During nisin biosynthesis, eight dehydrations and five 
cyclizations take place (Figure 1.6). To improve the extent of modifications, 
ProcALea_NisAStr peptide was also co-expressed with ProcM in E. coli. The in vivo co-
expression resulted in up to 6-fold dehydration in the NisA core peptide (Figure 2.4). Using 
iodoacetamide (IAA) assay to probe for unreacted cysteines, it was shown that 3~4 rings were 
formed as the majority of the products reacted with either one or two molecules of IAA (Figure 
2.5). As not all the five rings in nisin have known function in bioactivity, there was a possibility 
that the final product of the in vivo co-expression was still bioactive even though several Ser 
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or Thr residues were not dehydrated and one or two rings were not formed. In order to find out 
whether this situation was true, a protease cleavage site was introduced in the chimeric peptide 
to remove the leader peptide, which is known to keep the lantibiotics inactive.28 But the mutated 
chimeric peptide ProcALea-NisAStr G−1K was not as good a substrate as the original chimeric 
peptide, with a series of one to five dehydrations observed under the same assay conditions. It 
is possible that the double-glycine motif might be important to guide the enzymatic 
modification.  
 
Figure 2.4. MALDI-TOF mass spectra of the ProcALea-NisAStr chimeric peptide modified 
by ProcM in E. coli and treated with GluC to remove most of the leader peptide (black line), 
and unmodified ProcALea-NisAStr chimeric peptide treated under the same conditions (red 
line). Calculated and observed masses are shown in Table 2.4. 
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Figure 2.5. MALDI-TOF mass spectra of the ProcALea-NisAStr chimeric peptide modified 
by ProcM in E. coli, followed by subsequent digestion by GluC and treatment with IAA (black 
line), and unmodified ProcALea-NisAStr chimeric peptide treated under the same conditions 
(red line). Peaks labeled with the star symbol correspond to incomplete digestion when the 
glutamate at the -6 position in ProcA3.2 leader peptide skipped GluC digestion. Calculated and 
observed masses are shown in Table 2.4. 
 
Therefore one more mutant, ProcALea-K-NisAStr, was made. In this mutant, a lysine 
residue was inserted after the double-Gly motif. ProcM also catalyzed up to 6 dehydrations and 
3~4 cyclizations on this mutant in vivo (Figure 2.6 and Figure 2.7). The modified core peptide 
was protected from trypsin digestion, while the unmodified core peptide was not (Figure 2.8). 
The resulting core-containing peptides were tested for bioactivity, but no antimicrobial activity 
was observed against L. lactis HP even at 1.25 mM concentration (Figure 2.9). 
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Figure 2.6. MALDI-TOF mass spectra of the ProcALea-K-NisAStr chimeric peptide modified 
by ProcM in E. coli and treated with GluC to remove most of the leader peptide (black line), 
and unmodified ProcALea-K-NisAStr chimeric peptide treated under the same conditions (red 
line). Calculated and observed masses are shown in Table 2.4. 
 
Figure 2.7. MALDI-TOF mass spectra of the ProcALea-K-NisAStr chimeric peptide modified 
by ProcM in E. coli, followed by subsequent digestion by GluC and treatment with IAA (black 
line), and unmodified ProcA Lea-K-NisAStr chimeric peptide treated under the same 
conditions (red line). Calculated and observed masses are shown in Table 2.4. 
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Figure 2.8. MALDI-TOF mass spectra of the ProcALea-K-NisAStr chimeric peptide modified 
by ProcM in E. coli and treated with trypsin to remove the leader peptide (black line), and 
unmodified ProcALea-K-NisAStr chimeric peptide treated under the same conditions (red line).
Calculated and observed masses are shown in Table 2.4.
 
Figure 2.9. Antimicrobial assays against L. lactis HP. An aliquot of 5 L of the following 
samples were spotted: (1) 125 M ProcALea-K-NisAStr chimeric peptide modified by ProcM 
in E. coli and digested by trypsin; (2) 125 M unmodified ProcALea-K-NisAStr chimeric 
peptide digested by trypsin; (3) 1.25 mM ProcALea-K-NisAStr chimeric peptide modified by 
ProcM in E. coli and digested by trypsin; (4) 1.25 mM unmodified ProcALea-K-NisAStr 
chimeric peptide digested by trypsin; (5) negative control with buffer for protease digestion; 
(6-8) 10, 1, and 0.1 M authentic nisin. 
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2.2.3 Chimeric peptide with ProcA leader peptide and ElxA core peptide 
As no mature nisin was produced using the chimeric peptide strategy, I looked at other 
candidates. The in vitro enzymatic assays of ProcM and its native substrates resulted in a 
maximum of five-fold dehydration in the ProcAs studied.1 Analysis of the length of the core 
regions of the ProcAs and the numbers of maximum dehydrations that could occur suggested 
that most ProcM substrates were short and relatively simple. Therefore, we selected epilancin 
15X, which is a lantibiotic of great potential application. It has only three non-overlapping 
rings although eight dehydrations occurred during its biosynthesis (Figure 2.2). However, both 
in vivo and in vitro modifications of ProcALea-E-ElxAStr (a glutamate residue was inserted 
between the ProcA3.2 leader peptide and ElxA core peptide) resulted in a similar MALDI-TOF 
mass spectrum, with the maximum number of dehydrations being five and the majority of the 
peptide dehydrated only four-fold (Figure 2.10). By subjecting the product to an IAA assay, it 
was shown that 2~3 rings were formed (Figure 2.11). However, the bioactivity assay using 
L.lactis HP as indicator strain resulted in no zone of growth inhibition even at 1.25 mM 
concentration, which suggested that epilancin 15X without the Lac group was not generated 
either due to incomplete cyclization or incorrect ring formation (Figure 2.12).  
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Figure 2.10. MALDI-TOF mass spectra of the ProcALea-E-ElxAStr chimeric peptide 
modified by ProcM in E. coli and treated with GluC to remove the leader peptide (black line), 
and unmodified ProcALea-E-ElxAStr chimeric peptide treated under the same conditions (red 
line). Calculated and observed masses are shown in Table 2.4.
Figure 2.11. MALDI-TOF mass spectra of the ProcALea-E-ElxAStr chimeric peptide 
modified by ProcM in E. coli, followed by subsequent digestion by GluC and treatment with 
IAA (blank line), and unmodified ProcALea-E-ElxAStr chimeric peptide treated under the 
same conditions (red line). Calculated and observed masses are shown in Table 2.4. 
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Figure 2.12. Antimicrobial assays against L. lactis HP. An aliquot of 5 L of the following 
samples were spotted: (1) 125 M ProcALea-E-ElxAStr chimeric peptide modified by ProcM 
in E. coli and digested by GluC; (2) 500 M unmodified ProcALea-E-ElxAStr chimeric peptide 
digested by GluC; (3) 1.25 mM ProcALea-E-ElxAStr chimeric peptide modified by ProcM in 
E. coli and digested by GluC; (4) 1.25 munmodified ProcALea-E-ElxAStr chimeric peptide 
digested by trypsin; (5) negative control with buffer for protease digestion; (6-8) 10, 1, and 0.1 
M authentic nisin. 
 
2.2.4 Chimeric peptide with ProcA leader peptide and LctA core peptide 
The two class I lanthipeptide I selected in this study both require eight-fold dehydration in 
the core region to generate mature peptides, however, ProcM only showed a maximum of five-
fold dehydration on its native substrates.1 Therefore, the next candidate I studied was the class 
II lanthipeptide lacticin 481, which only requires four dehydrations and three cyclizations. A 
variety of other lantibiotics contain a similar ring topology as lacticin 481, which is often 
referred to as the lacticin 481 group.29 The same strategy could easily be expanded for the 
production and engineering of these lanthipeptides. 
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Figure 2.13. MALDI-TOF mass spectra of the ProcALea-LctAStr chimeric peptide modified 
by ProcM in E. coli, followed by subsequent digestion by LysC and treatment with IAA (black 
line), and unmodified ProcALea-LctAStr chimeric peptide treated under the same conditions 
(red line). Calculated and observed masses are shown in Table 2.4. 
 
The in vivo modifications of ProcALea-LctAStr resulted in up to five dehydrations in the 
core peptide with the majority of the peptide dehydrated three-fold (Figure 2.13).  As the wild-
type lacticin 481 was dehydrated four times, it is likely that Ser4 residue, which usually skips 
dehydration, was also modified. IAA assay demonstrated that 2~3 rings were formed (Figure 
2.14). The tandem MS data suggested for some of the products, the large overlapping ring was 
not formed (Figure 2.15). Interestingly, the bioactivity assay using the in vivo modified 
ProcALea-LctAStr digested with trypsin produced a clear zone of inhibition, which suggests 
the generation of wild-type lacticin 481 (Figure 2.16). On the other hand, the in vitro 
modification of ProcALea-LctAStr did not result in any bioactive product, which is consistent 
with the observation of higher modification efficiency in the in vivo assay than in vitro 
experiments. 
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Figure 2.14. MALDI-TOF mass spectra of the ProcALea-LctAStr chimeric peptide modified 
by ProcM in E. coli, followed by subsequent digestion by LysC and treatment with IAA (black 
line), and unmodified ProcALea-LctAStr chimeric peptide treated under the same conditions 
(red line). Calculated and observed masses are shown in Table 2.4. 
 
 
  
Figure 2.15. ESI-MSMS of the 4-fold dehydrated species of the ProcALea-LctAStr chimeric 
peptide modified by ProcM in E. coli, digested by trypsin and purified with analytical HPLC 
using a C18 column. The residues connected with dashed lines are potentially connected by a 
thioether crosslink.  
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Figure 2.16. Antimicrobial assays against L. lactis HP. An aliquot of 5 L of the following 
samples were spotted: (1) 250 ProcALea-LctAStr chimeric peptide modified by ProcM in 
E. coli and digested by trypsin ; (2) 250  unmodified ProcALea-LctAStr chimeric peptide 
digested by trypsin; (3) 250  ProcALea-LctAStr chimeric peptide modified by ProcM in 
vitro and digested by trypsin; (4) in vitro enzymatic assay mixture without ProcM enzyme and 
digested by trypsin.; (5) 10  authentic lacticin 481; (6) blank; (7) 10  LctA modified by 
LctM in vitro and digested by trypsin; (8) blank. Treatment with trypsin generated 1-lacticin 
lacking the N-terminal Lys residue. Previous studies have shown that 1-lacticin is about 3-
fold less active than authentic lacticin 481.27 
 
2.3  DISCUSSION AND OUTLOOK 
In this study, it is demonstrated that the highly promiscuous class II lanthionine synthetase 
ProcM was able to install thioether crosslinks in the core region of both class I and class II 
lanthipeptides that are attached to a ProcA leader peptide. In the case of two relatively long 
class I lanthipeptides, which require eight dehydrations for maturation, ProcM showed limited 
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capability to modify these core peptides to full extent. On the other hand, in the case of 
ProcALea-LctAStr, the in vivo modifications of ProcM in E. coli resulted in the successful 
generation of bioactive lacticin 481, which could be potentially applied to the production of 
relatively short lanthipeptides with a small number of rings. Moreover, this study provides 
insights on the evolutionary story of lanthionine synthetases and substrates. 
The availability of the rapidly growing number of bacterial genomes is starting to provide 
the first insights into the possible mechanisms by which lanthipeptide biosynthesis may have 
evolved. Most of the “modern” lanthipeptide synthetases are highly evolved and make single 
polycyclic products that are the result of a remarkably well-orchestrated set of reactions. The 
discovery of class III and IV lanthipeptide synthetases (chapter I) suggests that the biosynthetic 
machinery may have evolved from stand-alone kinases, phosphoThr/phosphoSer lyases, and 
Zn2+-dependent enzymes with a very common-toroidal core structure. The low sequence 
specificity of primitive progenitor enzymes appears to have been maintained with respect to 
the phosphorylation and elimination reactions, but an allosteric regulation mechanism that 
depends on a leader peptide has evolved that assures that the dehydratases do not non-
specifically act on any nascent polypeptide produced by the ribosome. The evolutionary origin 
of class I and II dehydratase machinery is less clear, but both involve activation of the Ser and 
Thr side chains, and presumably they have evolved from other enzymes that utilized 
nucleotides and Glu-tRNA. LanM enzymes from various phyla that like ProcM have three 
cysteines ligated to the active site zinc ion (as opposed to the more common Cys-Cys-His 
ligand set) cluster together in a phylogenetic tree.4, 13 Most importantly, the phylogenic data 
suggest that for some scaffolds, the ring topology of the final lanthipeptides may be determined 
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in part by the sequence of the precursor peptides and not just by the biosynthetic enzymes. This 
notion was supported by the studies in this chapter with chimeric peptides, suggesting that 
prochlorosin biosynthetic enzymes can produce the correct ring topology of lacticin 481. These 
results highlight the potential of lanthipeptide synthetases for bioengineering and combinatorial 
biosynthesis.  
The evolution of the precursor peptides and hence the structure of the final products is 
complex. For some systems, the progenitors of the precursor peptides can be inferred from the 
sequences of their leader peptides, with a group of class II peptides in cyanobacteria having 
descended from nitrogen-fixing proteins.30 But for the majority of lanthipeptide precursor 
peptides, their origins are unclear. Intriguing potential insights into the evolution of the 
posttranslational modification process that turns a linear peptide into a highly structured 
product that recognizes its target with exquisite selectivity31, 32 is provided by a subgroup of 
class II lanthipeptides in cyanobacteria that includes the prochlorosins.1 The observation of a 
large number of precursor peptides with highly conserved leader peptides but highly diverse 
core peptides that are converted into a library of products by one synthetase suggests that this 
may be a snap-shot of a system under evolution featuring a non-specific synthetase that can act 
on a large number of core peptide sequences. Some support has been obtained that the topology 
and stereochemistry generated by such a synthetase may be determined at least in part by 
inherent conformational preferences of the core peptide sequence, perhaps reinforced by 
interaction of the core peptide with the molecular surface of the synthetase. During evolution, 
such ancestral synthetases would have evolved to more specific enzymes when they made 
products that were beneficial to the organism, ultimately resulting in proteins that make one 
43 
 
product very efficiently. Many questions still remain for this model including how a non-
specific synthetase is maintained, whether such a synthetase is primitive or has evolved to have 
low substrate specificity, and how the biosynthetic enzymes interact with their leader and core 
peptides. Future studies will hopefully provide answers to these questions. The intriguing 
questions as to how these enzymes can tolerate so many different substrates is addressed in 
chapter III. 
 
2.4  EXPERIMENTAL PROCEDURES 
2.4.1 Materials 
All oligonucleotides were purchased from Integrated DNA Technologies and used as received. 
Restriction endonucleases, DNA polymerases and T4 DNA ligase were from New England 
Biolabs. Media components were obtained from Difco laboratories. E. coli DH5α cells were 
used as host for cloning and plasmid propagation, and E. coli BL21 (DE3) or E. coli Rosetta 2 
(DE3) cells were used as host for expression. Endoproteases were ordered from Roche 
Biosciences or New England Biolabs. Unless specified otherwise, chemicals were purchased 
from Sigma Aldrich or Fisher Scientific. 
2.4.2 Construction of the expression plasmids for chimeric peptides 
The plasmids pET15b-procA3.2, pET15b-procA3.31 pET15b-lctA,4 and pET15b-nisA33 were 
isolated from E. coli DH5α cells and used as templates for PCR reactions. The elxA gene was 
amplified from the genomic DNA of the producing strain Staphylococcus epidermidis 15X154. 
The DNA sequence for each chimeric peptide was amplified using overlapping PCR. In the 
first round PCR, the DNA sequence for leader peptide and core peptide were amplified 
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individually using one end primer containing the restriction site and one connection primer 
containing the C-terminal sequence of the leader and the N-terminal sequence of core peptide 
(Table 2.1). The PCR reactions were carried out using Phusion polymerase and 30 cycles of 
denaturing (94 °C for 30 s), annealing (55 °C for 30 s), and extending (72 °C, 1 min for each 
1.5 kb). The second round PCR was carried out using DNA purified from the first round PCR 
without any primers for 7 cycles to anneal the leader and core fragments, and with two end 
primers containing restriction sites for an additional 23 cycles to amplify the gene for the 
chimer peptide. The final PCR products were digested with NdeI and XhoI restriction enzymes 
and ligated into the pET15b vector to generate the constructs listed in Table 2.1. The sequences 
of the inserts were checked by DNA sequencing.  
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Table 2.1. Primers used in section 2.4.2. 
Construct Primer Name Primer Sequences (5’-3’) 
pET15b-procALea-
nisAStr  
(Template: 
pET15b-procA3.2, 
pET15b-nisA) 
Forward-1: 
procA3.2_NdeI_FP  
TCAGATCATATGATGTCAGAAG
AACAACTC 
 
Reverse-1: 
procA3.2Lea_nisAStr_
Conn_RP 
CATAGCGAAATACTTGTAATTC
CCCCAGCCACACCTTC 
 
Forward-2: 
procA3.2Lea_nisAStr 
_Conn_FP 
GAAGGTGTGGCTGGGGGAATT
ACAAGTATTTCGCTATG 
Reverse-2: 
nisA_XhoI_RP  
ACAGACGACTCGAGTTATTTGC
TTACGTGAATACTACAATGACA
AG 
pET15b-procALea-
K-nisAStr  
(Template: 
pET15b-procA3.2, 
pET15b-nisA) 
Forward-1: 
procA3.2_NdeI_FP  
TCAGATCATATGATGTCAGAAG
AACAACTC 
 
Reverse-1: 
procA3.2Lea_K_ 
nisAStr_Conn_RP 
CGAAATACTTGTAATTTTTCCC
CCAGCCACACCTTC 
Forward-2: 
procA3.2Lea_K_ 
nisAStr _Conn_FP 
GAAGGTGTGGCTGGGGGAAAA
ATTACAAGTATTTCG 
 
Reverse-2: 
nisA_XhoI_RP  
ACAGACGACTCGAGTTATTTGC
TTACGTGAATACTACAATGACA
AG 
pET15b-procALea-
E-ElxA 
(Template: 
pET15b-procA3.2, 
genomic DNA 
from 
Staphylococcus 
epidermidis  
15X154) 
Forward-1: 
procA3.2_NdeI_FP  
TCAGATCATATGATGTCAGAAG
AACAACTC 
 
Reverse-1: 
procA3.2Lea_E_ 
ElxAStr_Conn_RP 
AACAATACTAGCTGATTCTCCC
CCAGCCACACC 
 
Forward-2: 
procA3.2Lea_E_ 
ElxAStr_Conn_FP 
GGTGTGGCTGGGGGAGAATCA
GCTAGTATTGTT  
Reverse-2: 
ElxA_XhoI_RP  
 
GCCTCGAGTTATTTTTTACCAG
TAAAGTG 
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(Table 2.1 continued) 
pET15b-procALea-
lctAStr  
(Template: 
pET15b-procA3.2, 
pET15b-lctA) 
Forward-1: 
procA3.2_NdeI_FP  
TCAGATCATATGATGTCAGAAG
AACAACTC 
 
Reverse-1: 
procA3.2Lea_lctAStr 
_Conn_RP 
CTCCACTGCCGCCTTTTCCCCC
AGCCACACC 
Forward-2: 
procA3.2Lea_lctAStr 
_Conn_FP 
GGTGTGGCTGGGGGAAAAGGC
GGCAGTGGAG 
Reverse-2: 
lctA_XhoI_RP  
 
TCAGATCTCGAGTTAAGAGCA
GCAAGTAAATAC 
 
2.4.3 Construction of pRSF-Duet1-procM 
The plasmid pET28b-procM was isolated from E. coli DH5α cells.1 The procM gene was PCR 
amplified using Phusion polymerase by 30 cycles of denaturing (94 °C for 30 s), annealing 
(55 °C for 30 s), and extending (72 °C for 2 min) using procM_Duet1_EcoRI_FP as forward 
primer, procM_Duet1_NotI_RP as reverse primer (Table 2.2), and pET28b-procM as template. 
The PCR product was digested with EcoRI and NotI restriction enzymes and ligated into the 
first multiple cloning site (MCS1) in the pRSF-Duet1 vector to generate the construct pRSF-
Duet1-procM (MCS1). The sequence of the procM insert was checked by DNA sequencing.  
Table 2.2. Primers used in section 2.4.3. 
Primer Name Primer Sequences (5’-3’) 
procM _EcoRI_FP CAGGATCCGAATTCGATGGAAAGTCCATCATCTTG
G 
procM _NotI_RP AAGGAAAAAAGCGGCCGCTTATTCAGTAGGCCAG
AGA 
 
47 
 
2.4.4 Construction of the co-expression plasmids for chimeric peptides and ProcM  
The procM gene was amplified by PCR in 30 cycles of denaturing (98 °C for 30 s), annealing 
(55 °C for 30 s), and extending (72 °C, 1 min for each 1.5 kb) using the plasmid pRSF-Duet1-
procM as templates and using procM_Duet1_NdeI_FP as forward primer and 
procM_Duet1_KpnI_RP as reverse primer (Table 2.3). The PCR products were digested with 
NdeI and KpnI restriction enzymes and ligated into the second multiple cloning site (MCS2) 
in the pRSF-Duet1 vector to generate the construct pRSF-Duet1-procM (MCS2). The 
sequences of the resulting products were confirmed by DNA sequencing. 
Chimeric genes were amplified by PCR using 30 cycles of denaturing (98 °C for 10 s), 
annealing (55 °C for 30 s), and extending (72 °C for 15 s) using the primers listed in Table 2.3 
and the constructs generated in section 2.4.2 as templates. The resulting DNA inserts and the 
pRSF-Duet1 vector containing procM in MCS2 were digested with EcoRI and NotI and ligated. 
The sequences of the resulting products were confirmed by DNA sequencing.  
Table 2.3. Primers used in section 2.4.4. 
Primer Name Primer sequence (5’-3’) 
procM_Duet1_NdeI_FP GGTTGGTTCATATGGAAAGTCCATCATCTTGG 
procM_Duet1_KpnI_RP AAGTAGTTGGTACCTTATTCAGTAGGCCAGAGAC 
procA3.2_EcoRI_FP CAGGATCCGAATTCGATGTCAGAAGAACAACTCAAGG 
nisA_NotI_RP AAGGAAAAAAGCGGCCGCTTATTTGCTTACGTGAAT 
elxA_NotI_RP AAGGAAAAAAGCGGCCGCTTATTTTTTACCAGTAAAGT 
lctA_NotI_RP GGAAAAAAGCGGCCGCTTAAGAGCAGCAAGTA 
 
2.4.5 Expression and purification of unmodified and modified peptides 
E. coli BL21 (DE3) cells were transformed with pRSF-Duet1 constructs containing peptide 
and enzyme genes or pET15b constructs containing only the peptide gene via electroporation. 
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A single colony transformant was used to inoculate 20 mL of LB medium supplemented with 
50 μg/mL kanamycin (pRSF-Duet1 constructs) or 100 μg/mL amplicilin (pET15b constructs). 
The culture was grown at 37 °C for 12 h and was used to inoculate 1 L of LB medium containing 
50 μg/mL kanamycin or 100 μg/mL ampicillin and the cells were grown at 37 °C to OD600 ≈ 
0.6. For the pRSF-Duet1 constructs, the culture was incubated at 4 °C on ice for 20 min, then 
IPTG was added to a final concentration of 0.5 mM, and the culture was incubated at 18 °C 
with shaking for an additional 16-20 h. For the pET15b constructs, IPTG was added to a final 
concentration of 1 mM and the culture was incubated at 37 °C with shaking for an additional 3 
h. Cells were harvested by centrifugation at 12,000×g for 15 min at 4 °C, and the pellet was 
resuspended in 30 mL of LanA buffer A containing 6 M guanidine hydrochloride, 20 mM 
NaH2PO4, pH 7.5, 500 mM NaCl, and 0.5 mM imidazole. Cells were then lysed by sonication 
(5 min, 35% amplitude, 4.0 s ON, 9.9 s OFF) and the soluble and insoluble layers were 
separated by centrifugation at 23,700×g for 30 min at 4 °C. The unmodified peptides produced 
from pET15b constructs were found in the insoluble fraction, and the modified peptides 
produced by the pRSF-Duet1 co-expression constructs were mostly found in the soluble 
fraction. For the purification of unmodified peptides, the pellets were treated once more with 
LanA buffer A to remove any soluble proteins from the pellet. The pellet from the second wash 
was resuspended in 20 mL of LanA buffer B (6 M guanidine hydrochloride, 20 mM NaH2PO4, 
500 mM NaCl, 0.5 mM imidazole, pH 7.5). The insoluble portion was removed by 
centrifugation and the supernatant was clarified through 0.45 μm syringe filters prior to nickel 
affinity chromatography. For purification of modified peptides, the supernatant from the first 
sonication was directly filtered with 0.45 μm syringe filters. The resulting peptide solutions 
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were loaded onto a HisTrap nickel affinity column (GE healthcare), then the resin was washed 
with 2 column volumes (CV) each of LanA Buffer B and LanA Buffer C (4 M guanidine 
hydrochloride, 20 mM NaH2PO4, 300 mM NaCl, 30 mM imidazole, pH 7.5). The desired LanA 
peptide was eluted using 1–3 CV of LanA Buffer D (4 M guanidine hydrochloride, 20 mM Tris, 
100 mM NaCl, 1 M imidazole, pH 7.5). Imidazole removal from the His6-LanA peptides was 
achieved by preparative RP-HPLC using a Waters Delta-pak C4 column. Collected fractions 
were lyophilized and analyzed by MALDI-TOF MS.  
2.4.6 Expression and purification of LanM enzymes 
E. coli BL21 (DE3) or E. coli Rosetta 2 (DE3) cells were transformed via electroporation with 
pRSF-Duet1 or pET28b constructs containing the enzyme genes. A single colony transformant 
was used to inoculate a 50 mL of LB medium supplemented with 50 μg/mL kanamycin. The 
culture was grown at 37 °C for 12 h and was used to inoculate 4 L of LB medium containing 
50 μg/mL kanamycin. Cells were grown at 37 °C to OD600≈ 0.6. The culture was incubated on 
ice for 20 min, then IPTG was added to a final concentration of 0.5 mM, and the culture was 
incubated at 18 °C for an additional 16-20 h. Cells were harvested by centrifugation at 
12,000×g for 15 min at 4 °C, and the pellets were frozen in liquid nitrogen and stored at −80 °C. 
All protein purification steps were performed at 4 °C. The cell pellets were suspended in LanM 
buffer A (20 mM Tris, 1 M NaCl, pH 8.0), and the cells were lysed using a high pressure 
homogenizer (Avestin, Inc.). Cell debris was pelleted via centrifugation at 23,700×g for 40 min 
at 4 °C. The supernatant was filtered using 0.45 μm syringe filters and injected onto an ÄKTA 
fast protein liquid chromatography (FPLC) system (GE Healthcare Life Sciences) equipped 
with a 5 mL HisTrap HP IMAC column previously charged with Ni2+ and equilibrated in start 
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buffer. The column was washed with 50 mL of start buffer and the protein was eluted using a 
gradient of 0-100% LanM buffer B (200 mM imidazole, 20 mM Tris, pH 8.0, 1 M NaCl) at a 
flow rate of 1.5 mL/min. UV absorbance at 280 nm was monitored and fractions were collected 
and analyzed by SDS-PAGE (4-20% Tris-glycine READY gel, BioRAD). The fractions 
containing ProcM or ProcM mutant proteins were combined and concentrated using an Amicon 
Ultra-15 Centrifugal Filter Unit (30, 50 or 100 kDa MWCO, Millipore). The concentrated 
protein sample was injected onto an ÄKTA FPLC system equipped with an XK16 16/60 
column (GE Healthcare Life Sciences) packed with SuperDex 200 resin previously equilibrated 
in buffer A. The protein was eluted at a flow rate of 1 mL/min. UV absorbance at 280 nm was 
monitored and fractions were collected. Misfolded or aggregated protein was efficiently 
separated from soluble, correctly folded protein. The desired fractions were combined and 
concentrated using an Amicon Ultra-15 Centrifugal Filter Unit. Protein concentration was 
determined using a Bradford Assay Kit (Pierce) and A280nm. Typical yields were 5~20 mg per 
liter of cell culture. The resulting samples were frozen and stored at −80 °C. 
2.4.7 In vitro enzymatic assay and endoprotease digestion 
The lyophilized peptides were dissolved in ddH2O, and added to 100 μL of enzymatic assay 
solution. The final peptide and enzyme concentration varied because of different peptide 
solubility and reaction rates. The in vitro enzymatic assay included: 10 mM ATP, 1 mM TCEP, 
50 mM HEPES (pH 8.0), 10 mM MgCl2 and various amounts of peptide and enzyme. The 
reactions were incubated at room temperature for the time indicated in the figure legends and 
then quenched using 1% formic acid (final concentration). The pH was then adjusted to the 
optimal pH for the indicated endoprotease using 2.5 M NaOH. An aliquot of 2 μL of 
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endoprotease (LysC 6 U/L, GluC 1 mg/mL, trypsin 1 mg/mL, AspN 1 mg/mL) was added to 
the solution and incubated for 1~3 h at room temperature or 37 °C. The resulting mixtures were 
desalted by ZipTip (Millipore) and analyzed by MALDI-TOF MS using an UltrafleXtreme 
instrument (Bruker).  
2.4.8 Bioactivity assay  
The growth inhibition activity of peptide sample was determined against Lactococcus lactis 
HP. A 25 mL aliquot of liquid molten GM17 agar (4% M17, 0.5% glucose, 1.5% agar) was 
cooled to 42 °C and seeded with 200 μL of overnight culture (OD600=1) of the indicator strain 
L. lactis HP. After agar solidification in a Petri dish, peptide samples were added to the plate 
and dried near open flame for 1 hour. Plates were incubated for 15 h at 30°C and antibacterial 
activity was qualitatively determined by the presence or absence of a zone of growth inhibition. 
2.4.9 Iodoacetamide assay (IAA assay)  
An aliquot of 20 μL of the enzymatic reaction solution or untreated control peptide was 
incubated with 2 μL of 500 mM IAA, 1 μL of 50 mM TCEP, and 27 μL of 100 mM Tris-HCl 
(pH 8.9) at room temperature for 3 h. Protease was added to the mix and the sample was 
incubated for an additional 1~3 h in the dark at room temperature.  
2.4.10 ESI–LC-MS and tandem MS 
ESI-LC-MS and tandem MS analysis were performed with a Synapt ESI quadrupole TOF Mass 
Spectrometry System (Waters) coupled with an Acquity Ultra Performance Liquid 
Chromatography (UPLC) system (Waters). A sample of 5 μL of digested peptide was injected 
on a Phenomenex Jupiter C18 column, and separated by HPLC using a gradient of 2% mobile 
phase B to 40% mobile phase B over 20 min (mobile phase A: water with 0.1% formic acid, 
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mobile phase B: acetonitrile with 0.1% formic acid). Mass spectra were acquired in ESI 
positive mode in the range of 50-2000 m/z. The capillary voltage was 3500 V, and cone voltage 
was 40 V. The following parameters were also used: 120 oC source temperature; 300 oC 
desolvation temperature, 150 L/h cone gas flow, and 600 L/h desolvation gas flow. A transfer 
collision energy of 4 V was used for both MS and tandem MS, whereas the trap collision energy 
was set to 6 V for MS and a 20-50 V ramp for MSMS depending on the peptide. Glu- 
fibrinopeptide B (Sigma) was directly infused as lock mass. The tandem mass spectra were 
processed with MaxEnt3 and analyzed by Protein/Peptide Editor in BioLynx 4.1. The software 
for analyzing both precursor-ion and fragment-ion mass was set to report any mass within 0.3 
amu of the calculated expected values. 
2.4.11 Calculated and observed masses in the mass spectra  
Table 2.4. Calculated and observed masses in the mass spectra. 
 * monoisotopic masses plus one proton were shown for all peaks 
Figure Peak 
Calculated 
mass 
Observed  
mass 
Figure 2.4 
(Blank) 
M - 6 H2O 3729.7 3730.3 
M - 5 H2O 3747.8 3747.9 
M - 4 H2O 3765.8 3764.7 
Figure 2.4 
(Red) 
M 3837.8 
3833.9 
(Disulfide bond formation 
between the cysteines) 
Figure 2.5 
(Blank) 
M - 6 H2O 3729.7 3729.2 
M - 6 H2O + 1 IAA 3786.8 3785.8 
M - 5 H2O + 1 IAA 3804.8 3804.2 
M - 5 H2O + 2 IAA 3861.8 3861.0 
Figure 2.5 
(Red) 
M + 5 IAA 4122.9 4124.9 
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(Table 2.4 continued) 
Figure Peak 
Calculated 
mass 
Observed  
mass 
Figure 2.6 
(Black) 
M - 7 H2O 3839.8 3840.3 
M - 6 H2O 3857.8 3858.3 
M - 5 H2O 3875.8 3876.4 
M - 4 H2O 3893.9 3893.4 
M - 3 H2O 3911.9 3911.0 
Figure 2.6 
(Red) 
M 3965.9 
3963.2 
(Disulfide bond formation 
between the cysteines) 
Figure 2.7 
(Black) 
M - 6 H2O 3857.8 3858.4 
M - 5 H2O 3875.8 3876.4 
M - 6 H2O + 1 IAA 3914.9 3915.5 
M - 5 H2O + 1 IAA 3932.9 3933.5 
M - 4 H2O + 2 IAA 4007.9 4008.5 
Figure 2.7 
(Red) 
M + 5 IAA 4251.01 4251.0 
Figure 2.8 
(Black) 
M - 7 H2O 3370.6 3371.5 
M - 6 H2O 3388.6 3388.6 
M - 5 H2O 3406.6 3407.6 
M - 4 H2O 3424.6 3425.7 
M - 3 H2O 3442.6 3443.0 
Figure 2.10 
(Black) 
M - 5 H2O 3224.7 3226.0 
Figure 2.10 
(Red) 
M - 4 H2O 3242.7 3243.0 
M - 3 H2O  3260.8 3261.1 
M  3314.8 3313.1 
Figure 2.11 
(Black) 
M - 5 H2O 3224.7 3226.0 
M - 4 H2O 3242.7 3243.0 
M - 3 H2O 3260.8 3261.0 
M - 3 H2O + 1 IAA 3317.8 3318.1 
Figure 2.11 
(Red) 
M+ 3 IAA 3485.9 3486.0 
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(Table 2.4 continued) 
Figure Peak 
Calculated 
mass 
Observed  
mass 
Figure 2.13 
(Blank) 
M - 5 H2O 2754.1 2754.1 
M - 4 H2O 2772.2 2772.2 
M - 3 H2O 2790.2 2790.1 
Figure 2.13 
(Red) 
M  2844.2 
2841.7 
(Disulfide bond formation 
between the cysteines) 
Figure 2.14 
(Blank) 
M - 5 H2O 2754.1 2754.3 
M - 4 H2O 2772.2 2772.3 
M - 3 H2O 2790.2 2790.1 
M - 4 H2O + 1 IAA 2829.2 2829.4 
M - 3 H2O + 1 IAA 2847.2 2847.3 
Figure 2.14 
(Red) 
M + 3 IAA 3015.3 3016.0 
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CHAPTER III: MECHANISTIC STUDIES OF CLASS II 
LANTHIPEPTIDE SYNTHETASES* 
 
3.1  INTRODUCTION 
As introduced in chapter II, ProcM is a member of the class II bifunctional lanthipeptide 
synthetases (generically termed LanMs).1 ProcM is the only enzyme responsible for the 
dehydration and cyclization of 30 different substrates.1, 2 Similar class II systems with a single 
enzyme and multiple, diverse substrate peptides are also found in other cyanobacteria.2 In 
contrast, most LanM enzymes that have been investigated have only a single substrate.3 The 
molecular details that allow this high substrate tolerance are largely unknown. Previous 
mechanistic studies on ProcM4, 5 and NMR analysis of purified prochlorosin products6 support 
enzymatic formation of all the thioether rings and showed that specific structures were 
generated for several prochlorosins. However, whether ProcM forms only one product for each 
substrate, or whether multiple products were formed and only one isomer was purified and 
structurally characterized was unclear prior to the work presented in this chapter. Indeed, 
cyclization of substrates that contain multiple cysteines and dehydro amino acids could result 
in products with alternative ring topologies (Figure 3.1).  
________________________ 
*Reproduced in part with permission from Yu, Y., Mukherjee, S., and van der Donk, W. A. 
(2015) Product Formation by the Promiscuous Lanthipeptide Synthetase ProcM is under 
Kinetic Control, J. Am. Chem. Soc. 137, 5140-5148. 
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Using liquid chromatography electrospray ionization mass spectrometry (ESI-LC-MS), I 
show here that indeed ProcM is highly selective for the formation of one product from each 
substrate peptide, despite their highly diverse sequences. These remarkable observations 
prompted further investigations of the factors that contribute to both substrate tolerance and 
product selectivity.  
 
 
 
Figure 3.1. A peptide that contains two or more Cys residues and two or more dehydroamino 
acids can form multiple isomeric products as illustrated for a hypothetical example of a peptide 
with two cysteines and two dehydroamino acids. 
 
The C-terminal domains of LanM enzymes have low but detectable sequence identity with 
class I cyclases (generically termed LanCs)7 and the residues that are important for cyclization 
are strictly conserved based on structural8 and mutagenesis studies7 with the prototype NisC. 
For NisC, these residues include one histidine and two cysteines that serve as ligands to an 
active site zinc ion. These residues are also conserved in the cyclization domain of LanM 
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enzymes, and their importance has been experimentally confirmed in the case of the lacticin 
481 synthetase LctM.9 Surprisingly, a sequence alignment of ProcM with other LanM and 
LanC proteins (Figure 3.2) demonstrates that ProcM has three cysteines as the predicted zinc 
ligands. ProcM and its close homologues with three zinc-binding cysteines form a distinct clade 
in the phylogenetic tree of class II LanM synthetases,10 and generally (but not always) are 
associated with multiple substrate peptides with diverse sequences.2 As demonstrated in 
previous studies of other enzymes and model complexes, adding an additional sulfur-based 
ligand increases the reactivity of thiolates bound to a zinc ion.11-15 Thus, the three-cysteine 
ligand set may be responsible for the promiscuous catalytic ability of ProcM and its 
homologues. Herein, the importance of these active site residues was investigated by 
mutagenesis, and the cyclization activity and regioselectivity of ring formation were 
determined. The role of the unique cysteine in the ProcM clade (Cys971 in ProcM) was 
assessed for the first time in this work, which provides important information to understand the 
unusual substrate tolerance and selectivity. 
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Figure 3.2. Sequence alignment of cyclase domains of selected LanMs with selected LanCs. 
Active site residues that are conserved among the LanC and LanM proteins are in boldface 
underlined type. The unique zinc-binding cysteine in ProcM is shown in red. 
 
To understand better how ProcM can display both catalytic promiscuity and high 
specificity, several possible explanations were tested in this study. One possibility involves a 
highly organized order of the dehydration and cyclization reactions. To examine this hypothesis, 
the cyclization process was studied in isolation using dehydrated substrate and only the ProcM 
cyclase domain. A second recently suggested hypothesis to explain the properties of ProcM 
involves thermodynamic control of ring formation resulting in the accumulation of the most 
stable product. This hypothesis was born out of the observation that both NisC and the class II 
haloduracin synthetase HalM2 were able to efficiently catalyze retro-Michael additions on their 
products.16 Thermodynamic control not only requires that the enzymes reversibly catalyze the 
Michael additions found in their products, but also can correct alternate cyclization patterns. 
This hypothesis was tested by incubation of ProcM with peptides containing incorrect rings 
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and by searching for incorrect intermediates formed during catalysis by ProcM. A third 
hypothesis involves kinetic control of ring formation, with the earlier cyclization events 
determining the regioselectivity of later cyclizations. Our investigations on ProcM reported 
here support this last model providing important new insights into the enzymatic mechanism 
of this unique clade of substrate tolerant class II lanthipeptide synthetases.  
 
3.2  RESULTS 
3.2.1 The paradoxical catalytic promiscuity and high selectivity of ProcM  
For most of the lanthipeptides discovered to date, the thioether rings are installed by 
nucleophilic attack of Cys onto Dha or Dhb residues located N-terminal to the Cys.17 But for 
prochlorosins, the thioether rings are formed by the addition of Cys residues to Dha or Dhb 
that are localized either N- or C-terminal to the Cys.1 Five ProcA precursor peptides (ProcA1.1-
G−1E, ProcA2.8, ProcA2.11, ProcA3.2, and ProcA3.3) were chosen for investigation out of 
the 30 possible substrates to provide a representative set of different ring topologies, ring size, 
and direction of cyclization (Figure 3.3). For Pcn1.1 (prochlorosin formed from ProcA1.1) and 
Pcn2.8, structures with two non-overlapping rings are formed, and for Pcn2.11, Pcn3.2, and 
Pcn3.3, structures with overlapping rings are generated.1 The precursor peptides of these five 
prochlorosins containing an N-terminal hexa-histidine tag were co-expressed with ProcM in E. 
coli, and the modified peptides were purified by Ni2+ affinity chromatography and digested 
with endoproteases to remove all or most residues of the leader peptides. Samples were treated 
with iodoacetamide (IAA) to test for any partially cyclized products by reaction with free thiols 
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(Figure 3.4), and the resulting peptides were analyzed by ESI-LC-MS experiments. For all five 
peptides, the extracted ion chromatograms of fully dehydrated and cyclized products showed 
formation of one major product (Figure 3.3); any products with alternative ring patterns were 
only present in less than 5% of the major product. Tandem ESI-MS confirmed that the 
structures of the products were consistent with those determined in previous reports (Figure 
3.5). The presence of y”9, y”8, y’’5 ions in the tandem MS spectrum for ProcA1.1 G-1E, and 
y”9, b39, y”8 ions for ProcA2.8 indicates these peptides contain two non-overlapping rings, 
whereas the absence of any y”12 through y”3 ions for ProcA3.3 strongly suggests that 
overlapping structures are present. These findings are also in full agreement with the structures 
determined by NMR spectroscopy.6 Hence, this analysis confirmed that ProcM is both 
remarkably promiscuous with respect to its substrates and at the same time curiously specific 
in its product formation. 
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Figure 3.3. Extracted ion chromatograms (EICs) of the ESI-LC-MS experiments showing the 
fully dehydrated core-containing peptide ions from ProcA peptides co-expressed with ProcM, 
followed by digestion by endoproteases and treatment with IAA: ProcA1.1-G−1E and 
ProcA3.2 digested by GluC, ProcA2.11 digested by LysC, ProcA2.8 digested by trypsin and 
ProcA3.3 digested by AspN. The star symbol represents a short peptide sequence remaining 
from the leader peptide after treatment with the commercial proteases: ProcA2.8 
(*=DELEGVAGG), ProcA2.11 (*=EDLNSHRQTLSEDELESVAGG), and ProcA3.2 
(*=GVAGG). Arrow symbol stands for the site of AspN cleavage in ProcA3.3 core peptide. 
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Figure 3.4. MALDI-TOF mass spectra of ProcA peptides co-expressed with ProcM, followed 
by digestion by endoproteases and treatment with IAA: ProcA1.1-G−1E and ProcA3.2 by GluC, 
ProcA2.11 digested by LysC, ProcA2.8 digested by trypsin and ProcA3.3 digested by AspN. 
Calculated and observed masses are shown in Table 3.3. 
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Figure 3.5. Tandem ESI-MS of the fully dehydrated core-containing peptide ions from ProcA 
peptides co-expressed with ProcM, followed by digestion by endoproteases and treatment with 
IAA: ProcA1.1-G−E and ProcA3.2 digested by GluC, ProcA2.8 and ProcA2.11 digested by 
LysC and ProcA3.3 digested by AspN. 
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3.2.2 The three zinc-binding cysteines are important for cyclization 
Unlike other lanthipeptide cyclases that utilize two Cys and one His as zinc ligands, ProcM 
contains a Cys instead of a His at position 971, suggesting that it likely uses three Cys residues 
(Cys924, Cys970, and Cys971) for binding of the active site zinc ion. To confirm that these 
three Cys residues are important for zinc binding and for the cyclization activity of ProcM, a 
series of individual mutants were generated (C924A, C970A, C971A and C971H). The zinc 
content of WT ProcM and mutant proteins was measured by a spectrophotometric assay using 
the metallochromic indicator 4-(2-pyridylazo)resorcinol (PAR).18 The proteins were expressed 
in E. coli, and then analyzed after purification and exhaustive dialysis in chelex-treated buffer. 
The resulting samples were treated with guanidine hydrochloride and 5,5´-dithio-bis(2-
nitrobenzoic acid) (DTNB) to oxidize reactive cysteines to disulfides as previously described.19 
The orange Zn(PAR)2 complex was formed after the addition of PAR and was quantified by 
the absorbance at 500 nm. Wild type (WT) ProcM and ProcM-C971H contained nearly 
stoichiometric quantities of zinc, while the relative zinc content for ProcM-C924A and ProcM-
C970A was decreased by 50% (Figure 3.6). ProcM-C971A precipitated during the dialysis 
treatment in two independent attempts, thus zinc content could not be determined for this 
mutant.  
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Enzyme Relative Zinc content 
ProcM WT 1.00a 
ProcM C924A 0.49 
ProcM C970A 0.49 
ProcM C971A N/A 
ProcM C971H 1.25 
                          aWild type ProcM contained 0.88 eq of zinc/protein. 
Figure 3.6. Zinc content of WT ProcM and mutants.  
 
 
Figure 3.7. MALDI-TOF mass spectra of 25 M ProcA2.8 peptide modified by 2 M WT 
ProcM, ProcM-C924A, ProcM-C970A, ProcM-C971A, and ProcM-C971H in vitro for 1 h, 
followed by digestion by LysC. 
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The dehydration activities of WT ProcM and mutants were studied by in vitro enzymatic 
assays on the substrate ProcA2.8 followed by endoprotease LysC removal of most of the leader 
peptide and analysis by matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS). As anticipated since the mutations are in the cyclization 
domain, the dehydration activities were not affected by these zinc ligand mutations (Figure 3.7). 
To study the cyclization activities, IAA was added to the LysC cleavage reaction to detect free 
cysteines in the peptides. With ProcA2.8 as substrate, all four Cys mutants showed a significant 
decrease in the cyclization activity compared to the WT enzyme, with the majority of the 
products carrying one IAA adduct, which indicated one ring was not formed (Figure 3.8). 
Considering about half of these mutants are apo-protein based on the zinc content analysis, 
these reactions were also performed with supplemented zinc or with four times the amount of 
enzyme, but similar results were observed. The partially cyclized peptides were analyzed by 
ESI-LC-MS of LysC-digested samples, which showed that it was the Cys3-Dha9 ring in 
ProcA2.8 that was formed slower for all four mutants (Figures 3.9 and 3.10, Table 3.4 lists the 
calculated and observed masses of each ion in the tandem MS analyses). Collectively, these 
experiments demonstrate that having three Cys ligands is important for the cyclization activity 
of ProcM. It is worthy to mention that assays using ProcM triple mutant (ProcM-
C924A/C970A/C971A) resulted similar cyclization in ProcAs as the single mutants. 
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Figure 3.8. MALDI -TOF mass spectra of 25 M ProcA2.8 peptide modified by 2 M WT 
ProcM, ProcM-C924A, ProcM-C970A, ProcM-C971A, and ProcM-C971H in vitro for 1 h, 
followed by digestion by LysC and treatment with IAA. 
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Figure 3.9. Extracted ion chromatograms (EICs) of the ESI-LC-MS experiments showing the 
fully dehydrated core-containing peptide ions of ProcA2.8 from Figure 3.7. Peptide a is fully 
cyclized, peptide b does not contain a ring between Cys3 and Dha9 (see Figure 3.10). 
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Figure 3.10. Tandem ESI-MS analysis of peptide a and peptide b shown in Figure 3.9. Peptide 
a is fully cyclized, peptide b does not contain a ring between Cys3 and Dha9. For calculated 
and observed masses, see Table 3.4. 
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3.2.3 Product distribution and cyclization rate of WT ProcM and ProcM mutants 
Incubation of ProcA1.1 or ProcA2.8 with WT ProcM or ProcM-C971H in vitro resulted in 
formation of the same products as observed with WT ProcM (Figures 3.9 and 3.12). The rate 
of cyclization with these two substrates was studied in vitro by quenching the reaction at 
different time points. With WT ProcM, the first cyclization of Cys16 to Dhb12 in ProcA1.1 
was almost completed in 30 min under the assay conditions used, and the second cyclization 
of Cys3 to Dhb7 was almost completed in 3 h (Figures 3.11 and 3.12, Table 3.5 lists the 
calculated and observed masses of each ion in the tandem MS analyses). With ProcM-C971H, 
the first cyclization of Cys16 to Dhb12 was nearly completed in 1 h, but the second cyclization 
was much slower, with less than 10% fully cyclized product observed at 3 h (Figure 3.11). The 
ratio was calculated using the ion counts for signals corresponding to the fully modified peptide 
and peptides with IAA adducts in the mass spectrum. 
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Figure 3.11. MALDI-TOF mass spectra of 10 M ProcA1.1 modified by 0.2 M WT ProcM 
(red) and ProcM-C971H (blue) for 15 min, 30 min, 60 min, and 180 min, followed by digestion 
by GluC and treatment with IAA. 
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Figure 3.12. A. EICs of the ESI-LC-MS experiments showing the fully dehydrated core-
containing peptide ions of ProcA1.1 from the reactions at 180 min from Figure 3. B. Tandem 
ESI-MS analysis of peptide c and peptide d. For calculated and observed masses, see Table 3.5. 
 
The enzymatic assay with ProcA2.8 showed similar results (experiments performed by 
Subha Mukherjee). For WT ProcM, the first cyclization of Cys19 to Dha13 was completed in 
less than 15 min under the assay conditions used, and the second cyclization of Cys3 to Dha9 
was almost completed in 1 h. With ProcM-C971H, the first cyclization of Cys19 to Dha13 was 
also completed in less than 15 min, but the rate of the second cyclization was decreased 
significantly, with <30% fully cyclized product observed after 90 min. By increasing the 
concentration of ProcM-C971H to 30 M (with 50 M peptide), the ratio of fully cyclized to 
partially cyclized ProcA2.8 after 1 h was increased (experiments performed by Subha 
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Mukherjee). This observation shows that ProcM-C971H was able to catalyze the second 
cyclization, although the rate was considerably slower compared to WT enzyme. 
Surprisingly, for one of the investigated ProcAs, ProcA3.3, co-expression with ProcM-
C971H in E. coli generated two different final products in contrast to WT ProcM, which made 
one specific product (peptide 1, Figure 3.13A). The major product generated by ProcM-C971H 
(peptide 2) was demonstrated by tandem ESI-MS to contain a novel non-overlapping ring 
topology (Figure 3.13B). ProcA3.3 was also incubated with ProcM-C971H and the other 
mutants in vitro for 3 h, and the product distribution was analyzed by ESI-LC-MS. The ring 
patterns of each product and intermediate were determined by tandem ESI-MS and verified by 
comparison to standards (Figure 3.14). Tandem mass spectra of each product and intermediate 
are shown in Figures 3.13 and 3.15, and Table 3.6 lists the calculated and observed masses of 
each ion in the tandem MS analyses. For all zinc-ligand mutants, peptide 2 was the major final 
product and peptide 5 was the major intermediate that leads to the formation of peptide 2 
(Figures 3.14 and 3.16). Mutating the proposed active site residue H859 (Figure 3.2) to Ala 
resulted in a complete loss of the cyclization activity of ProcM (Figure 3.16), which is 
consistent with previous mutagenesis studies on NisC.9 While mutating D804 to Asn, which is 
the residue that forms a hydrogen bond with the active site histidine residue in the NisC crystal 
structure,11 resulted in a dramatic decrease in the cyclization rate but no changes in the 
regioselectivity of the product formation (Figure 3.16).  
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Figure 3.13. A. EICs of the ESI-LC-MS experiments showing the 3-fold dehydrated Δ1 core 
peptide ion (Δ1 because the first Gly is removed by AspN) produced by ProcA3.3 co-expressed 
with WT ProcM or ProcM-C971H, and subsequently digested with AspN and treated with IAA. 
B. Tandem ESI-MS of peptide 1 and peptide 2. For calculated and observed masses, see Table 
3.6. 
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Figure 3.14. EICs of the ESI- LC-MS experiments showing the 3-fold dehydrated Δ1 core 
peptide ion obtained by AspN digestion of 25 M ProcA3.3 incubated with 2 M WT ProcM, 
ProcM-C971A, and ProcM C971H for 3 h. Standards: 1 (blue), ProcA3.3 co-expressed with 
WT ProcM; 1 and 2 (red), ProcA3.3 co-expressed with ProcM-C971H; 3 (purple), semi-
synthetic ProcA3.3 containing a ring between Cys14 and Dhb18 (provided by Subha 
Mukherjee); 4 and 5 (orange), semi-synthetic ProcA3.3 with Cys14 protected that was 
modified by WT ProcM and subsequent deprotected (provided by Subha Mukherjee); and 6 
(grey), dehydrated ProcA3.3. Non-enzymatic: dehydrated ProcA3.3 incubated with reaction 
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buffer at pH 8 for 3 h or 72 h. All the peptides were digested by AspN to remove the leader 
peptide.   
 
 
Figure 3.15. Tandem ESI-MS analysis of peptides 3, 4, 5 and 6 shown in Figure 3.14. For 
calculated and observed masses, see Table 3.6. 
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Figure 3.16. EICs of the ESI-LC-MS experiments showing the 3-fold dehydrated Δ1 core 
peptide ion from 25 M ProcA3.3 incubated with 2 M ProcM mutants for 3 h. All the 
reactions were treated by AspN prior to ESI-LC-MS analysis.  
 
Given the interesting observation of a switch in product distribution with ProcA3.3, we 
also examined the time dependence of processing. Incubation of ProcA3.3 with WT ProcM 
resulted in near completion of the first cyclization of Cys14 to Dha18 in 15 min under the assay 
conditions, whereas the second cyclization of Cys21 to Dha11 took up to 90 min to complete 
(Experiments performed by Subha Mukherjee). For ProcM-C971H, the first cyclization of 
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Cys21 to Dha18 was nearly completed in 90 min, but the second cyclization of Cys14 to Dha11 
was much slower, with less than 10% fully cyclized product observed at 90 min.  
To determine the intrinsic regioselectivity of ring formation, non-enzymatic cyclization of 
ProcA3.3 was studied. First, the two cysteines in ProcA3.3 were linked by a disulfide bridge 
using oxidized glutathione, which resulted in the expected mass loss of two Da. The oxidized 
ProcA3.3 was dehydrated by ProcM in vitro, and the 3-fold dehydrated product was purified. 
Reduction by TCEP treatment shifted the mass of the peptide by two Da (Figure 3.17). Upon 
TCEP reduction, the non-enzymatic cyclization was investigated at the same pH of the 
enzymatic assay (pH 8) for 3 h. Very little cyclization occurred compared to the enzymatic 
reactions, illustrating that the mutants still accelerated the cyclization process (Figure 3.14). 
The regioselectivity of non-enzymatic cyclization was very similar to that of the zinc ligand 
mutants, with the predominant products being peptide 2 and intermediate 5 that leads to peptide 
2 (Figure 3.14).  
 
 
Figure 3.17. MALDI-TOF mass spectra of the GluC-cleaved dehydrated ProcA3.3 before (red) 
and after (blue) TCEP reduction.  
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3.2.4 The order of dehydration and cyclization does NOT determine the ring topology 
It has been reported for nisin, haloduracin, and curvopeptin that the dehydration and 
cyclization reactions are alternating processes during biosynthesis.5, 20-22 Thus, a possible 
explanation for the unusual selectivity of the ring formation in the structurally diverse 
prochlorosins is that the ring patterns are determined by the order of dehydration and 
cyclization. The order of dehydration has been established in a previous study for ProcA2.8 
and ProcA3.3.4 To study cyclization in isolation, the putative cyclase domains of WT ProcM 
and ProcM-C971H were obtained by expressing the C-terminal domains spanning residues 
655-1068 (ProcM-655-1068 and ProcM-C971H-655-1068). The cyclization reaction catalyzed 
by ProcM-655-1068 was studied with dehydrated ProcA3.3 that was generated as described in 
the previous section. As will be shown in section 4.2.3, incubation of WT ProcM-655-1068 
with fully dehydrated ProcA3.3 resulted in a similar product distribution as with the WT 
enzyme at a similar extent of conversion, strongly favoring peptide 1 and intermediate 3 leading 
to peptide 1. Conversely, incubation of ProcM-C971H-655-1068 with fully dehydrated 
ProcA3.3 resulted in preference for intermediate 5 leading to peptide 2. These results are not 
consistent with a tight regulation of the order of dehydration and cyclization as a determining 
factor for the selectivity for certain ring patterns in prochlorosins, since decoupling of the 
dehydration reaction from the cyclization events gave very similar product distributions 
compared to the selectivities observed with the full length proteins.  
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3.2.5 Thermodynamic control involving reversible ring formation is NOT observed 
One attractive explanation for the catalytic selectivity of ProcM is thermodynamic control 
over the selectivity of ring formation. This model requires reversibility of the cyclization 
reaction to allow the generation of the most stable product. Indeed, reversible ring formation 
has recently been observed for the haloduracin synthetase HalM2 and the nisin cyclase NisC.16 
Thermodynamic control not only requires ring opening of the rings found in the final product, 
but also ring opening of energetically less favored “incorrectly” cyclized products and 
intermediates. At present, such activity has not been investigated for any lanthipeptide. To 
probe this model for ProcM, three different experiments were carried out. First, the non-
physiological product 2 was obtained by co-expressing ProcA3.3 with ProcM-C971H and 
peptide 2 was subjected to the in vitro enzymatic assay with WT ProcM. Conversion of peptide 
2 to peptide 1 was not observed (Figure 3.18A) Furthermore, ProcM-C971H did not convert 
peptide 1 to peptide 2 either (Figure 3.18B). However, it is possible that the final cyclized 
peptides were not accessible to the active site of the enzyme. Indeed, for all substrates 
investigated in this study, the second cyclization event was very slow, possibly reflecting 
decreasing affinity of the enzyme for the peptide as more rings are installed. Therefore, we also 
investigated potential reversibility on an incorrectly cyclized intermediate. A ProcA3.3 
derivative with a Cys21-Dhb18 ring was generated by orthogonal protection of Cys14 
(performed by Subha Mukherjee).4 Incubation of the intermediate with WT ProcM did not 
result in conversion of this “wrong intermediate” to the correct product with overlapping rings, 
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but instead a product with non-overlapping rings was formed. In other words, once the incorrect 
first ring was installed, ProcM proceeded to the incorrect product.  
 
Figure 3.18. A. EICs of the ESI- LC-MS experiments showing the Δ1 core peptide ion from 
ProcA3.3 co-expressed with ProcM-C971H (red), and subsequently treated with WT ProcM 
(blue). B. EICs of the ESI-LC-MS experiments showing the Δ1 core peptide ion from ProcA3.3 
co-expressed with WT ProcM (red), and subsequently treated with ProcM-C971H (blue). All 
peptides were digested by AspN and treated with IAA. 
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As a final test of potential thermodynamic control, the in vitro enzymatic assay of WT 
ProcM and ProcA3.3 was quenched at different time points and analyzed by ESI-LC-MS to 
identify the intermediates (Figure 3.19). At all time points, peptides 1 and 3 were detected at 
significant levels whereas incorrect intermediate peptide 5 was only observed at very low levels 
(possibly from background non-enzymatic cyclization). Collectively, these results argue 
against thermodynamic control of product formation for ProcM. 
 
Figure 3.19. EICs of the ESI-LC-MS experiments showing the 3-fold dehydrated Δ1 core 
peptide ion from ProcA3.3 incubated with WT ProcM for 15 min, 30 min, 1 h, and 3 h. The 
reactions were digested by AspN.   
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3.3  DISCUSSION AND OUTLOOK 
In this study, I demonstrated that, curiously, the substrate promiscuity of ProcM does not 
come with a cost of reduced product selectivity as for all the peptides investigated, the enzyme 
makes essentially single products, with only very minor amounts, if any, of alternative ring 
topologies observed. We investigated several possibilities for the determinants of the observed 
selectivity for certain ring topologies. In a previous study, we ruled out that the high selectivity 
for the final ring topology is a consequence of non-enzymatic processes.4 Here we again show 
that non-enzymatic cyclization is much slower than the enzymatic process, and we show that 
the regioselectivity for non-enzymatic cyclization of ProcA3.3 is different than that observed 
with WT ProcM. Hence, the enzyme must exert a specific influence on the regiochemistry of 
cyclization and is not simply accelerating formation of a product that is already favored by the 
substrate.  In this work we ruled out that the selectivity is caused by tight control between the 
dehydration and cyclization activities, or by thermodynamic control. A very recent study 
illustrated that two lantibiotic cyclization processes involved in the biosynthesis of the class I 
lantibiotic nisin and the class II lantibiotic haloduracin are reversible when the cyclization  
enzymes NisC and HalM2, respectively, were exposed to their final correctly cyclized 
products.16 ProcM on the other hand appears much less reactive towards its products. All 
attempts to detect products of retro-Michael processes using the same methodology as used for 
NisC and HalM2,16 whether with the native ProcM products or incorrectly cyclized products 
or intermediates, have been unsuccessful. No ring-opened products were detected with ProcM 
(~5% estimated detection limit), whereas NisC and HalM2 generated substantial amounts of 
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peptides in which up to five and four rings were opened, respectively.16 These observations 
may be explained by the very different kinetic profiles of the enzymes.5 The reactions that 
HalM2 catalyzes on its substrate HalA2 become progressively faster, whereas the opposite is 
observed here and in a previous study5 for ProcM. A well-known problem in feeding 
intermediates to enzymes is that they cannot always access the catalytically competent form of 
their cognate enzyme, for instance if such an intermediate is normally processed further while 
still bound in the enzyme active site. However, ProcM is not processive in its catalysis with 
wild type substrates as shown here and in a previous study,5 and hence this explanation for the 
lack of reversibility does not hold. Instead, we believe that the difference between HalM2/NisC 
and ProcM is the result of poor recognition of cyclized intermediates by the latter enzyme. We 
have suggested that the HalA2 peptide becomes increasingly complementary to the HalM2 
active site as the posttranslational modifications take place, whereas ProcM, which makes 30 
structurally very different products, cannot be complementary in shape and/or electrostatics to 
all its products.5 Thus, the fully processed HalA2 peptide likely interacts much more favorably 
with HalM2 than the processed ProcA peptides interact with ProcM, explaining the observed 
reversibility for HalM2 and the apparent lack of reversibility for ProcM. 
If neither the inherent reactivity, nor the thermodynamics of the products or tight coupling 
between dehydration and cyclization events determine the outcome of ProcM catalyzed 
cyclization reactions, what might govern the high observed regioselectivities? One possibility 
is that the enzyme-catalyzed selectivity for formation of the first ring determines the overall 
outcome. The mature products of ProcA1.1, 2.8, and 3.3 all have two rings in their final 
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products but with different ring sizes and topologies. With all three peptides, ProcM forms the 
first ring much faster than the second ring. Since we demonstrated that ProcM does not open 
up any formed rings, kinetic control over the regioselectivity of formation of the first ring 
determines the final ring topology for these peptides. The regioselectivity of the formation of 
that first ring is enzyme controlled because for ProcA3.3, non-enzymatic cyclization is both 
much slower and results in a different first ring compared to ProcM.  
Zn2+ is often used in enzymes that catalyze alkylation of thiols, and it has been noted that 
these enzymes typically have a net negatively charged zinc site in their substrate-bound form 
(i.e. more than two negatively charged ligands from enzyme + substrate).12 In addition, the 
negatively charged ligands in these enzymes typically are predominantly thiolates. It has been 
suggested that this ligand environment might either serve to facilitate substrate thiolate 
dissociation to release the nucleophile, or to increase the reactivity of the Zn-bound thiolate of 
the substrate in an associative process.12  Although studies on model complexes have shed 
some light onto this question,13, 14, 23, 24 at present, it is not clear whether the enzymes use a 
dissociative or associative mechanism. Therefore, the exact nature of substrate activation in 
lanthipeptide cyclases is not yet clear, but this study is in agreement with the notion that an 
increase in thiolate ligands increases the enzyme’s activity.15,16,19 Interestingly, all the zinc 
ligand mutants that perturb the three Cys ligand set (four Cys after binding of the substrate, 
Figure 3.20) display the same general regioselectivity as the non-enzymatic reaction. All these 
mutants also have attenuated cyclization activity. Hence, it appears that the unique three-
cysteine ligand set not only increases the reactivity of the zinc site, but that this increased 
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reactivity also can overcome the inherent selectivity of the substrate. How this is achieved for 
a very diverse set of substrates is not clear, and likely involves substrate-enzyme interactions 
that await structural information on ProcM and its complexes with the substrates. What is clear 
is that the high reactivity afforded by the three-cysteine ligand set may be required for full 
cyclization of the prochlorosins at a reasonable rate since the second cyclization was very slow 
for all the mutant enzymes. 
 
 
Figure 3.20. Proposed mechanism for the cyclization reaction catalyzed by ProcM illustrated 
for the formation of the Cys14 to Dhb18 ring in ProcA 3.3.  
 
3.4 EXPERIMENTAL PROCEDURES 
3.4.1 Construction of the expression plasmids for ProcM mutants 
The generation of pRSF-Duet1-procM was described in section 2.4.3. The ProcM mutant 
constructs were generated by site-directed mutagenesis using pRSF-Duet1-procM (MCS1) as 
temperate and the primers in Table 3.1. The ProcM-C924A/C970A/C971A construct was 
generated from pRSF-Duet1-procM-C924A (MCS1) using procM_C970A/C971A_FP and 
procM_C970A/C971A_RP as primers. PCR amplifications were performed using Phusion 
polymerase by 30 cycles of denaturing (94 °C for 30 s), annealing (55 °C for 30 s), and 
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extending (72 °C for 3.5 min). The resulting PCR product was treated by DpnI, purified using 
Qiagen gel extraction kit, and used to transform E. coli DH5. The sequences of the mutants 
were checked by DNA sequencing.  
The genes encoding WT ProcM-655-1068 and ProcM-C971H-655-1068 were PCR amplified 
using Phusion polymerase by 30 cycles of denaturing (94 °C for 30 s), annealing (55 °C for 30 
s), and extending (72 °C for 45 s) using procM_655_EcoRI_FP as forward primer, 
procM_Duet1_NotI_RP as reverse primer, and pRSF-Duet1-procM (MCS1) and pRSF-Duet1-
procM-C971H (MCS1) as templates. The PCR products were digested with EcoRI and NotI 
restriction enzymes and ligated into the first multiple cloning site of a pRSF-Duet1. The 
sequence of the insert was checked by DNA sequencing.  
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Table 3.1. Primers used in section 3.4.1. 
Primer Name Primer Sequences (5’-3’) 
procM_C924A_FP CTTCATGGCTAGCTGGGCCCATGGTGCCCC
GGGTATTG 
procM_C924A_RP CAATACCCGGGGCACCATGGGCCCAGCTAG
CCATGAAG 
procM_C970A_FP GTTTCGACGGATCATCTTGCCTGCGGATCA
CTGGGTTTGATG 
procM_C970A_RP CATCAAACCCAGTGATCCGCAGGCAAGATG
ATCCGTCGAAAC 
procM_C971A_FP GTTTCGACGGATCATCTTTGCGCCGGATCA
CTGGGTTTGATG 
procM_C971A_RP CATCAAACCCAGTGATCCGGCGCAAAGATG
ATCCGTCGAAAC 
procM_C971H_FP GTTTCGACGGATCATCTTTGCCACGGATCA
CTGGGTTTGATG 
procM_C971H_RP CATCAAACCCAGTGATCCGTGGCAAAGATG
ATCCGTCGAAAC 
procM_Duet1_EcoRI_FP CAGGATCCGAATTCGATGGAAAGTCCATCA
TCTTGG 
procM_655_EcoRI_FP GAATCCGAATTCGATGTCATCATCGGCTGA
GACGA 
procM_C970A/ C9701_FP GTTTCGACGGATCATCTTGCCGCCGGATCA
CTGGGTTTGATG 
procM_C970A/ C9701_RP CATCAAACCCAGTGATCCGGCGGCAAGAT
GATCCGTCGAAAC 
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3.4.2 Construction of the co-expression plasmids for ProcAs and ProcM /ProcM mutants 
The procM and procM mutant genes were amplified by PCR in 30 cycles of denaturing (98 °C 
for 30 s), annealing (55 °C for 30 s), and extending (72 °C for 2 min) with the plasmid pRSF-
Duet1-procM/procM mutants as templates and using procM_Duet1_NdeI_FP as forward 
primer and procM_Duet1_KpnI_RP as reverse primer. The PCR products were digested with 
NdeI and KpnI restriction enzymes and ligated into the second multiple cloning site (MCS2) 
in the pRSF-Duet1 vector to generate the construct pRSF-Duet1-procM/procM mutant (MCS2). 
The sequences of the resulting products were confirmed by DNA sequencing. 
ProcA genes were amplified by PCR using 30 cycles of denaturing (98 °C for 10 s), annealing 
(55 °C for 30 s), and extending (72 °C for 15 s) using the primers listed in Table 3.2 and the 
plasmids pET15b-procA1.1/procA2.8/proc3.3 as templates.1, 25 The resulting DNA inserts and 
the pRSF-Duet1 vector containing procM/procM mutants in MCS2 were digested with EcoRI 
and NotI and ligated. The sequences of the resulting products were confirmed by DNA 
sequencing.  
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Table 3.2. Primers used in section 3.4.2. 
Primer Name Primer sequence (5’-3’) 
procM_Duet1_NdeI_FP GGTTGGTTCATATGGAAAGTCCATCATCTTGG 
procM_Duet1_KpnI_RP AAGTAGTTGGTACCTTATTCAGTAGGCCAGAGAC 
procA1.1_EcoRI_FP AAGAATTCGATGAAAAAGCGACTCAAC 
procA1.1_NotI_RP AAGCGGCCGCTCAGCACACATTGATAG 
procA2.8_EcoRI_FP GGTGAGTGGAATTCGATGTCAGAAGAGCAACTGAAGG
C 
procA2.8_NotI_RP ATATAATGCGGCCGCTTAGCACTCACCCTC 
procA3.3_EcoRI_FP GGTGAGTGGAATTCGATGTCAGAAGAACAACTCAAGG
C 
procA3.3_NotI_RP ATAATTTAGCGGCCGCCTATGCGCGGC 
 
3.4.3 Generation of dehydrated ProcA3.3 
A sample of 1 mL of ProcA3.3 (6 mg/mL) was oxidized with 5 mM oxidized glutathione 
(GSSG) at room temperature for 3 h. The peptide was purified using a C4 SPE column (Vydac), 
and the eluted peptide was lyophilized. The oxidized peptide was dissolved in 1 mL of ddH2O. 
An in vitro dehydration reaction was set up with 50 mM HEPES (pH 8.0), 5 mM ATP, 10 mM 
MgCl2, 0.5 mM GSSG, 50 μM oxidized peptide, and 5 μM ProcM, and incubated at room 
temperature for 24 h. ProcM was removed from the assay by using Amicon 100 KD filters. 
The dehydrated peptide was reduced by TCEP and then purified using a C4 SPE column.  
3.4.4 PAR assay 
All flasks and beakers used were prerinsed with 20% HNO3 and Milli-Q water. Dialysis was 
performed with Slidalyzers (Pierce) presoaked in 20 mM HEPES, pH 8.0, containing 10 g/liter 
Chelex-100 (Bio-Rad). ProcM and ProcM mutants were dialyzed against four changes of 20 
mM HEPES, 1 M NaCl, pH 8.0, with 25–50 g/liter Chelex-100 in the beaker, over a total time 
of 48 h at 4 °C. The Chelex-100-treated protein was then concentrated with Amicon 50 KD 
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filters that had been presoaked in 20 mM Tris, pH 7.5, and containing 10 g/liter Chelex-100. 
The reactions were performed in 20 mM HEPES, 1 M NaCl, pH 8.0, that was treated with 25–
50 g/liter Chelex-100 and filtered. Aliquots of 40 μL protein solutions or the zinc standard 
solutions were incubated with 160 μL 100 μM PAR in 4 M guanidine hydrochloride at room 
temperature. An aliquot of 10 μL 3.5 mM DTNB was then added to the reaction mixture to 
further release the zinc ion. The absorption of PAR-Zn2+ complex at 500 nm was measured, 
and the concentration of zinc was determined by using a standard curve that was prepared with 
zinc chloride solutions. 
3.4.5 Experimental procedures listed in other chapters 
Expression and purification of unmodified and modified peptides (section 2.4.5); Expression 
and purification of LanM enzymes (section 2.4.6); 
In vitro enzymatic assay and endoprotease digestion (section 2.4.7); 
Iodoacetamide assay (section 2.4.9); 
ESI–LC-MS and tandem MS (section 2.4.10). 
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3.4.6 Calculated and observed masses in the tandem mass spectra  
Table 3.3. Calculated and observed masses in the mass spectra. 
 * monoisotopic masses plus one proton were shown for all peaks 
 
 
 
 
Figure Peak Calculated mass Observed mass
M- 4 H2O (ProcA1.1-G-1E) 1783.8 1784.2
M- 4 H2O + 1 IAA (ProcA1.1-G-1E) 1840.9 1841.3
M- 2 H2O (ProcA2.8) 3435.4 3435.6
M- 2 H2O + 1 IAA (ProcA2.8) 3492.4 3492.7
M- 3 H2O (ProcA3.3) 2199.0 2198.5
M- 3 H2O + 1 IAA (ProcA3.3) 2256.0 2255.2
M- 5 H2O (ProcA2.11) 4090.8 4091.4
M- 5 H2O + 1 IAA (ProcA2.11) 4147.8 4148.4
M- 3 H2O (ProcA3.2) 3222.5 3221.1
M- 3 H2O + 1 IAA (ProcA3.2) 3279.5 3278.1
M- 2 H2O (WT) 5034.7
M- 2 H2O (C924A) 5035.4
M- 2 H2O (C970A) 5034.5
M- 2 H2O (C971A) 5035.1
M- 2 H2O (C971H) 5035.0
M- 2 H2O (WT) 5034.7
M- 2 H2O (C924A) 5034.8
M- 2 H2O (C970A) 5035.0
M- 2 H2O (C971A) 5035.2
M- 2 H2O (C971H) 5035.4
M- 2 H2O + 1 IAA (WT) 5091.7
M- 2 H2O + 1 IAA(C924A) 5091.8
M- 2 H2O + 1 IAA (C970A) 5092.1
M- 2 H2O + 1 IAA (C971A) 5092.0
M- 2 H2O + 1 IAA (C971H) 5092.4
Figure 3.4
Figure 3.7
Figure 3.8
5035.2
5035.2
5092.2
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(Table 3.3 continued) 
 
 
Figure Peak Calculated mass Observed mass
M- 2 H2O (WT, 15 min) 2124.6
M- 2 H2O (WT, 30 min) 2124.7
M- 2 H2O (WT, 60 min) 2124.5
M- 2 H2O (WT, 180 min) 2124.7
M- 2 H2O (C971H, 60 min) 2124.6
M- 2 H2O (C971H, 180 min) 2124.7
M- 2 H2O + 1 IAA (WT, 15 min) 2181.5
M- 2 H2O + 1 IAA (WT, 30 min) 2181.7
M- 2 H2O + 1 IAA (WT, 60 min) 2181.5
M- 2 H2O + 1 IAA (WT, 180 min) 2181.7
M- 2 H2O + 1 IAA (C971H, 15 min) 2181.6
M- 2 H2O + 1 IAA (C971H, 30 min) 2181.7
M- 2 H2O + 1 IAA (C971H, 60 min) 2181.6
M- 2 H2O + 1 IAA(C971H, 180 min) 2181.7
M + 2 IAA (WT, 15 min) 2274.5
M + 2 IAA (WT, 30 min) 2274.6
M + 2 IAA (WT, 60 min) 2274.4
M + 2 IAA (C971H, 15 min) 2274.5
M + 2 IAA (C971H, 30 min) 2274.7
M + 2 IAA (C971H, 60 min) 2274.6
2125.0
2182.0
2275.1
Figure 3.11
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Table 3.4. Calculated and observed masses of each ion resulting from fragmentation in the 
core region in the tandem MS analysis of the 2-fold dehydrated core peptide ion of ProcA2.8 
after digestion by AspN (Figure 3.10). The presence of the ions highlighted in yellow are 
indicative of the absence of a Dha9-Cys3 ring. 
ion calculated 
mass 
observed 
peptide 
a 
observed 
peptide 
b 
y’’8 952.35 952.38 952.43 
y’’9 1049.40 1049.44 1049.49 
y’’12 1346.52  1346.58 
b36 3690.67  3690.85 
b39 3987.79 3988.10 3988.12 
Table 3.5. Calculated and observed masses of each ion resulting from fragmentation in the 
core region in the tandem MS analysis of the 2-fold dehydrated core peptide ion of ProcA1.1 
after digestion by GluC (Figure 3.13). The presence of the ions highlighted in yellow are 
indicative of the absence of a Dhb7-Cys3 ring. 
ion calculated 
mass 
observed 
peptide c 
observed 
peptide d 
b6 490.25 490.33 490.33 
y’’5 531.26 531.39 531.39 
b7 637.32  637.41 
y’’6 678.33  1282.66 
b8 740.33  740.48 
y’’7 834.43  834.65 
b9 839.40  839.60 
y’’8 948.47 948.69 948.70 
y’’9 1019.51 1019.76 1019.76 
y’’10 1102.55  1102.69 
y’’11 1159.57  1159.77 
y’’14 1489.70 1490.08 1490.08 
y’’15 1636.78 1637.14 1637.10 
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Table 3.6. Calculated and observed masses of each ion in the tandem MS analysis of the 3-fold 
dehydrated core peptide ion of ProcA3.3 after digestion by AspN (Figure 3.13 and 3.15). The presence 
of the ions highlighted in green are indicative of the absence of a Dhb18-Cys21 ring, the ions highlighted 
in yellow are indicative of the absence of the Dhb18-Cys14 ring, and the ions highlighted in blue are 
indicative of the absence of the Dhb11-Cys14 ring. Finally, all colored ions are consistent with the 
absence of a Dhb11-Cys21 ring. 
 
ion calculated 
mass 
observed 
peptide 1 
observed 
peptide 2 
observed 
peptide 3 
observed 
peptide 4 
observed 
peptide 5 
observed 
peptide 6 
b1 116.03 116.07 116.05   116.09  
b2 199.07 199.13 199.09 199.13 199.13 199.13 199.13 
y’’2 246.16 246.23 246.19     
b3 256.09 256.23 256.12 256.17 256.17 256.17 256.17 
y’’4 480.21   480.34   480.37 
y’’5 608.30   608.47   608.49 
y’’7 748.36      748.56 
y’’8 805.38  805.46   805.59 805.66 
y’’9 968.44      968.71 
y’’11 1128.48   1128.76  1128.57 1128.80 
y’’12 1199.51   1199.85  1200.09 1199.85 
y’’13 1282.55 1282.92 1282.66 1282.90 1282.90 1282.91 1282.92 
y’’14 1419.61 1420.01 1419.73 1420.00 1420.01 1420.01 1420.08 
y’’15 1532.69 1533.13 1532.83 1533.11  1533.12 1533.12 
y’’16 1631.76 1632.27 1631.88 1632.15 1632.15 1632.18 1631.50 
y’’17 1702.80 1703.29 1702.93 1703.24 1703.26 1703.27 1703.30 
y’’18 1830.86 1831.35 1831.03 1831.30 1831.45 1831.38 1831.35 
y’’19 1943.94 1944.47 1944.08  1944.42 1944.45 1944.39 
y’’20 2000.96 2001.46 2001.09 2001.48 2001.47 2001.49 2001.46 
y’’21 2084.00 2084.53 2084.13 2084.55 2084.55 2084.60 2084.53 
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CHAPTER IV: STUDYING THE INDIVIDUAL DOMAINS OF CLASS II 
LANTHIPEPTIDE SYNTHETASES USING TRUNCATED ENZYMES 
 
4.1  INTRODUCTION 
As discussed in chapter I, the four classes of lanthipeptides are modified by different 
lanthionine synthetases (Figure 1.4). Class II lanthipeptide synthetases are typically 900-1,200 
residues in length and are composed of a proposed dehydratase domain at the N-terminus and 
a cyclase domain at the C-terminus (Figure 1.4).1-3 The LanM dehydratase domains have no 
homology to class I dehydratase LanBs or other characterized proteins in the databases, while 
the cyclase domains have ~25% sequence identity to LanC, including the conserved residues 
that have been reported to be crucial for cyclization in the nisin cyclase NisC (Figure 3.2).4 
Similar to LanBs and LanCs, LanM enzymes do not share high degree of sequence identity 
with each other.1  
The first successful in vitro reconstitution of a LanM enzyme was reported in 2004 by Xie 
and co-workers, using the precursor peptide LctA and the enzyme LctM generated by 
heterologous expression in E. coli.5 LctM is the lanthionine synthetase for lacticin 481, a 
tricyclic lantibiotic isolated from Lactococcus lactis subsp. lactis. CNRZ 481 in the early 
1990s.6 The proposed biosynthetic pathway for lacticin 481 is shown in Figure 4.1. This report 
provided a platform for mutagenesis studies of LctM7, 8 and the production of lacticin 481 
analogs including incorporation of nonproteinogenic amino acids, which in several cases 
improved the antimicrobial activity.9, 10 11 LctM utilizes ATP and Mg2+ to phosphorylate 
serine/threonine residues in the LctA precursor peptide and to subsequently eliminate the 
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resulting phosphate ester to yield Dha/Dhb (Figure 1.1A). LctM does not contain any known 
ATP-binding domain at the sequence level, but conserved residues involved in phosphorylation 
resemble critical catalytic residues in serine/threonine kinases.8 The cyclization on the other 
hand is ATP-independent and Zn2+-dependent (Figure 1.1B).7  
 
 
Figure 4.1. The posttranslational maturation process of lacticin 481.5 The precursor peptide 
LctA is synthesized ribosomally, followed by dehydration of Ser and Thr (red) residues in the 
core peptide region of LctA and the conjugate addition of three Cys residues in a regio- and 
stereospecific manner to three of the Dha and Dhb (red) residues to generate three cyclic 
thioethers. The leader peptide is proteolytically removed by the N-terminal protease domain of 
the LctT ABC-type transporter that excretes the final product. Abu, 2-aminobutyric acid. 
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Lacticin 481 demonstrates inhibitory activity against L. lactis. subsp. cremoris HP with an 
MIC value of 1.56 M,10 which is only moderate compared to more potent lantibiotics such as 
nisin (MIC = 32 nM).12 A variety of other lantibiotics contain a similar ring topology as lacticin 
481, including nukacin ISK-1 and members of the salivaricin family. These lantibiotics are 
often referred to as the lacticin 481 group, and they display diverse antimicrobial scope and 
potency.13 The A ring of the lacticin 481 group is similar to the C ring of mersacidin, which is 
a known lipid II binding motif.14 A study in 2009 demonstrated lacticin 481 may form 
complexes with lipid II using thin-layer chromatography.15 In 2012, another study 
demonstrated that the A ring of nukacin ISK-1 is the binding motif for lipid II using isothermal 
titration calorimetry.16 Together, these reports suggest that the lacticin 481 group demonstrate 
antimicrobial activities against gram-positive bacteria through the interaction with the 
membrane component lipid II. 
The enterococcal cytolysin is a two-component lantibiotics produced by many clinical 
isolates of Enterococcus faecalis.17-19 Cytolysin is made up of two separate lanthipeptides 
CylLL'' and CylLS'' and is toxic to a broad range of gram-positive bacteria.18 Besides its 
antimicrobial activities, cytolysin also possesses unique hemolytic activity against eukaryotic 
cells, which contributes to the virulence of the pathogenic strains.20, 21 The linear precursor 
peptides for both components of cytolysin (CylLL and CylLS) are modified by the same 
lanthionine synthetase CylM to install the Lan/MeLan rings,22 and these cyclized peptides are 
then digested to remove most of the leader peptide and secreted to the extracellular space by 
CylB.23 Next, another protease CylA removes the six additional residues from the leader 
peptide to generate the mature products. In a recent work published by Tang and co-workers,24 
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the structures of CylLL'' and CylLS'' were for reported (Figure 4.2A). Interestingly, this study 
for the first time reported lanthipeptides with other stereochemistry of the Lan/MeLan 
structures besides the canonical DL-configuration (Figure 4.2B).24 The Dhx-Dhx-Xxx-Xxx-
Cys motif in the precursor peptides have been proven to be important for the unusual LL-
configuration,25 but the role of CylM in the regioselective ring formation has not been fully 
investigated.  
 
 
Figure 4.2. A. Structures of the large and small subunits of cytolysin from E. faecalis. B. The 
observed stereochemistry of the different rings. The stereochemistry of the -carbon 
originating from Cys is R in both cases, but the stereochemistry at the  and  carbons 
originating from Thr (R = Me) is inverted showing that the two types of rings are formed by 
anti addition to opposite faces of the dehydrobutyrine (or dehydroalanine for R = H).
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As discussed in chapters II and III, prochlorosins were discovered in 2010 from the 
planktonic marine cyanobacterium Prochlorococcus MIT9313 in a genome-mining effort to 
search for novel lanthipeptides in the unexplored genomes.26 ProcM and its close homologues 
with three zinc-binding cysteines form a distinct clade in the phylogenetic tree of LanM (Figure 
1.5),27 and generally (but not always) are associated with multiple substrate peptides with 
diverse sequences.28  
For all the class II lanthipeptide synthetases, no crystal structures have been reported so 
far. In fact, before 2014, the only crystal structure reported for any lanthionine synthetase was 
for the nisin cyclase NisC.29 In 2014, the dehydratase for nisin biosynthesis (NisB) was also 
successfully crystallized to provide detailed structure information for deeper understanding of 
class I lanthipeptide biosynthesis. A possible reason of the lack of structural information of 
LanM enzymes is that they are multidomain proteins and relatively large in size. As the cyclase 
domains of LanMs are homologous to LanCs, it is reasonable to speculate that the individual 
cyclase domain might have similar behaviors as LanCs and might crystallize under the similar 
conditions used for NisC crystallization. The three LanMs discussed above are responsible for 
the production of distinct products: LctM processes a single product with Lan/MeLan rings of 
DL-configuration; CylM generates two products with a mixture of DL- and LL-Lan/MeLan 
rings; while ProcM manages to modify 30 products with DL-Lan/MeLan rings. While it is 
difficult to obtain information about the difference of these enzymes at the sequence level, the 
structures of these enzymes might reveal the unique properties of each enzyme. The idea of 
truncating LanM into individual domains was initially motivated by the possibility to obtain 
crystal structures of these domains to allow further understanding of class II lanthipeptide 
107 
 
biosynthesis. Also, obtaining individual domains of LanMs for the first time allows studying 
the dehydration and cyclization of class II lanthipeptide in isolation, which is important to 
understand the product selectivities of LanM enzymes. Moreover, this study will also provide 
insights on the evolution of the lanthionine synthetases as it is proposed that the LanM enzymes 
might have evolved from a fusion event of two ancestor enzymes that are responsible for 
dehydration and cyclization respectively. 
 
4.2  RESULTS 
4.2.1 Cloning, heterologous expression, purification and crystallization attempts of 
truncated LanM enzymes  
To determine the possible cleavage sites to split LanMs into two individual domains, the 
amino acid sequences of several LanMs were aligned with NisC using the NCBI online 
alignment tool Cobalt.30 As indicated in Figure 4.3, pRSF-Duetl constructs containing the 
following truncated enzymes were made by molecular cloning methods as described in the 
Experimental Procedures section 4.4.2: ProcM-1-660, ProcM-655-1068, LctM-1-543, LctM-
544-922, CylM-1-658, and CylM-659-993.  
These truncated enzymes were expressed heterologously in Escherichia coli as N-
terminally His6-tagged fusion proteins. Expression of the LanM proteins using the pRSF-Duet1 
vector resulted in higher expression level as well as less protein produced in the inclusion 
bodies than using the pET28b vector. The purification processes are described in detail in 
section 4.4.3. ProcM-655-1068, LctM-1-543 and CylM-1-658 were expressed solubly, and the 
proteins were isolated as monomers and used for downstream experiments. ProcM-1-660 was 
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also expressed solubly, but existed in various oligomeric states. The oligomers of lower 
molecular mass were collected and used for downstream experiments. LctM-544-922 was 
expressed at a reasonable level, but protein of the predicted mass was only found in the 
insoluble portion of the cell lysate. CylM-659-993 was handed to group member Weixin Tang 
for further characterization. ProcM-1-660, ProcM-655-1068 and LctM-1-543 were used to set 
up multiple 96-well trays to test different crystallization conditions, but no crystal was observed 
in all experiments. CylM-1-543 was also used for crystallization attempts by Dr. Shihui Dong 
in Professor Satish Nair Lab, but also no crystal was obtained although full length CylM was 
successfully crystallized (unpublished data when this chapter is written).  
 
Figure 4.3. Sequence alignment of several LanMs and NisC showing the possible boundary 
between the dehydration and cyclization domains. The residues highlighted in yellow are the 
residues at the same position as the first residue of NisC. The residues highlighted in blue 
indicate the sites for the truncation, which were chosen to be within a few amino acids from 
the highlighted residues.  
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4.2.2 The dehydratase domain of ProcM modifies its substrates with reduced rate 
ProcM-1-660 includes the putative dehydratase domain. The activity of ProcM-1-660 was 
tested in parallel with WT-ProcM against two ProcA substrate peptides: ProcA1.1 and 
ProcA3.3. The in vitro enzymatic assays were carried out at room temperature using the 
standard conditions for ProcM: 10 mM ATP, 1 mM TCEP, 50 mM HEPES (pH 8.0), and 
various amounts of peptide and enzyme. As shown in Figure 4.4A and Figure 4.4B, ProcM-1-
660 was able to catalyze one dehydration of both ProcA1.1 and ProcA3.3. Even though the 
majority of the starting peptides were converted to the one-fold dehydrated species, no signals 
corresponding to the two-fold dehydrated peptide were detected. It is obvious that the 
dehydration activity of ProcM-1-600 was significantly reduced compared to WT-ProcM, but it 
is still interesting to see the dehydratase domain alone was active. To test if the specificity of 
the enzyme was retained, ProcM-1-660 was also tested against LctA. As shown in Figure 4.4C, 
no dehydration was observed in LctA. Since ProcM was able to modify a chimeric peptide 
consisting of the ProcA leader peptide and LctA core peptide,27 the dehydratase domain of 
ProcM must specifically recognize the ProcA leader peptide in the chimeric peptide analog. 
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Figure 4.4. MALDI-TOF mass spectra of (A) ProcA1.1 peptide (25 M) modified by either 2 
M WT ProcM (blue) or ProcM-1-660 (red) for 45 min, followed by subsequent digestion by 
GluC; (B) ProcA3.3 peptide (25 M) modified by either 2 M WT ProcM (blue) or ProcM-1-
660 (red) for 45 min, followed by subsequent digestion by GluC; (C) LctA peptide (2 M) 
incubated with either 2 M ProcM-1-660 (red) or no enzyme (blue) for 3 h. M=unmodified 
starting peptide. 
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4.2.3 The cyclase domain of ProcM determines the ring formation of the products 
ProcM-655-1068 includes the putative cyclase domain. In order to test the cyclization 
activity of ProcM-655-1068, the first requirement was the generation of linear dehydrated 
ProcA. ProcA3.3 was treated with 5 mM oxidized glutathione to introduce a disulfide bond 
between the two cysteines, which prevents the cysteines from attacking the unsaturated amino 
acids during the dehydration process. WT ProcM was able to take the peptide with the disulfide 
bridge as substrate and catalyzed the 3-fold dehydration of the core peptide. The activity of 
ProcM-655-1068 was tested using this dehydrated ProcA3.3, and the cyclization reaction was 
monitored by the iodoacetamide (IAA) assay described in section 2.4.9. ProcM-655-1068 was 
able to fully cyclize ProcA3.3 and the majority of the product did not react with IAA (Figure 
4.5). The negative control shows the level of non-enzymatic cyclization in the in vitro 
enzymatic assay, and only about 20% peptide formed one ring non-enzymatically, and no fully 
cyclized peptide was detected (Figure 4.5). This result clearly demonstrated that the cyclase 
domain was fully active on its own. 
 
112 
 
 
Figure 4.5. MALDI-TOF mass spectra of dehydrated ProcA3.3 peptide (25 M) incubated 
with either 2  ProcM-655-1068 (red) or reaction buffer with no enzyme (blue) for 3 h, 
followed by subsequent digestion by GluC and IAA treatment. The minor peaks in the negative 
control (NC) correspond to incomplete dehydration: 1, M − 2 H2O; 2, M − H2O; 3, M − 2 H2O 
+ 1 IAA; 4, M − H2O + 1 IAA; 5, M + 1 IAA. These species were present at lower intensity in 
the top mass spectrum due to the better ionization of the cyclized peptide. 
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Figure 4.6. EICs (Extracted ion chromatograms) of the ESI-LC-MS experiments showing the 
Δ1 core peptide ion obtained by endoprotease AspN digestion of dehydrated ProcA3.3 
incubated with WT ProcM, ProcM-655-1068, ProcM-C971H, and ProcM-C971H-655-1068. 
The generation of standards was described in the legend of Figure 3.14. All the peptides were 
digested by AspN to remove the leader peptide. 
 
As described in chapter III, a single mutation of the zinc ligand Cys971 to a histidine 
residue altered the regioselectivity of the enzyme and resulted in the formation of a different 
major product for ProcA3.3. To test if this regioselectivity was retained with ProcM-655-1068, 
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dehydrated ProcA3.3 was incubated with either the WT-ProcM or ProcM-655-1068 for 3 h, 
subsequently digested by AspN protease and analyzed by liquid chromatography electrospray 
ionization mass spectrometry (ESI-LC-MS) to differentiate the ProcA3.3 core peptide with 
different potential cyclization patterns. As depicted in Figure 4.6, both the full length enzyme 
and the isolated cyclase domain prefer the formation of product 1 and intermediate 3. 
Interestingly, both the full length ProcM-C971H and its isolated cyclase domain with the 
C971H mutation prefer the formation of product 2 and intermediate 5 instead, which strongly 
suggests that the cyclase domain of ProcM is able to determine the ring formation of ProcAs. 
As shown in section 4.2.2, the dehydration activity of ProcM is leader-dependent, which 
suggests a leader binding site in the dehydratase domain. To test whether the cyclase domain 
has its own leader binding site or whether it depends on the dehydratase domain for substrate 
binding, the leader-dependence of ProcM-655-1068 was tested using dehydrated ProcA3.3 
core peptide (peptide generation described in section 4.4.4). In Figure 4.7, it is shown that there 
was no difference in the IAA assay between the enzyme-treated core peptide and the negative 
control. This experiment suggests that the activity of the cyclase domain is also leader-
dependent, and ProcM may have two independent leader binding sites, one in each of its two 
domains. 
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Figure 4.7. MALDI-TOF mass spectra of dehydrated ProcA3.3 core peptide (~20 M) 
incubated with 5 M ProcM-655-1068 (red) or no enzyme (blue) for 3 h, followed by 
subsequent digestion by GluC and treatment with IAA. 
4.2.4 Synergistic action of two ProcM domains 
As discussed in section 4.2.2, ProcM dehydratase domain was only able to catalyze one-fold 
dehydration. This observation suggested the possibility that the two domains collaborate with 
each other to modify the substrate, and that the cyclization domain might facilitate the 
dehydration reaction. Indeed, it has been reported for nisin, haloduracin, and curvopeptin that 
the dehydration and cyclization reactions are alternating processes during biosynthesis.31-34 
Although ProcM catalyzes all dehydration reactions before commencing cyclization processes 
for the substrates that have been investigated thus far,33, 35 no studies were carried out with 
individual dehydratase and cyclase domains. It would be interesting to see if the dehydration 
and cyclization domains show cooperative behavior. Surprisingly, a dramatic improvement in 
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the dehydration of both ProcA1.1 and ProcA3.3 was indeed observed when the cyclase domain 
was added (Figure 4.8). Not only did the ProcM-1-660 catalyze 3-fold dehydration in presence 
of the cyclase domain, the rate of the dehydration reaction was also increased to a level similar 
as that of the WT enzyme.  
 
Figure 4.8. MALDI-TOF mass spectra of (A) ProcA1.1 (25 M) modified by 2 M ProcM-1-
660 with (red) or without ProcM-655-1068 (blue) for 1 h, and subsequently digested by GluC; 
(B) ProcA3.3 (25 M) modified by 2 M ProcM-1-660 with (red) or without ProcM-655-1068 
(blue) for 1 h, followed by subsequent digestion by GluC. 
117 
 
4.2.5 The binding affinity of ProcA3.2 leader peptide to ProcM individual domains 
As discussed in section 4.2.2 and 4.2.3, ProcM may have two independent leader binding 
sites since both the dehydratase and cyclase domains of ProcM process leader peptide-
dependent activities. In order to confirm that ProcA leader peptide indeed binds to these two 
domains, fluorescence polarization experiments were used to evaluate the binding affinity 
between ProcA leader peptide and truncated ProcM enzymes. His6-ProcA3.2 leader peptide 
was obtained using the construct generated as described in section 4.4.5, and fluorescently 
labelled with fluorescein isothiocyanate (FITC) which primarily reacts with the N-terminal free 
amine group of the peptide (section 4.4.6). Using procedures described in section 4.4.7, the 
binding affinity of FITC-ProcA3.2Lea to WT ProcM, ProcM-655-1068, and ProcM-1-660 
were measured. As shown in Figure 4.9, the cyclase domain of ProcM showed a binding 
affinity similar to WT ProcM (8.0 ± 1.2 M). The binding of FITC-ProcA3.2Lea to the 
dehydratase domain was also detected, but the binding affinity was about 8-fold weaker 
compared to that to WT ProcM. 
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Figure 4.9. Fluorescence polarization assays with WT ProcM (A), ProcM-655-1068 (B) and 
ProcM-1-660 (C) using 10 nM FITC-ProcA3.2Lea. 
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4.2.6 The dehydratase domains of LctM and CylM are fully active 
Residues 1-543 constitute the putative dehydratase domain of LctM. The activity of LctM-
1-543 was tested in parallel with WT-LctM against LctA peptide. Unlike ProcM-1-660, LctM-
1-543 was able to catalyze all four possible dehydrations in LctA, and with a similar efficiency 
compared to the WT enzyme (Figure 4.10). Notably, the major intermediate observed for WT 
enzyme was two-fold dehydrated LctA, but this intermediate did not accumulate in the reaction 
catalyzed by LctM-1-543 for unknown reason. 
LctM was reported to be able to catalyze the in trans modifications of truncated LctA core 
peptide in the presence of the LctA leader peptide. 10 It was of interest to see if the dehydratase 
domain could do the same. Indeed, LctM-1-543 was able to modify the LctA core peptide when 
the leader peptide was provided in trans, again with a similar rate as the WT enzyme (Figure 
4.11). As will be discussed in chapter V, the binding of LctA leader peptide to LctM-1-543 was 
confirmed using fluorescence polarization experiments with a KD value of 9.6±2.1 M.  
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Figure 4.10. MALDI-TOF mass spectra of LctA (20 M) modified by 5 M LctM-1-543 or 
LctM for 1 h, or 3 h. The numbers above the peaks correspond to the number of dehydration 
events. 
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Figure 4.11. MALDI-TOF mass spectra of LctA N15R/F21H core peptide (20 M) modified 
by 5 M LctM-1-543 (red) or LctM (blue) with or without 2M LctA leader peptide for 1 h, 
or 3 h. The numbers above the peaks correspond to the number of dehydration events. 
 
Residues 1-658 form the putative dehydratase domain of CylM. Like the truncated LctM, 
CylM-1-658 was also able to fully dehydrate one of its substrate (CylLs) (Figure 4.12). Besides 
the fully dehydrated product (4-fold dehydrated), a peak corresponding to the 5-fold dehydrated 
product and a peak corresponding to a 4-fold dehydrated and phosphorylated product were also 
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detected. This observation might indicate one extra dehydration in the leader region because 
the core peptide contains only four Ser and Thr residues (Figure 4.3). 
 
 
 
Figure 4.12. MALDI-TOF mass spectra of CylLS (10 M) incubated with 5 M CylM-1-548 
(red) or no enzyme (blue) for 1 h. The peak labeled with the star symbol corresponds to the 
five-fold dehydrated peptide. Since the maximum number of dehydrations that can occur in the 
CylLS core peptide is four, it is possible that the serine at the -7 position in the leader peptide 
is dehydrated. NC=negative control. 
 
4.2.7 The chimeric enzymes  
As mentioned in a previous study,36 ProcM was able to produce active lacticin 481 using 
a chimeric peptide containing the ProcA leader peptide and LctA core peptide. However, this 
strategy did not work for all lanthipeptides as ProcM only catalyzed partial modifications in 
the NisA and ElxA core peptides attached to the ProcA leader peptide. As shown in section 
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4.2.3, the cyclase domain itself determines the ring topology of the product. Thus, it was of 
interest to see if a chimeric ProcM-LctM enzyme with the highly promising ProcM dehydratase 
domain and a specific LctA cyclase domain would be active against the native or chimeric 
ProcA/LctA peptides. LctM-ProcM chimeric enzyme consisting of the LctM dehydratase 
domain and the ProcM cyclase domain as well as a ProcM-NisC enzyme with the ProcM 
dehydratase domain and the NisC cyclase were constructed. ProcM-LctM and LctM-ProcM 
were successfully expressed in E. coli, but the ProcM-NisC protein did not express. LctM-
ProcM showed weak dehydration activity on LctA (3-fold dehydrated peptide was observed), 
but no activity against ProcALea-LctAStr (a chimeric peptide consisting of the ProcA leader 
peptide and the LctA core peptide) and ProcA3.3 (Figure 4.13). Only minor cyclization activity 
was observed upon LctA incubation with LctM-ProcM, which is attributed to non-enzymatic 
cyclization. Similarly for ProcM-LctM, weak dehydration activity was observed for ProcA3.3, 
but not for ProcALea-LctAStr and LctA (Figure 4.14). The cyclization reaction was also 
negligible.  
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Figure 4.13. MALDI-TOF mass spectra of 25 M LctA, ProcALea-LctAstr, or ProcA3.3 
incubated with 5 M LctM-ProcM for 3 h, followed by protease digestion and analysis with 
(red) or without (blue) IAA assay. LctA and ProcALea-LctAstr were digested by LysC, and 
ProcA3.3 was digested by GluC. 
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Figure 4.14. MALDI-TOF mass spectra of 25 M ProcA3.3, ProcALea-LctAstr, or LctA 
incubated with 5 M LctM-ProcM for 3 h, followed by protease digestion and analysis with 
(red) or without (blue) IAA assay. LctA and ProcALea-LctAstr were digested by LysC, and 
ProcA3.3 was digested by GluC. 
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4.3  DISCUSSION AND OUTLOOK 
In summary of this chapter, the individual dehydration and cyclization domains of three 
class II lanthionine synthetases (ProcM, LctM, and CylM) were constructed and the proteins 
were obtained by heterologous expression in E. coli. For all the proteins that were solubly 
expressed, at least partial activities were observed against their native substrate which suggests 
the two LanM domains are able to function independently. Except for the ProcM dehydratase 
domain, all other truncated enzyme characterized in this study were able to catalyze full 
conversion of the substrate, and in the case of LctM dehydratase domain, it was demonstrated 
to have a similar reaction rate compared to the WT-LctM.  
For the dehydratase domain, the truncated enzymes from different LanM displayed 
different behavior. The LctM and CylM dehydratase domains both showed full activity on their 
substrates, and these two enzymes are relatively close in a phylogenetic tree (Figure 1.5). Both 
enzymes belong to the LanM clade from Firmicutes, while ProcM and its homologues are in a 
distinct clade. It is likely that LanM enzymes have several subgroups due to different 
evolutionary paths, and enzymes from each group might display different catalytic properties. 
This hypothesis is supported by the fact that the substrate tolerance, reaction rate and 
regioselectivity of these three LanM are different from each other.  
The ProcM dehydratase domain did not have the ability of catalyzing multiple dehydration 
in the substrate. The reason for this loss of function cannot be explained solely by the decrease 
of the dehydration rate, since the majority of the starting material was converted to the 1-fold 
dehydrated species, but no signals corresponding to the 2 or 3-fold dehydrated peptide was 
observed even with extended incubation time. With the presence of the cyclase domain in trans, 
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the dehydratase domain was able to fully dehydrate ProcAs at a rate that is comparable to the 
WT-ProcM. Clearly the cyclase domain did not catalyze the dehydration reaction directly, 
because incubation of the cyclase domain alone with the substrates did not result in dehydration. 
Thus, there are two possible explanations of this synergistic effect of the two ProcM domains: 
the first one is that the binding of the cyclase domain induces conformational changes in the 
dehydratase domain that activates the enzyme; the second one is that cyclization of the partially 
dehydrated intermediates results in tighter binding to the enzyme and preventing immature 
substrate release. Because cyclization has been shown to commence only after dehydration is 
completed,34, 35 the second explanation does not hold. 
The ProcM cyclase domain is the only cyclase tested in this study. Not only did the cyclase 
domain catalyze full conversion of the dehydrated ProcA3.3 peptide, it also formed product 
with the correct ring topology. As discussed in chapter III, if a zinc ligand of ProcM was 
mutated, the mutant enzyme lost ability to convert ProcA3.3 into a product with two-
overlapping rings and this change in regioselectivity was accompanied with a decrease in the 
cyclization rate. It is interesting that the complete removal of the large dehydratase domain 
seems to bring no changes at all for the cyclase domain. This observation supports the idea that 
LanM enzymes evolved by a fusion event of a dehydratase domain and the LanC-like ancestor. 
Previous work performed by Goto and coworkers demonstrated the phosphorylation 
activity of the individual kinase domain and the elimination activity of the individual lyase 
domain of the class IV lanthionine synthetase VenL, but no activity was reported for the 
individual cyclase domain.37 Also, in a recent study on NukM,38 only the dehydratase domain 
displayed activity on NukA and no activity was reported for the cyclase domain. This chapter 
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demonstrates a successful example to study the dehydration and cyclization reaction catalyzed 
by LanM in isolation in order to understand the relationship between these two processes. It is 
been applied in other studies for the mechanistic investigation of the LanM enzymes,36 and it 
can be generally applied for all LanM enzymes. Furthermore, for class III and IV lanthionine 
synthetases with three domains, studying each domain individually is also beneficial to 
understand the molecular detains of lanthionine formation and the evolutionary history of these 
complex enzymes.  
 
4.4  EXPERIMENTAL PROCEDURES 
4.4.1 Construction of the expression plasmids for truncated enzymes 
The plasmids pET28b-procM,26 pRSFDuet1-procM-C971H,36 pET28b-lctM,5 and pRSFDuet-
1-cylM-224 were isolated from E. coli DH5α cells and used as templates for PCR reactions. The 
DNA sequence for each truncated enzyme was PCR amplified using Phusion polymerase by 
30 cycles of denaturing (98 °C for 30 s), annealing (55 °C for 30 s), and extending (72 °C, 1 
min for each 1.5 kb) using forward primer and reverse primer indicated in Table 4.1. The PCR 
product was digested with EcoRI and NotI restriction enzymes and ligated into the first 
multiple cloning site (MCS1) in the pRSF-Duet1 vector to generate the constructs listed in 
Table 4.1. The sequences of the inserts were checked by DNA sequencing.  
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Table 4.1. Primer sequence used in section 4.4.1. 
Construct Primer Name Primer Sequences (5’-3’) 
pRSFDuet1-
procM-1-660 
(Template: 
pET28b-procM) 
Forward: 
procM _EcoRI_FP 
CAGGATCCGAATTCGATGGAA
AGTCCATCATCTTGG 
Reverse: 
procM _660_NotI_RP 
CTCAGCGCGGCCGCTCACTCA
GCCGATGATGACATC 
 
pRSFDuet1-
procM-655-1068 
(Template: 
pET28b-procM) 
Forward: 
procM_655_EcoRI_ 
FP 
GAATCCGAATTCGATGTCATCA
TCGGCTGAGACGA 
Reverse: 
procM _NotI_RP 
 
AAGGAAAAAAGCGGCCGCTTA
TTCAGTAGGCCAGAGA 
pRSFDuet1-
procM-655-1068-
C971H 
(Template: 
pRSFDuet1-
procM-C971H) 
Forward: 
procM_655_EcoRI_F
P 
GAATCCGAATTCGATGTCATCA
TCGGCTGAGACGA 
Reverse: 
procM _NotI_RP 
AAGGAAAAAAGCGGCCGCTTA
TTCAGTAGGCCAGAGA 
pRSFDuet1-lctM-
1-543 
(Template: 
pET28b-lctM) 
Forward: 
lctM_EcoRI_FP 
CATATGGAATCCGATGAAAAA
AA AGACTTAC 
 
Reverse: 
lctM_543_NotI_RP 
CTCAGCGGCGCGCCTCATGAA
AGCTCATTTATCGC 
 
pRSFDuet1-lctM-
544-922 
(Template: 
pET28b-lctM) 
Forward: 
lctM_544_EcoRI_FP 
GCTGAGGAATTCGAGTATCTT 
AGAAAACAAT GC 
 
Reverse: 
lctM_NotI_RP 
CTCAGCGCGGCCGCTTAATCAA
CATATGGC 
 
pRSFDuet1-cylM-
1-658 
(Template: 
pRSFDuet-1-cylM-
2) 
Forward: 
cylM_EcoRI_FP 
 
AAAAAGAATTCGGAAGATAAT
CTGATTAA T 
Reverse: 
cylM_658_NotI_RP 
 
CTCAGCGCGGCCGCTCATTCAA
TTTTCTGGCAGGCC 
pRSFDuet1-cylM-
659-993 
(Template: 
pRSFDuet-1-cylM-
2) 
Forward: 
cylM_659_EcoRI_FP 
CAGGATCCGAATTCGAAAAAA
ATCTTTAAACGTGC 
 
Reverse: 
cylM_NotI_RP 
AAAAAGCGGCCGCTTACAGTT
CAAACAGCA G 
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4.4.2 Construction of the expression plasmids for chimeric enzymes 
The plasmids pET28b-procM,26 pET28b-lctM, and pRSFDuet-1-cylM-224 were isolated from 
E. coli DH5α cells and used as templates for PCR reactions. The DNA sequence for each 
truncated enzyme was PCR amplified using Phusion polymerase by 30 cycles of denaturing 
(98 °C for 30 s), annealing (55 °C for 30 s), and extending (72 °C, 1 min for each 1.5 kb) using 
forward and reverse primers indicated in Table 4.2. The chimeric enzymes were constructed in 
two steps: 1. the gene for the N-terminal domain (with no stop codon) was inserted between 
EcoRI and AscI restriction sites in the first multiple cloning site (MCS1) in the pRSF-Duet1 
vector. The sequences of the inserts were checked by DNA sequencing. 2. Constructs generated 
in step 1 were used as vector to insert the gene for the C-terminal domain between AscI and 
NotI restriction sites. The sequences of the second inserts were checked by DNA sequencing.  
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Table 4.2. Primer sequence used in section 4.4.2. 
Construct Primer Name Primer Sequences (5’-3’) 
pRSFDuet1-procM-
1-660-AscI 
(Template: 
pET28b-procM) 
Forward: 
procM _EcoRI_FP 
 
CAGGATCCGAATTCGATGGAA
AGTCCATCATCTTGG 
Reverse: 
procM_660_AscI_RP 
CTCAGCGGCGCGCCCTCAGCC
GATGATGACATC  
 
pRSFDuet1-procM-
lctM 
(Template: 
pRSFDuet1-procM-
1-660-AscI) 
Forward: 
lctM_655_AscI_FP 
 
GCTGAGGGCGCGCCAAGTATC
TT AGAAAACAAT GC 
Reverse: 
lctM _NotI_RP 
 
CTCAGCGCGGCCGCTTAATCAA
CATATGGC 
 
pRSFDuet1-procM-
nisC 
(Template: 
pRSFDuet1-procM-
1-660-AscI) 
Forward: 
nisC_AscI_FP 
 
GCTGAGGGCGCGCCAATGAGG
ATAATGATG 
Reverse: 
nisC_NotI_RP 
 
CTCAGCGCGGCCGCTCATTTCC
TCTTCCCTCC 
 
pRSFDuet1-lctM-1-
543-AscI 
(Template: 
pET28b-lctM) 
Forward: 
lctM_EcoRI_FP 
CATATGGAATCCGATGAAAAA
AA AGACTTAC 
 
Reverse: 
lctM_543_AscI_RP 
CTCAGCGGCGCGCCTGAAAGC
TCATTTATCGC 
 
pRSFDuet1-lctM- 
procM 
(pRSFDuet1-lctM-
1-543-AscI) 
Forward: 
procM_661_AscI_FP 
CTTTCAGGCGCGCCAACGAGT
CTGGAGGCAGC 
 
Reverse: 
procM _NotI_RP 
AAGGAAAAAAGCGGCCGCTTA
TTCAGTAGGCCAGAGA 
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4.4.3 Construction of the expression plasmids for chimeric peptides 
The generation of pET15b-ProcALea_NisAStr and pET15b-ProcALea_LctAStr constructs were 
described in section 2.4.2. The pET15b-LctLea_ProcAStr plasmids was constructed following 
the same procedures using primers and templates described in Table 4.3. The sequences of the 
inserts were checked by DNA sequencing. Unmodified CylLs peptide was obtained from 
Weixin Tang. 
Table 4.3. Primer sequence used in section 4.4.3. 
pET15b-lctALea-
procA3.3Str  
(Template: 
pET15b-lctA, 
pET15b-procA3.3) 
Forward-1: 
lctA_NdeI_FP  
 
GGCAGCCATATGATGAAAGAA
CAAAACTCT 
 
Reverse-1: 
lctA3.2Lea_ 
procA3.3Str 
_Conn_RP 
CTTATTTTAGGTGCAGGCGATA
CCGGCATC 
 
Forward-2: 
lctA3.2Lea_ 
procA3.3Str 
_Conn_FP 
CTTATTTTAGGTGCAGGCGATA
CCGGCATC 
 
Reverse-2: 
ProcA3.3_XhoI_RP  
ATACAATCCTCGAGCTATGCG
CGGCACATTTTGG 
 
4.4.4 Generation of dehydrated ProcA3.3 core peptide 
Oxidized dehydrated ProcA3.3 peptide was generated using procedures described in section 
3.4.3. An aliquot of 300 μL peptide was treated with 10 μL GluC (2 mg/mL) for 3 h, and the 
resulting peptide was injected to an analytical C18 HPLC column, and separated by HPLC 
using a gradient of 2% mobile phase B to 100% mobile phase B over 45 min (mobile phase A: 
water with 0.1% trifluoroacetic acid, mobile phase B: acetonitrile with 0.1% trifluoroacetic 
acid). The core peptide was collected and reduced with TCEP in the in vitro assays. 
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4.4.5 Construction of the expression plasmids for ProcA3.2 leader peptide 
The plasmid pET15b-procA3.226 was isolated from E. coli DH5α cells and used as template 
for PCR reaction. The DNA sequence for ProcA3.2 leader was PCR amplified using Phusion 
polymerase by 30 cycles of denaturing (98 °C for 30 s), annealing (55 °C for 30 s), and 
extending (72 °C for 15 s) using forward primer and reverse primer indicated in Table 4.4. The 
PCR product was digested with NdeI and XhoI restriction enzymes and ligated pET15b vector 
to generate the construct pET15b-procA3.2Lea. The sequences of the inserts were checked by 
DNA sequencing.  
Table 4.4. Primer sequence used in section 4.4.5. 
pET15b-
procA3.2Lea 
(Template: 
pET15b-procA3.2) 
Forward: 
procA3.2_NdeI_FP  
 
TCAGATCATATGATGTCAGA
AGAACAACTC 
 
Reverse: 
procA3.2Lea_XhoI_RP  
TCAGATCTCGAGCTATCCCC
CAGCCACACCTTC 
 
4.4.6 Labelling ProcA3.2 leader peptides with fluorescein isothiocyanate (FITC) 
FITC (purchased from Sigma) was dissolved in DMF at 10 mg/mL. An aliquot of 1 mg His6-
tagged ProcA3.2 leader peptide was dissolved in 0.5 mL of conjugation buffer (50 mM borate 
buffer, pH 8.5). An excess amount of FITC was added (FITC concentration was 20-fold that 
of the peptide concentration) to the peptide solution and the mixture was incubated at room 
temperature in the dark for 24 h. The resulting peptide mixture was subjected to extensive 
dialysis in the 20 mM HEPES buffer (pH 7.5) to remove DMF and unreacted FITC, followed 
by repeated desalting using an Amicon Ultra-15 Centrifugal Filter Unit (3kDa MWCO) until 
all excess FITC was removed from the peptide solution. 
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4.4.7 Fluorescence polarization (FP) assay using FITC-ProcA3.2Lea 
All FP experiments were performed on a Synergy H4 Hybrid plate reader (BioTek) using a 96-
well black opaque half area plate (Costar 3694). Increasing amounts of LanM or truncated 
LanM enzymes were added to fluorescein-labeled peptides (10 or 20 nM) in LanM Start buffer 
(20 mM HEPES, 1 M NaCl, pH 7.5). Data analysis was performed using Origin 9.0, and curves 
were fitted to a hyperbolic equation to calculate KD (y = (a*x)/(KD +x) + c). 
4.4.8 Experimental procedures listed in other chapters 
Expression and purification of unmodified and modified peptides (section 2.4.5); Expression 
and purification of LanM enzymes (section 2.4.6); 
In vitro enzymatic assay and endoprotease digestion (section 2.4.7); 
Iodoacetamide assay (section 2.4.9); 
Generation of dehydrated ProcA3.3 (section 3.4.3). 
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4.4.9 Calculated and observed masses in the mass spectra 
Table 4.5. Calculated and observed masses in the mass spectra. 
 * monoisotopic masses plus one proton were shown for all peaks 
 
 
Figure Peak Calculated mass Observed mass
M - H2O (Red) 2143.0 2142.5
M (Red) 2161.0 2160.5
M - 2 H2O (Blue) 2125.0 2124.0
M - H2O (Red) 2635.2 2634.6
M (Red) 2653.2 2652.6
M - 3 H2O (Blue) 2599.2 2598.3
M - 2 H2O (Blue) 2617.2 2616.3
M - H2O (Blue) 2635.2 2634.6
M  (Red) 7705.6 7703.3
M (Blue) 7705.6 7703.6
M - 3 H2O (Red) 2599.2 2599.6
M - 3 H2O + 1 IAA (Red) 2656.2 2656.6
M - 3 H2O (Blue) 2599.2 2599.0
M - 3 H2O + 1 IAA (Blue) 2656.2 2656.6
M - 3 H2O + 2 IAA (Blue) 2713.2 2713.1
M - 3 H2O + 2 IAA (Red) 2713.2 2714.0
M - 2 H2O + 2 IAA (Red) 2731.2 2732.0
M - 3 H2O + 2 IAA (Blue) 2713.2 2713.2
M - 2 H2O + 2 IAA (Blue) 2731.2 2731.2
M - H2O (Blue) 2143.0 2142.7
M (Blue) 2161.0 2160.7
M - 2 H2O (Red) 2125.0 2124.9
M - H2O (Blue) 2635.2 2635.0
M (Blue) 2653.2 2654.0
M - 3 H2O (Blue) 2599.2 2599.9
M - 2 H2O (Blue) 2617.2 2617.9
M - H2O (Blue) 2635.2 2634.0
Figure 4.8 (B)
Figure 4.4 (A)
Figure 4.4 (B)
Figure 4.4 (C)
Figure 4.5
Figure 4.7
Figure 4.8 (A)
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(Table 4.5 continued) 
 
 
 
 
 
 
Figure Peak Calculated mass Observed mass
M -  H2O (Red,  Lct A core, 1 h) 2986.3 2986.5
M  (Red,  Lct A core, 1 h) 3004.3 3004.6
M - H2O (Red,  Lct A core, 3 h) 2986.3 2987.0
M - 3 H2O (Red,  leader + core, 1 h) 2950.3 2950.8
M - 3 H2O (Red,  leader + core, 3 h) 2950.3 2950.8
M -  H2O (Blue,  Lct A core, 1 h) 2986.3 2986.5
M  (Blue,  Lct A core, 1 h) 3004.3 3004.5
M - H2O (Blue,  Lct A core, 3 h) 2986.3 2986.7
M - 3 H2O (Blue,  leader + core, 1 h) 2950.3 2950.7
M - 3 H2O (Blue,  leader + core, 3 h) 2950.3 2950.7
M - 5 H2O (Red) 8788.2 8791.9
M - 4 H2O (Red) 8806.2 8808.8
M - 5 H2O + PO3- (Red) 8868.2 8969.6
M  (Blue) 8878.2 8878.1
M - 3 H2O (LctA) 2790.2 2790.1
M  (LctA) 2844.2 2844.1
M - 3 H2O + 1 IAA (LctA, IAA) 2847.2 2847.4
M - 3 H2O + 2 IAA (LctA, IAA) 2904.2 2904.4
M + 3 IAA (LctA, IAA) 3015.2 3015.5
M  (ProcALea-LctAstr) 2844.2 2844.2
M  (ProcA3.3) 2653.2 2653.1
M - H2O (ProcA3.3) 2635.2 2635.1
M  (ProcA3.3) 2653.2 2653.0
M - H2O + 1 IAA (ProcA3.3, IAA) 2692.2 2691.5
M + 2 IAA (ProcA3.3, IAA) 2767.2 2767.5
M  (ProcALea-LctAstr) 2844.2 2843.9
M  (LctA) 2844.2 2843.8
Figure 4.11
Figure 4.12
Figure 4.13
Figure 4.14
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CHAPTER V: YEAST SURFACE DISPLAY OF LANTHIPEPTIDE 
LEADER PEPTIDES 
 
5.1 INTRODUCTION 
As described in chapter I, the precursor peptides of lanthipeptides are ribosomally 
translated and are composed of an N-terminal leader peptide and a C-terminal core peptide. 
During the biosynthesis of lanthipeptides, post-translational modifications occur in the core 
peptides, followed by the removal of the leader peptides to generate the mature product. The 
leader peptides are believed to carry out the following functions: First, keep the modified core 
peptide inactive in order to protect the producing strains;1-3 Second, act as a secretion signal to 
be recognized by the lanthipeptide transporters;2, 3 Third, serve as a recognition motif for the 
biosynthetic enzymes and guide the process of the post-translational modifications;3-6 And 
fourth, bind to the biosynthetic enzymes and shift the equilibrium between the inactive and 
active enzyme towards the latter form.3, 7  
The leader peptides of different lanthipeptides preserve a certain degree of sequence 
conservation, especially the protease recognition motif just before the core region.3 The leader 
peptides of class I lanthipeptides are about 25 amino acids in length and are rich in aspartate 
residues, and contain a conserved FNLD box.8 The leader peptides of class II lanthipeptides 
are also rich in aspartate and glutamate residues, contain an ELXXBX motif (B = V, L or I), 
and usually end in a double glycine motif. A recent paper reported the first co-crystal structure 
of a lanthionine synthetase (NisB) in complex with its substrate peptide (NisA),9 which 
provides insight into the substrate recognition of this group of enzymes. In the co-crystal 
142 
 
structure, the FNLD motif of NisA interacts with an anti-parallel  strand motif of NisB, and 
this scheme of substrate binding might be general among the lanthionine synthetases.  
There are several motivations to engineer lanthipeptide leader peptides for tighter binding 
affinity to the modification enzymes. The first reason is to facilitate crystallographic studies of 
the lanthipeptide synthetases. When this project was carried out, there was no crystal structure 
reported for the LanB dehydratases and the bifunctional LanM synthetases although extensive 
efforts were made. The cyclase NisC in the nisin biosynthetic pathway is one of the few 
lanthipeptide modification enzymes for which a crystal structure has been solved. The crystal 
structure of NisC was solved to a resolution of 2.5 Å and efforts were made to obtain a co-
crystal structure of NisC with its substrate in its binding pocket.10 The difficulties in obtaining 
co-crystal structures of the lanthionine synthetase and the substrate might be due to the 
relatively weak binding affinity. In order to solve this problem, yeast surface display was 
selected to evolve the lanthipeptide leader peptides for tighter binding, which might also be 
useful to obtain crystals of the lanthionine synthetases without reported structures.  
A previous study in our lab carried out by Dr. Oman showed that LctM fused with the 
LctA leader peptide (ConFusion LctM) catalyzed the modification of the LctA core peptide 
without its leader peptide attached to it.11 However, the catalytic efficiency was dramatically 
decreased compared to the catalytic efficiency of wild type LctM on its natural substrate. It 
was envisioned that if LctM is fused with a more tightly bound LctA leader peptide, the leader 
peptide might be able to trap the enzyme in its active form and increase the catalytic efficiency 
of the fusion enzyme. We are interested in engineering ConFusion LctM because by utilizing 
this enzyme, lacticin 481 could be produced in vitro efficiently and the purification process 
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would be largely simplified. This new strategy could also be applied to the production of other 
class II lanthipeptides, and to synthetic core peptides containing non-natural amino acids. 
As described in chapter II, ProcM was able to dehydrate and cyclize non-natural peptides 
attached to the ProcA leader peptide.12 This unusual catalytic promiscuity of ProcM was 
utilized for cyclic peptide library generation (work of lab member Xiao Yang). However, not 
all chimeric peptides were modified completely by ProcM. The modification efficiency, 
especially the cyclization efficiency was not satisfactory for some of the substrates. 
Considering leader peptides may act as an activator for the modification enzymes, engineering 
the ProcA leader peptide may be helpful in terms of solving this problem. It is possible that if 
the binding affinity of the leader peptide to the enzyme is too high, the substrate will not be 
released by the enzyme. But it may be feasible to avoid this problem by engineering a leader 
peptide with a desired binding affinity that meets both requirements. 
 
5.2 RESULTS
5.2.1 The yeast surface display system  
In the yeast surface display system, lanthipeptide libraries are displayed on the surface of yeast 
cells by fusing to the yeast surface protein AGA-2 (Figure 5.1).13 The fusion proteins are recruited 
to the yeast surface by the membrane bound AGA-1 protein and disulfide bonds are formed 
between these two partners. To detect the binding of lanthipeptides and their modifying enzymes, 
the yeast libraries were incubated with purified enzymes containing either an epitope tag or a EGFP 
(enhanced green fluorescent protein)-tag. FACS (fluorescence-activated cell sorting) analysis of 
the yeast libraries using flow cytometry was used to identify and separate yeast cells bound to 
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fluorescently labelled enzyme. To engineer lanthipeptide leader peptides with stronger binding 
affinity, yeast libraries of lanthipeptides with diversified leader regions were generated. Because 
the detection of the initial binding between the truncated leader peptides and the modification 
enzymes were not achieved easily, the full length lanthipeptides were displayed to increase the 
initial binding to the modification enzymes and facilitate the sorting process. For the ProcA library, 
only the leader peptides were displayed because the ProcA leader peptides were relatively long and 
there was no sequence conservation between the core peptides.14 
To construct the desired lanthipeptide peptide libraries, the first step is to insert the genes 
encoding lanthipeptides after the AGA-2 gene in the yeast display vector pCT302 (Figure 5.1.B 
and section 5.4.2). The presence of HA and c-myc tags at both ends of the lanthipeptide gene 
enabled the detection of the lanthipeptide expression by immunostaining. Error prone PCR using a 
long reverse primer was carried out using these constructs to introduce random mutations into the 
leader region only (Figure 5.1.C). 
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Figure 5.1. The yeast surface system: (A) Diagram of a lanthipeptide library with diversified 
leader regions displayed on the surface of yeast cells fused to Aga-2. A detection scheme 
involving EGFP-tagged post-translational modification enzyme (PTM) bound to the 
lanthipeptide library may be used to evaluate the binding affinity; (B) the pCT302 construct of 
the AGA-2-lanthipeptide fusion protein showing the arrangement of the gene elements; (C) the 
primer design for the generation of the lanthipeptide library with a diversified leader region. 
 
5.2.2 The evaluation and sorting of lanthipeptide yeast libraries 
The yeast libraries of three lanthipeptides (NisA, LctA and ProcA3.2Lea) with diversified 
leader regions were generated as discussed in section 5.2.1. To evaluate the error rate of the 
libraries, the error prone PCR products were ligated into a T-vector and used to transform E. 
coli DH5 cells. For each library, 20 colonies were picked for plasmid extraction and DNA 
sequencing. The sequencing results were used to estimate the error rate in the leader region. 
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For all the lanthipeptide libraries, an error rate of 0.5% was achieved using protocols descried 
in section 5.4.3. The yeast cell library construction and sorting processes are described in detail 
in section 5.4.4-5.4.8.  
For the NisA library, all the isolated yeast colonies from the sorting process contained 
peptide genes with shifts in the open reading frame, which resulted in the expression of 
unrelated peptides. For the ProcA3.2Lea library, only colonies with false positive signals were 
sorted. Thus, further selection was not carried out for these two libraries. A subset of 60 
colonies (yeast colony-LctA-1 to 60) were selected from the 6th round of sorting of the first 
generation of LctA library. After the induction of peptide overexpression, yeast cell cultures 
containing individual plasmids (pCT302-LctA-1 to 60) were stained with EGFP-LctM and the 
mean fluorescence intensity (MFI) was measured for each yeast colony. Plasmids were isolated 
from colonies with increased MFI compared to a colony with WT pCT302-LctA and were used 
to transform E. coli DH10B cells. Plasmids isolated from DH10B cells were used for DNA 
sequencing. Some of these plasmids had identical LctA sequences, and plasmids with different 
DNA sequences were used to transform fresh electrocompetent yeast cells. The reason for 
transforming fresh yeast cells is to avoid any mutations in the yeast genome that might 
contribute to the enhanced fluorescence signal in the sorting process. Yeast colony-LctA-34 
was isolated from the above procedures, which had an N8D mutation in the leader region 
(Figure 5.2). The pCT302-LctA-34 plasmid was used as the template for the construction of 
the second generation LctA library. The sorting and characterization processes were the same 
as for the first generation library, and four LctA mutants (LctA-34-7, LctA-34-11, LctA-34-13, 
and LctA-34-28) were isolated, which all had the Q4L, N5D, N8D, and S16D mutations 
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(Figure 5.2). Yeast colony-LctA-34-28 showed the highest MFI and the pCT302-LctA-34-28 
plasmid was used as template for the construction of the third generation LctA library. However, 
the isolated plasmids from this library contained no mutation in the leader region, instead, they 
all contained mutations resulting in open reading frame shift. As a result, no further sorting 
processes were carried out.  
 
  
Figure 5.2. The amino acid sequences of WT LctA and engineered LctA peptides obtained 
from the sorting of the LctA library. The mutations are labelled in red, and the three conserved 
aspartic acid mutations are highlighted with red box.  
 
5.2.3. Yeast colonies with the engineered LctA lanthipeptide bind stronger to EGFP-LctM 
As described in section 5.2.2, the isolated plasmids obtained from the yeast library sorting 
were used to transform fresh electrocompetent yeast cells, and the yeast surface expression of 
the engineered LctA peptides was induced. The binding affinity of LctA analogs to LctM was 
first evaluated by FACS analysis to measure the MFI of the yeast population after staining with 
EGFP-LctM. The MFI values of the best binders isolated from the first and second generation 
of the LctA library were compared to a yeast colony displaying WT LctA. Yeast colony-LctA-
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34 showed about 10-fold increase in MFI compared to the yeast colony with WT peptide, while 
yeast colony-LctA-34-28 showed a 30-fold increase (Figure 5.3). This result ruled out the 
possibility that mutations in the yeast genome resulted in false positive selection, and suggested 
that the binding affinity of engineered LctA peptide (LctA-34-28) to LctM was improved 
compared to the WT peptide. 
 
 
Figure 5.3. The mean fluorescence intensity for yeast colony displaying WT LctA and 
engineered LctA peptides after staining with 3.6  EGFP-LctM. 
 
5.2.4 The engineered LctA leader peptide binds stronger to LctM than WT leader peptide 
The MFI of the yeast colony could be influenced by other factors besides the binding 
affinity of the expressed peptide to the fluorescently labelled protein, such as expression level 
of the peptides and non-specific binding to the EGFP tag. In order to directly measure the 
binding affinity between the peptide and the modification enzymes, several in vitro 
experiments using purified peptide and enzymes were carried out. Isothermal titration 
calorimetry (ITC) experiments were first attempted, however, the LctM enzyme precipitated 
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in the metal sample cell in all experiments. Therefore, another technique, fluorescence 
polarization (FP), was applied. First, the WT LctA leader peptide (obtained from Dr. Champak 
Chatterjee, generated using solid-phase peptide synthesis) was fluorescently labeled with 
fluorescein isothiocyanate (FITC) which primarily reacts with amine groups (described in 
section 5.4.11 and 5.4.12). The ESI-MS (Figure 5.4A) and analytical HPLC (Figure 5.4B) 
showed the purity of the product FITC-LctALea, and the tandem MS data showed that the 
FITC group was attached to the N-terminal amine group specifically and not to the amine group 
of the lysine residue at the second position (Figure 5.4C). LctA-34-28 leader peptide (ordered 
from United Peptide) was also labelled with FITC and purified using the same protocol.  
Fluorescence polarization experiments (section 5.4.13) using FITC-LctALea peptide and 
purified LctM showed a KD value of around 5.2 M (Figure 5.5). As the activity of LctM 
requires ATP,15 the binding affinity of FITC-LctALea was also measured in the presence of 
the non-hydrolysable ATP analog (AMP-PNP) at increasing concentration (Figure 5.5). But no 
significant changes in the KD or any correlations of the KD to AMP-PNP concentration were 
observed, which indicates that the binding of LctA leader peptide to LctM is not likely to be 
ATP-dependent. The KD of FITC-LctALea and FITC-LctALea-34-28 to LctM were measured 
by FP experiments (section 5.4.13), and the engineered LctA leader peptide showed a 4-5 fold 
stronger binding affinity (Figure 5.6).  
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Figure 5.4. Analysis of the FITC-LctALea peptide: (A) ESI-MS showing the observed mass 
of FITC-LctALea (calculated mass: 3109.8, observed mass: 3110.0); (B) analytical HPLC 
showing the unlabeled peptide was removed in the purification process; (C) tandem MS data 
showing that the FITC group was attached to the N-terminal free amine group. 
 
 
Figure 5.5. Fluorescence polarization assays with LctM using 20 nM FITC-LctALea in the 
presence of 0 mM, 1 mM，2 mM and 5 mM AMP-PNP.  
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Figure 5.6. Fluorescence polarization assays with LctM using 5 nM FITC-LctALea or FITC-
LctALea-34-28. 
 
To minimize any interference of the bulky FITC group, WT LctA leader peptide and 
engineered LctA leader peptide were also labelled with FITC-Ahx at the N-terminus (Ahx is a 
linear six carbon aminohexanoic group inserted between the FITC group and the leader 
peptide). FITC-Ahx-LctALea and FITC-Ahx-LctALea-34-28 were purchased from United 
Peptide and the purity was > 95% for both peptides. The KD of FITC-Ahx-LctALea and FITC-
Ahx-LctALea-34-28 binding to LctM were measured using the same protocol, and again a 4~5 
fold increase in the binding affinity was observed for the engineered LctA leader peptide 
(Figure 5.7). 16 
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Figure 5.7. Fluorescence polarization assays with LctM using 5 nM FITC-Ahx-LctALea or 
FITC-Ahx-LctALea-34-28. 
 
However, LctA peptides were shown to form soluble aggregation16 and the peptide 
aggregates are likely to bind to LctM with different binding affinity and interfere with the 
binding assay. To avoid this problem, MBP-tagged LctALea and LctALea-34-28 peptides were 
constructed (section 5.4.10) and used in competitive FP assays. These proteins were analyzed 
by FPLC using an analytical size exclusion column, and it was shown that they existed as a 
stable protein monomer. MBP-LctALea-34-28 showed ~3 fold smaller KD value (Figure 5.8), 
which is consistent with the results obtained by direct titration with FITC-labeled peptides. 
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Figure 5.8. Competitive fluorescence polarization binding assays with 1.7 M LctM using 
MBP-LctALea or MBP-LctA-34-28Lea to displace FITC-Ahx-LctA-34-28Lea (20 nM).  
 
5.2.5 LctA containing the engineered leader peptide binds stronger to LctM 
To measure the binding affinity of full length LctA and LctA-34-28, competitive 
fluorescence polarization assays (section 5.4.13) were carried out. His6-LctA and His6-LctA-
34-28 (constructed as described in section 5.4.10) were used to displace FITC-Ahx-34-28 in 
the LctM binding assay, and the engineered full length LctA also showed 4-5 fold increase in 
the binding affinity (Figure 5.9). Similarly to section 5.2.4, the same displacement assay was 
carried out using MBP-tagged peptides. However, MBP-tagged full length LctA and LctA-34-
28 existed as aggregates, and the FP data was not successfully fitted to a hyperbolic curve to 
calculate the binding affinity. 
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Figure 5.9. Competitive fluorescence polarization binding assays with LctM using His6-LctA 
(red) or His6-LctA-34-28 (blue) to displace FITC-Ahx-LctA-34-28Lea (20 nM). 
 
5.2.6 The engineered LctA leader peptide binds stronger to the LctM dehydratase domain 
As described in chapter IV, the two domains of LanM enzymes are active independently 
and the activities of both the dehydratase and cyclase domains are leader-dependent, which 
suggests two possible leader binding sites in LanMs.17 The binding affinity of FITC-Ahx-
LctALea and FITC-Ahx-LctALea-34-28 to LctM-1-543 (putative dehydratase domain of LctM) 
were measured. Similar to the observations with WT LctM, the engineered LctA leader peptide 
bound 4-5 fold stronger (Figure 5.10). It is of interest to see whether the two putative leader 
peptide binding sites prefer the same leader peptide sequences and whether both have increased 
affinity for the engineered leader peptide. However, this experiment could not be carried out 
because of the insolubility of LctM-544-922 (putative cyclase domain). MBP tagged LctM-
544-922 was envisioned to increase the solubility, however, no overexpression of MBP-LctM-
544-922 was observed.  
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Figure 5.10. Fluorescence polarization assays with LctM-1-543 using 5 nM FITC-Ahx-
LctALea or FITC-Ahx-LctALea-34-28. 
 
5.2.7 The engineered LctA is a more efficient substrate for LctM  
There are several potential applications of the tighter binding LctA leader peptide: 1. the 
possible generation of a co-crystal structure of LctM in complex with its substrate; 2, an 
improved ConFusion LctM (section 5.1) with higher catalytic efficiency; 3, a more efficient 
substrate for LctM. The first application has not been achieved so far due to the lack of crystal 
structure of either the full length LctM or the dehydratase domain of LctM. To see if engineered 
leader peptides could be applied for the second purpose, ConFusion LctM-34 and ConFusion 
LctM-34-28 were generated as described in section 5.4.9 and their activities were tested in 
assays with the LctA core peptide (section 5.4.14). The 4-fold dehydrated core peptide and 
starting material were quantified by the ion counts of the corresponding peak area in ESI-LC-
MS experiments and normalized to be compared with the WT ConFusion-LctM. As shown in 
Figure 5.11, although ConFusion LctM-34 showed about 20% increase in the product 
conversion, ConFusion-34-28 showed about 56% decrease in efficiency. This result is not 
understood at present. 
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Figure 5.11. The relative product formation efficiency of ConFusion LctM enzymes in the 
assays with the LctA core peptide. 
 
Next, the catalytic efficiency of LctM was studied using WT LctA and LctA-34-28. In 
vitro enzymatic assays were carried out using 25 peptides and 1 LctM, the reactions 
were quenched at different time points, treated with LysC to remove the leader peptide and 
spotted on a bioactivity assay plate to detect the formation of final product. As shown in Figure 
5.12, the modification of LctA-34-28 was nearly completed within 5 min in the conditions used, 
but for the WT LctA, less product was formed even at 45 min.  
A significant improvement in the efficiency of product turnover was observed with the 
engineered LctA peptide which is promising in the application of lanthipeptide production, 
however, it is difficult to tell whether this improvement is caused by increased catalytical 
efficiency or less aggregation of the substrate with three additional negatively charged residues, 
or a combination of both. 
 
157 
 
 
Figure 5.12. Antimicrobial assays against L. lactis HP. An aliquot of 10 L of the following 
samples were spotted: (1-6) 25 WT LctA incubated with 1 LctM for 15 s, 1, 2, 5, 10 
and 45 min, followed by the LysC digestion to remove the leader; (7-12) LctA-34-28 treated 
under the same conditions.  
We have experienced challenges in analyzing the product conversion by mass 
spectrometry due to the poor ionization efficiency of the unmodified WT LctA substrate. The 
product to substrate ratio was often largely over-estimated for the WT LctA, but for the 
engineered LctA, this problem was much less severe. The bias in product/substrate ionization 
makes it impossible to compare the product formation of these two substrate by MS techniques 
accurately. But still, the in vitro enzymatic assays using LctA-34-28 showed a moderate 
increase in product formation in the mass spectra than assays using WT LctA (Figure 5.13). 
Efforts were made to eliminate the aggregation of the substrate and compare the actual rate of 
production formation without the interference of the aggregates. However, LctA and LctA-34-
28 peptides with MBP, EGFP or SUMO tag at the N-terminal still existed as soluble protein 
aggregates. Since MBP-tagged LctA leaders exist as stable monomers, it is possible that 
peptide monomers could be obtained from the MBP-tagged LctA peptides with shorter core 
region. Therefore, MBP-LctA-1-38 and MBP-LctA-34-28-1-38 were constructed as described 
in section 5.4.10, however, these two proteins were not successfully overexpressed in E. coli. 
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Figure 5.13. MALDI-TOF mass spectra of 25  WT LctA (blue) and LctA-34-28 (red) 
incubated with 1  LctM and treated with LysC to remove the leader peptide. Expected 
masses: M - 4 H2O (2772.1), M (2844.2); calculated masses (WT at 45 min): M - 4 H2O 
(2772.0), M (2844.1). 
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5.3 DISCUSSION AND OUTLOOK 
Yeast surface display has several advantages over other display systems.18 First, the 
relative large yeast cells can be sorted by fluorescence activated cell sorting (FACS), which is 
an extremely efficient high-throughput screening method compared to other traditional sorting 
methods such as 96-well plate sorting. Moreover, the application of FACS analysis also allows 
quantitative comparisons between mutants. In addition, ligand-binding affinity to target 
molecules may be directly measured on the yeast cell surface. Yeast surface display has been 
successfully applied to the engineering of many bioreceptor proteins including antibodies.18, 19 
In this chapter, yeast surface display was applied to engineer lanthipeptide leader peptides for 
tighter binding to their modification enzymes. The engineered LctA leader peptide (LctALea-
34-28) showed 4-5 fold increase in the binding affinity compared to WT leader peptide in all 
FP and competitive FP experiments demonstrated in this chapter, which shows that this 
technique is suitable for the engineering of lanthipeptide leader peptides.  
Previously, the engineering efforts of lanthipeptides mainly utilized site-directed 
mutagenesis and several studies generated lanthipeptide variants with enhanced activities.20, 21 
While site-directed mutagenesis allows the incorporation of specific mutations in the peptide, 
it suffers from several shortcomings: 1. mutagenesis of individual residues is time and effort-
consuming, and in most cases, only part of the peptide sequence is covered; 2. the 
characterization of individual analogs is very low-throughput; 3. with limited knowledge about 
the peptide-enzyme binding in lanthipeptide biosynthesis, mutations are usually introduced 
randomly. In this chapter, a high-throughput engineering and screening strategy was applied to 
lanthipeptides, which could potentially solve these problems for the leader peptide. As 
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discussed in section 5.1, the generation of tighter-binding leader peptide could be applied in 
many aspects of lanthipeptide studies. Yeast surface display could potentially also be applied 
to engineer core peptide for desired properties, to tune the functions of lanthionine synthetases, 
or to generate a cyclic peptide library to screen for target functions such as disrupt specific 
protein-protein interactions.22-24 
In the two rounds of sorting of the LctA yeast library, four mutations were found in all 
isolated yeast colonies with increased fluorescent signal. Three of these mutations were the 
substitution of a neutral amino acids with aspartic acid (N5D, N8D, and S16D), and one of 
these mutations (Q4L) was mutating a polar residue with the hydrophobic residue leucine. In 
addition, the only positively charged residue (Lys at the second position) was mutated to a 
neutral residue for all the mutants. The mutations were also inspected at nucleotide level, and 
biased mutations were observed. The leader peptides of lanthipeptides are naturally enriched 
with negatively charged residues,3 and the accumulation of three conserved aspartic residues 
in the leader region is unlikely a coincidence. It is likely that negatively charged residues are 
beneficial to the leader-enzyme binding. Although from the NisB-NisA co-crystal structure,18 
only one aspartic acid in the leader peptide interacts with NisB, these negatively charged 
residues might contribute to the binding indirectly. More structural and biochemistry studies 
are needed to support this hypothesis. 
The WT LctA peptide suffers from the problem of forming soluble aggregation and 
difficulty to ionize in the mass spectrometry studies, thus it is difficult to study the changes in 
the catalytic efficiency of LctM on the engineered LctA without the interference of these factors. 
However, the engineered LctA might have either increased product formation rate, or resulted 
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in less peptide aggregation, or very likely both. It can be concluded that by using yeast surface 
display I have generated a more efficient substrate for LctM, although the reasons for the 
improved product formation rate remain unclear. It is of interest to study the catalytic rates of 
LctM on substrates with different binding affinity, because this study could provide us with 
information about the rate limiting steps in lanthipeptide modifications.  
There is room for improvements in this project in several aspects: First, in order to inspect 
the relationships between the catalytic rates of LctM and substrate binding affinity, it is 
required to eliminate the aggregation of the substrates. Methods described in this chapter 
including adding solubility tags were not successful in solving this problem. To solve this 
problem efficiently, the region of LctA peptides which causes aggregation needs to be 
investigated to make stable LctA peptide variants. Second, the application of engineered LctA 
leader peptides should be further explored. As mentioned in the introduction, a tighter binding 
leader peptide is useful in obtaining co-crystal structures with the synthetases. However, as no 
crystal structure was obtained for LctM, no crystallographic studies were carried out using the 
engineered peptide. A tighter binding leader peptide might lock the synthetase in the active 
state and facilitate the crystallization process, however, the 4-5 fold increase in binding affinity 
might not be enough for that purpose. The efforts to further engineer LctA leader peptide were 
unsuccessful due to the high frequency of ORF (open reading frame) shifts, but it is still 
possible that leader peptides with higher binding could be generated using LctA-34-28 as 
template. Third, the yeast surface display system described in this chapter could be applied to 
engineer other lanthipeptides for tighter binding affinity to the synthetases. With the peptide 
substrates which have no solubility and aggregation problems, the relationships between 
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catalytic rates and binding affinity could be inspected without complications. These 
experiments might also be informative in terms of enzymatic mechanisms of lanthionine 
syntheses and the evolution of lanthipeptide leader peptides. It is also possible to obtain a 
lanthionine synthetase which is locked in the active state by a tight binding leader. Such 
enzymes could be useful to provide a more efficient method for lanthipeptide production, 
which is especially important for the lanthipeptides of commercial interest.   
 
5.4 EXPERIMENTAL PROCEDURES 
5.4.1 Materials 
Strains  
Saccharomyces cerevisiae yeast display strain EBY100 (a GAL1-AGA1::URA3 ura3-52 trp1 
leu2D1 his3Δ200 pep4::HIS2 prb1Δ1.6R can1 GAL) is commercially available from Invitrogen 
(cat. no. C839-00). In this study, the yeast strain was obtained from Professor David M. Kranz’s 
lab.  
E. coli strain used for cloning was DH10B™ (Invitrogen cat. no. 18290-015).  
Yeast Display Plasmid  
Yeast display plasmid pCT302 is commercially available from Invitrogen as pYD1 (cat. no. 
V835-01).  
Restriction Enzymes  
NheI (Invitrogen cat. no.15444-011), BglII (Invitrogen cat. no. 15213-010), XhoI (Invitrogen 
cat. no. 15231-012), and DpnI (Invitrogen cat. no. 15242-019) were used as per the 
manufacturer’s recommendations.  
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DNA Purification Kits  
Plasmid rescue and purification kits used to purify plasmids from from E. coli were the 
QIAprep spin miniprep kit (QIAGEN cat. no. 27104). For plasmid purification from yeast the 
Zymoprep kit I or II (Zymoresearch cat. no. D2001 (I)) was used. QIAquick PCR purification 
kit (QIAGEN cat. no. 28104) was used to purify PCR products. 
Yeast Media  
The reecipe for YPD media for propagation of EBY100 was: 5 g yeast extract (BD Bacto cat. 
no. 212750), 10 g peptone (BD Bacto cat. no. 211677), and 10 g dextrose (EMD cat. no. 346351) 
dissolved in ddH2O to give a final volume of 500 mL. YPD media was autoclaved and stored 
at room temperature. To make 1 sleeve of YPD plates, 7.5 g of agar was added to the above 
recipe.  
The recipe for SD-citrate-CAA media for propagation of EBY100 transformed with pCT302 
contained 7.4 g sodium citrate (Fisher cat. no. S279-500), 2.1 g citric acid monohydrate (Sigma 
cat. no. C1909), 2.5 g casamino acids (BD/Bacto cat. no. 223120), 10 g dextrose, and 3.35 g 
yeast nitrogen base without amino acids (Sigma cat. no. Y0626), dissolved in ddH2O to make 
the final volume to be 500 mL. The dissolved media was filtered to sterilize and stored at 4 °C. 
For SD-citrate-CAA plates, 91 g sorbitol (Sigma cat. no. S1876), 7.5 g agar, 7.4 g sodium 
citrate, and 2.1 g citric acid monohydrate were dissolved in ddH2O to make the final volume 
to be 400 mL, and autoclaved to sterilize. In a separate container, 2.5 g casamino acids, 10 g 
dextrose, and 3.35 g yeast nitrogen base without amino acids were dissolved in ddH2O to make 
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the final volume to be 100 mL; then filtered to sterilize and added to the autoclaved solution 
when it was cool. The media was mixed thoroughly and poured into sterile petri dishes.  
The SG-citrate-CAA media for induction of the yeast display construct was made as described 
above for 500 mL SD-citrate-CAA but substituting an equal mass of D-(+)-galactose (Sigma 
cat. no.G-0625) for dextrose.  
Flow Cytometry/FACS Reagents  
Phosphate-buffered saline (PBS): 1 X PBS solution was purchased from FISHER-Mediatech 
(cat. no. 21040CV). To make 100 mL PBS/0.5% BSA solution, 0.5 g bovine serum albumin 
(Sigma cat. no. A8531-1VL) was added to 1 X PBS solution and the solutions was filtered to 
sterilize. 
Monoclonal antibodies were purchased: anti-c-myc chicken antibody (Molecular Probes cat. 
no. A-21281), Alexa488-labeled goat-anti-mouse secondary antibody (Invitrogen cat. no. A-
11017), Alexa647-labeled goat-anti-chicken secondary antibody (Molecular Probes cat. no. A-
21449), anti-flag M2 mouse antibody (Sigma cat. no. F3165). 
5.4.2 Construction of yeast surface display plasmids for WT lanthipeptides  
The lanthipeptide genes were PCR-amplified using Phusion polymerase by 30 cycles of 
denaturing (94 °C for 30 s), annealing (55 °C for 30 s), and extending (72 °C for 15 s) using 
primers and templates listed in Table 5.1. The PCR products were digested with NheI and XhoI 
restriction enzymes and ligated into the pCT302 vector to generate the construct pCT302-LctA-
myc/NisA-myc/ProcA3.2-myc using a subcloning competent E. coli strain, such as DH10B. The 
sequence of the fused gene in the vector was confirmed using “Splice 4/L” and “T7 reverse” 
primers that flank the insert.  
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Table 5.1. Primers used in section 5.4.2. 
Construct Primer Name Primer Sequences (5’-3’) 
pCT302-LctA-myc 
(Template: pET15b-
LctA15) 
LctA_NheI_FP  GGTTCTGCTAGCATGAAAGAACA
AAACTCT 
LctA_myc_XhoI_RP TCAGATCTCGAGTTACAGATCTTC
TTCAGAAATAAGTTTTTGTTCTTA
AGAGCAGCAAGT 
pCT302-NisA-myc 
(Template: pET15b-
NisA14) 
NisA_NheI_FP GCTAGCATGAGTACAAAAGATTT
TAACTTGG 
NisA_myc_XhoI_RP GCGTTCCTCGAGTTACAGATCTTC
TTCAGAAATAAGTTTTTGTTCTTT
GCTTACG 
pCT302-
ProcAA3.2Lea-myc 
(Template: pET15b-
procA3.214) 
ProcA3.2_NheI_FP GGTTCTGCTAGCATGTCAGAAGA
ACAACTCAAGG 
 
ProcA3.2Lea-myc_ 
XhoI_RP 
GGTTCTCTC GAG TTA CAG ATC 
TTC TTC AGA AAT AAG TTT TTG 
TTC TCC CCC AGC CAC ACC  
Sequencing primers 
 
Splice 4/L  GGCAGCCCCATAAACACACAGTA
T 
T7 reverse TAATACGACTCACTATAG 
 
5.4.3 Error prone PCR 
The PCR reaction mixture was prepared by adding 10 mM dNTPs, 0.3 ng/μL template DNA 
(gene of interest in pCT302 vector), primers listed in Table 5.2, 5 ng/μL Bovine Serum Albumin 
(BSA), 3.325 mM MgCl2, 0.5 mM MnCl2, 1:10 dilution of Taq Polymerase Reaction Buffer, 1 
μL (5 unit) Taq Polymerase, and ddH2O to take the final volume to be 100 μL. The target gene 
was PCR amplified by 30 cycles of denaturing (94 °C for 30s), annealing (55 °C for 30 s), and 
extending (72 °C for 30 s). The amplification was checked by running the PCR product on a 
1% agarose gel. The PCR reaction was digested with 1 μL (20 unit) DpnI for 1 h at 37°C to 
reduce insert background from remaining template. The reaction was then cleaned up by using 
a PCR Clean-up Kit from Qiagen, and eluted with 30 μL elution buffer. 
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Table 5.2. Primers used in section 5.4.3. 
Primer Name Primer Sequences (5’-3’) 
YSD_Error-prone_FP GTTCTGGTGGTGGTGGTTCTGGTGGTGGTGG
TTCTGCTAGC 
YSD_Error-Prone_ 
LctA_RP 
 
CAAAGTCGATTTTGTTACATCTACACTGTTGTTATCA
GATCTCGAGTTACAGATCTTCTTCAGAAATAAGTTT
TTGTTCAGAGCAGCAAGTAAATACAAATTGCCAGCT
ATTCATATTACATTCATGAGAAATTGTATGAATAACT
CCACTGCCGCCTTT 
YSD_Error-Prone_ 
NisA_RP 
 
CAAAGTCGATTTTGTTACATCTACACTGTTGTTATCA
GATCTCGAGTTACAGATCTTCTTCAGAAATAAGTTT
TTGTTCTTTGCTTACGTGAATACTACAATGACAAGT
TGCTGTTTTCATGTTACAACCCATCAGAGCTCCTGT
TTTACAACCGGGTGTACATAGCGAAATACTTGTAAT 
YSD_Error-Prone_ 
ProcA3.2_RP 
 
TACAGTGGGAACAAAGTCGATTTTGTTACATCTACA
CTGTTGTTATCAGATCTCGAGTTACAGATCTTCTTCA
GAAATAAGTTTTTGTTC 
 
5.4.4 Preparation of pCT302 vector 
Empty pCT302 vector was obtained from a Qiagen mini-prep and an aliquot of 50~80 μg vector 
was digested with NheI in appropriate buffer overnight at 37 °C. The digested reaction was 
cleaned up using the PCR Clean-up Kit from Qiagen. The NheI-digested vector was treated 
with XhoI in appropriate buffer for at least 1 h at 37 °C. The reaction was then cleaned up using 
the PCR Clean-up Kit. The NheI and XhoI digested vector was treated again with BglII in 
appropriate buffer for at least 1 h at 37 °C. Digesting with all three enzymes decreased the 
possibility of remaining full-length vector with the potential to re-circularize. The reaction was 
cleaned up using the PCR Clean-up Kit, and dephosphorylated using Calf Intestine Phosphatase 
(CIP) for 1 h at 37 °C in order to reduce vector background when transforming the yeast library. 
The final product was purified again using PCR Clean-up Kit.  
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5.4.5 Preparation of electrocompetent yeast for library construction 
Two days before preparation of the library, 2 to 3 mL cultures of sterile YPD media were 
inoculated with a colony of EBY100 cells from a freshly-streaked YPD plate. The culture was 
grown to stationary phase (30 °C, 48 h, 220 rpm). The night before library transformation, a 2 
L sterile flask containing 500 mL of YPD medium was inoculated with 5–9 mL of starter 
EBY100 culture. The culture was grown overnight at 30 °C with vigorous shaking until the 
cells reached an OD600 of 1.3–1.5. The culture was harvested in sterile centrifuge bottles that 
can hold 500 mL by spinning at 4,000× g at 4 °C. The pellet was resuspended vigorously in 80 
mL of sterile ddH2O. An aliquot of 10 mL of sterile 10× TE buffer (pH 7.5) was added to the 
yeast suspension and swirled to mix. An aliquot of 10 mL of 10× Lithium Acetate stock solution 
(1 M) was added to the yeast suspension and swirled to mix. The yeast suspension was then 
placed on an incubation shaker for 45 min at 30 °C with a speed of 100 rpm. After that, 2.5 mL 
of 1 M DTT was freshly prepared and added to the yeast suspension while swirling. The yeast 
suspension was then placed on an incubation shaker for 15 min at 30 °C with a speed of 100 
rpm. The yeast suspension was diluted to 500 mL with sterile water. The cells were washed 
and concentrated three times by centrifuging at 4,000–6,000 × g, and pellets were resuspended 
successively with 250 mL of ice-cold water, 20–30 mL of ice-cold 1 M sorbitol, and 0.5 mL of 
ice-cold 1 M sorbitol. The final volume of resuspended, electrocompetent yeast cells was 1–
1.5 mL. 
5.4.6 Construction of EGFP-tagged enzymes 
The egfp gene was amplified by PCR in 30 cycles of denaturing (98 °C for 30 s), annealing 
(55 °C for 30 s), and extending (1 min for each 1.5 kb) using the plasmid pCDNA3-EGFP 
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(obtained from Dr. Min Zeng) as templates and primers listed in Table 5.3. The PCR products 
were digested with NheI and BamHI restriction enzymes and ligated into pET28b vector treated 
with the same enzymes to generate the construct pET28b-N-EGFP. The sequences of the 
resulting products were confirmed by DNA sequencing. 
Lanthionine synthetase genes were amplified by PCR using 30 cycles of denaturing (98 °C for 
10 s), annealing (55 °C for 30 s), and extending (1 min for each 1.5 kb) using the primers listed 
in Table 5.3. The resulting DNA inserts and the pET28b-N-EGFP construct were digested with 
BamHI and XhoI and ligated. The sequences of the resulting products were confirmed by DNA 
sequencing.  
 
Table 5.3. Primers used in section 5.4.6. 
Construct Primer Name Primer Sequences (5’-3’) 
pET28b-N-EGFP  
(Template: 
pCDNA3-EGFP) 
EGFP _NheI_FP GGCTAGCATGGTGAGCAAGGGCGA
GGA 
EGFP _BamI_RP CGGATCCTCACTTGTACAGCTCGTC
CAT 
pET28b-N-EGFP- 
LctM  
(Template:  
pET28b-LctM15, 
pET28b-N-EGFP) 
LctM_BamI_FP CATATGGGATCCATGAAAAAAAAG
ACTTAC 
LctM _XhoI_RP GTGGTGCTCGAGTTAATCAACATA
TGG 
pET28b-N-EGFP- 
Nisc 
(Template:  
pET15b-NisC11, 
pET28b-N-EGFP) 
NisC _BamI_FP GGACGAGCTGTACAAGGGATCCAT
GAGGATAATGATGAA 
NisC _XhoI_RP CGCTCGAGATCGCATTTCCTCTTCC
CTCCTTT 
pET28b-N-EGFP- 
procM 
(Template:  
pET28b-ProcM14, 
pET28b-N-EGFP) 
ProcM_EcoRI_FP CAGGATCCGAATTCATGGAAAGTC
CATCATCTTGG 
 
ProcM _NotI_RP AAGGAAAAAAGCGGCCGCTTATTC
AGTAGGCCAGAGA 
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5.4.7 Transformation and Characterization of Library  
A mixture of error-prone PCR insert and linearized vector DNA was prepared at approximately 
a 6:1 molar ratio. In addition to the error-prone library mixture, additional controls were 
prepared to transform yeast cells: linearized vector alone (the same final concentration as in 
the library DNA mixture), error-prone insert alone (the same final concentration as in the 
library DNA mixture), unmutated gene in pCT302, and no DNA in the transformation. In a 
sterile, ice-cold Eppendorf tube, 40 μL of concentrated, electrocompetent yeast cells was mixed 
with 10–100 ng DNA (≤5 μL). The yeast cells were transferred to an ice-cold disposable 
electroporation cuvette (0.2 cm gap) and pulsed at 1.5 kV, 25 μF, 200 Ω. The time constant 
reported varied between 4.2 and 4.9 ms. An aliquot of 1 mL of ice-cold sorbitol was added to 
the cuvette to recover the yeast cells with gentle pipetting. The recovered yeast cell library from 
the experimental tube was collected in a single, sterile conical tube, while the controls were 
kept in separate tubes. An aliquot of 10 μL cells from each control transformation was spread 
onto a SD citrate-CAA plate. A 10 μL aliquot of undiluted, 100-fold diluted, or 500-fold diluted 
yeast cell library obtained above was plated onto SD-citrate-CAA plates to determine the size 
of the library. The plates were grown at 30°C for 48 to 72 h. The positive control transformation 
(pCT302 construct with WT lanthipeptide gene) was grown in several 3 mL culture tubes of 
SD-citrate-CAA media supplemented with 100 μg/mL ampicillin. The yeast cell library was 
allowed to recover by culturing in 500 mL SD-citrate-CAA media supplemented with 100 
μg/mL ampicillin. The yeast cells were incubated at 30 °C with shaking at 220 rpm for 48 h. 
An aliquot of 10–50 mL of the expanded library was used to seed 1,000 mL SD-citrate-CAA 
media with 100 μg/mL ampicillin. The culture was incubated at 30 °C with shaking at 220 rpm 
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for another 24 h to reduce the number of untransformed or unhealthy cells. After the second 
passage of the library, 10–30 aliquots of the library containing 1 mL of dense culture 
(approximately 108 cells/mL) were mixed with 70 μL of DMSO and flash frozen. The 
remaining passaged library was stored in 3 mL aliquots in sterile culture tubes at 4 °C. 
To analyze the library for diversity, plasmids were isolated from an aliquot of 0.5 mL of dense 
yeast cells from the library using the Zymoprep II kit. The isolated DNA was used transform 
E. coli DH10B cells. About 8–10 colonies were cultured. Plasmids were isolated from these 
cultures, and sent for sequencing using the “Splice 4/L” primer (Table 5.1). 
5.4.8 Analyzing and Sorting by FACS  
An aliquot of 1 mL of freshly passaged, dense library culture in SD-citrate-CAA media (about 
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yeast) was centrifuged in a sterile Eppendorf tube for 3 min at 3,000 rpm (800×g) in a 
tabletop microcentrifuge. The supernatant was removed by pipetting. The yeast cells were 
resuspended in SG-citrate-CAA media (galactose was substituted with glucose), and spun 
down again for 3 min at 3,000 rpm (800×g). The yeast cell pellet was resuspended in SG-
citrate-CAA media containing 100 μg/mL ampicillin. This culture was incubated at 20 °C with 
shaking at 220 rpm for 24–48 h to induce the yeast cells to express AGA2- lanthipeptides. After 
the induction, the yeast was stored at 4 °C in SG-citrate-CAA media for up to 2 weeks.  
The cells were stained for flow cytometry or sorting. First, the appropriate number of cells in 
SG-citrate-CAA media was centrifuged at 3,000 rpm (800×g) for 3 min. The supernatant was 
discarded, and pellet was rinsed one time with PBS/0.5% BSA. The cells were resuspended in 
an appropriate volume of PBS/0.5% BSA containing the desired primary staining reagent. 
Large samples for sorting by FACS were stained in a large enough volume to stay in suspension 
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(often 0.5–1.0 mL for 108 cells). Smaller, test samples (0.5–1.0 × 106
 
cells) were stained in 20–
50 μL of PBS/0.5% BSA. The yeast cells were incubated in the staining solution at room 
temperature for 30 min or on ice for 45 min. The yeast cells were gently agitated several times 
to make sure that they remain in suspension. The cells were centrifuged at 3,000 rpm (800×g) 
for 3 min, and washed with a large excess (20 volumes) ice-cold of PBS/0.5% BSA. All the 
steps from this point forward were performed on ice. The yeast cells were resuspended in the 
appropriate volume of ice-cold secondary staining solution (fluorescently labeled reagents in 
PBS/0.5% BSA). Samples were incubated on ice in the dark for 30–45 min. Control samples 
were incubated with secondary, but not primary stain to determine the level of nonspecific 
binding of the secondary reagent. To stain yeast cells with EGFP-tagged enzymes, only one 
round of staining and washing was performed at room temperature. 
The cells were spun down at 3,000 rpm (800×g) for 3 min, washed with 1 mL of ice-cold 
PBS/0.5% BSA, and resuspended to an appropriate volume of ice-cold PBS/0.5% BSA for 
flow cytometry analysis or sorting. The samples were run on the flow cytometer or FACS 
instrument, using a gate on the forward scatter vs. side scatter plot to focus only on the live, 
healthy cells. Within the live population, a second gate was set up based on fluorescence that 
collects the yeast cells with the highest expression of the fluorescent probe of interest. In the 
first round of sorting, about 5% of the most positive yeast cells with enhanced fluorescence 
signal were collected. Smaller fractions of the yeast cells were collected on subsequent sorts, 
down to 0.1–1%. The yeast cells inside of both gates (scatter and fluorescence) were sorted 
into a sterile cell culture tube on ice. Usually at least 50,000 cells were collected. The collected 
yeast cells were diluted into SD-citrate-CAA media with ampicillin and transferred to a culture 
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tube and incubated at 30 °C with shaking at 220 rpm. The resulting cultures were used for the 
next round of sorting process. 
The library sorting and expansion procedures were repeated until a distinctly positive 
population in the expanded library appeared. The yeast cells from that population were isolated 
and used for plasmid extraction. The obtained plasmids were used to transform fresh yeast cells. 
The yeast colonies with individual plasmids were cultured and analyzed by FACS to measure 
the mean fluorescence intensity after staining the EGFP-tagged enzymes. The best hit was used 
as template for the next round of library construction and sorting. The overall process is shown 
in Figure 5.15. 
 
Figure 5.15. Flow chart showing the sorting process of yeast cell library. 
 
5.4.9 Construction of ConFusion LctM enzyme  
The pET28b LctCE-(GS)15 plasmid was used as template.
25 Subcloning was carried out to 
displace the WT LctA leader peptide with an engineered leader peptide using primers listed in 
Table 5.4. 
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Table 5.4. Primers used in section 5.4.9. 
Construct Primer Name Primer Sequences (5’-3’) 
LctCE-(GS)15-34 
(Template: pCT302-
LctA-34) 
LctA_NheI_FP CGCGGCACGGCTAGCATGAAAG
AACAAAAC 
 
LctALea_SpeI_RP  CCAGAACCACTAGTTGCACCTAA
AATAAGTCCAA 
 
LctCE-(GS)15-34-28 
(Template: pCT302-
LctA-34-28) 
LctA-34-28_NheI_FP CGCGGCACGGCTAGCATGAATG
AACTAGAC 
 
LctALea_SpeI_RP CCAGAACCACTAGTTGCACCTAA
AATAAGTCCAA 
 
5.4.10 Construction of LctA/LctALea expression plasmids 
The peptide genes were amplified by PCR in 30 cycles of denaturing (98 °C for 30 s), annealing 
(55 °C for 30 s), and extending (72 °C for 15 s) using the plasmids isolated from yeast surface 
display as templates and primers listed in Table 5.5. The PCR products were digested with the 
indicated restriction enzymes and ligated into vectors listed in Table 5.5. The sequences of the 
resulting products were confirmed by DNA sequencing.  
Table 5.5. Primers used in section 5.4.10. 
Construct Primer Name Primer Sequences (5’-3’) 
pET15b-LctA-34 
(template: 
pCT302-LctA-34, 
vector: pET15b) 
LctA-
34_NdeI_FP 
GGTTCTCATATGGGAAAAGAAC
AAAACTCATT TG 
LctA_XhoI_RP  GCCCGCGGATCCTTAAGAGCA
GCAAGTA 
pET15b-LctA-34-28 
(template: 
pCT302-LctA-34-28 
vector: pET15b) 
LctA-34-
28_NdeI_FP 
GGTTCTCATATGGGAAATGAAC
TAGACTCTTTTG 
LctA_XhoI_RP GCCCGCGGATCCTTAAGAGCA
GCAAGTA 
pET15b-MBP-LctA 
(template: 
pET15b-LctA 
vector: pET28b-MBP*) 
LctA_BamHI_ 
FP 
 
AAAAAAGGATCCATGAAAGAA
CAAAACTC 
 
LctA_XhoI_RP GCCCGCGGATCCTTAAGAGCA
GCAAGTA 
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(Table 5.5 continued) 
pET15b-MBP-LctA-34-
28 
(template: 
pCT302-LctA-34-28 
vector: pET28b-MBP*) 
LctA-34-28_ 
BamHI_FP  
 
AAAAAAGGATCCATGAATGAACTAG
ACTC  
LctA_XhoI_ 
RP 
GCCCGCGGATCCTTAAGAGCAGCAA
GTA 
 
pET15b-MBP-LctALea 
(template: 
pET15b-LctA 
vector: pET28b-MBP*) 
LctA_BamHI_ 
FP 
 
AAAAAAGGATCCATGAAAGAACAAA
ACTC 
 
LctALea_ 
XhoI_RP 
CGGATCCTCGAGTTATGCACCTAAAA
TAAGGTC 
pET15b-MBP-LctALea-
34-28 
(template: 
pCT302-LctA-34-28 
vector:pET28b-MBP*) 
LctA-34-28_ 
BamHI_FP  
 
AAAAAAGGATCCATGAATGAACTAG
ACTC  
LctALea_ 
XhoI_RP 
CGGATCCTCGAGTTATGCACCTAAAA
TAAGGTC 
pET-SUMO-LctA 
(template: 
pET15b-LctA 
vector: pET-SUMO*) 
LctA_BamHI_
FP 
 
AAAAAAGGATCCATGAAAGAACAAA
ACTC 
 
LctA_NotI_RP GGAAAAAAGCGGCCGCTTAAGAGC
AGCAAGTA  
pET-SUMO-LctA-34-
28 
(template: 
pCT302-LctA-34-28 
vector: pET-SUMO*) 
LctA-34-28_ 
BamHI_FP  
 
AAAAAAGGATCCATGAATGAACTAG
ACTC  
LctA_NotI_RP GGAAAAAAGCGGCCGCTTAAGAGC
AGCAAGTA  
pET15b-MBP-LctA-1-
38 
(template: 
pET15b-LctA 
vector: pET28b-MBP*) 
LctA_BamHI_
FP 
 
AAAAAAGGATCCATGAAAGAACAAA
ACTC 
 
LctA1-38_ 
XhoI_ RP 
AAAAAACTCGAGCTAACATTCATGA
GAAATTG 
pET15b-MBP-LctA-34-
28-1-38 
(template: 
pCT302-LctA-34-28 
vector:pET28b-MBP*) 
LctA-34-28_ 
BamHI_FP  
 
AAAAAAGGATCCATGAATGAACTAG
ACTC  
LctA1-38_ 
XhoI_ RP 
AAAAAACTCGAGCTAACATTCATGA
GAAATTG 
* The plasmid pET28b-MBP was obtained from Manny Ortega, pET-SUMO was obtained 
from Yue Hao. 
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5.4.11 Labelling LctA leader peptides with fluorescein isothiocyanate (FITC) 
FITC (purchased from Sigma) was dissolved in DMF at 10 mg/mL. An aliquot of 1 mg peptide 
was dissolved in 0.5 mL of conjugation buffer (50 mM borate buffer, pH 8.5). An excess 
amount of FITC was added (FITC concentration was 20-fold that of the peptide concentration) 
to the peptide solution and the mixture was incubated at room temperature in the dark for 1~3 
h. The resulting peptide mixture was subjected to analytical HPLC analysis and the labelled 
peptide was purified.  
5.4.12 Analytical HPLC analysis  
Samples were run on an Agilent analytical HPLC system equipped with a Thermo Scientific 
Gold C18 column. The solvent used was 98% solvent A and 2% solvent B for 1 min, followed 
by an increase to 100% solvent B over 45 min with a flow rate of 1.0 mL/min (solvent A: 80% 
acetonitrile with 0.086% TFA, solvent B: ddH2O with 0.1% TFA). 
5.4.13 Fluorescence polarization (FP) assay 
All FP experiments were performed on a Synergy H4 Hybrid plate reader (BioTek) using a 96-
well black opaque half area plate (Costar 3694). Increasing amounts of LctM enzyme were 
added to fluorescein-labeled peptides (5 or 20 nM) in LanM Start buffer (20 mM HEPES, 1 M 
NaCl, pH 7.5). Data analysis was performed using Origin 9.0, and curves were fitted to a 
hyperbolic equation to calculate KD (y = (a*x)/(KD +x) + c).Competitive FP assays were 
completed with LctM (1.7 μM) and a fluorescein-labeled peptide (5 or 20 nM) in LanM Start 
buffer. Increasing amounts of unlabeled peptide were added to displace the labeled peptide. 
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5.4.14 In vitro reconstitution of the activity of LctM and ConFusion enzymes  
The in vitro enzymatic assay included: 1 mM ATP, 10 mM DTT, 50 mM HEPES (pH 7.5), 25 
μg/mL bovine serum albumin, 10 mM MgCl2 and various amounts of peptide and enzyme 
indicated in the figure legends. The in trans assay included: LctA core peptide (final 
concentration 20 μM), purified His6-LctCE (final concentration 2 μM), 10 mM MgCl2, 2 mM 
ATP, 10 mM DTT, 25 μg/mL bovine serum albumin and 50 mM HEPES buffer (pH 7.5). The 
extent of reaction was monitored by periodically removing aliquots of the reaction, which were 
quenched by the addition of formic acid to 0.5% final concentration (pH 1-2), desalted by 
ZipTipC18 and analyzed by downstream experiments. 
5.4.15 Experimental procedures listed in other chapters 
Expression and purification of unmodified and modified peptides (section 2.4.5);  
Expression and purification of LanM enzymes (section 2.4.6); 
Bioactivity assay (section 2.4.8); 
Iodoacetamide assay (section 2.4.9); 
ESI-LC-MS experiments (section 2.4.10). 
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